Survival response in the skin by PELTZER M. de las N. A.,

Unicentre 
CH-1015 Lausanne 
http://serval.unil.ch 
 
 

Year : 2012 
 
SURVIVAL RESPONSE IN THE SKIN 
 
PELTZER Maria de las Nieves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PELTZER Maria de las Nieves,2012, SURVIVAL RESPONSE IN THE SKIN 
 
Originally published at : Thesis, University of Lausanne 
 
Posted at the University of Lausanne Open Archive. 
http://serval.unil.ch 
 
 
Droits d’auteur 
L'Université de Lausanne attire expressément l'attention des utilisateurs sur le fait que tous les 
documents publiés dans l'Archive SERVAL sont protégés par le droit d'auteur, conformément à la 
loi fédérale sur le droit d'auteur et les droits voisins (LDA). A ce titre, il est indispensable d'obtenir 
le consentement préalable de l'auteur et/ou de l’éditeur avant toute utilisation d'une oeuvre ou 
d'une partie d'une oeuvre ne relevant pas d'une utilisation à des fins personnelles au sens de la 
LDA (art. 19, al. 1 lettre a). A défaut, tout contrevenant s'expose aux sanctions prévues par cette 
loi. Nous déclinons toute responsabilité en la matière. 
 
Copyright 
The University of Lausanne expressly draws the attention of users to the fact that all documents 
published in the SERVAL Archive are protected by copyright in accordance with federal law on 
copyright and similar rights (LDA). Accordingly it is indispensable to obtain prior consent from the 
author and/or publisher before any use of a work or part of a work for purposes other than 
personal use within the meaning of LDA (art. 19, para. 1 letter a). Failure to do so will expose 
offenders to the sanctions laid down by this law. We accept no liability in this respect. 
 
Département de Physiologie 
 
 
SURVIVAL RESPONSE IN THE SKIN 
 
 
 
Thèse de doctorat ès sciences de la vie (PhD) 
 
présentée à la  
 
Faculté de biologie et de médecine 
de l’Université de Lausanne 
 
par 
 
 
Maria de las Nieves PELTZER 
 
Biotechnologiste de l'Universidad Nacional de Quilmes (UNQUI), Buenos Aires 
 
 
Jury 
 
 
Prof. Jean-Pierre Hornung, Président 
Prof. Christian Widmann, Directeur de thèse 
 
  
Prof. Wim Declercq, expert 
Prof. Liliane Michalik, expert 
  
 
 
Lausanne 2012 
 


	  
	  
	  
	  
	  
A mi papa, mi mama y mis hermanas. Por el amor, la confianza y el aguante. 
Por todos los sacrificios realizados para que esto se cumpla. Por estar 
siempre, en las buenas y en las malas, aca y alla… 
 
 
A Alessandro, por darme la fuerza para llegar hasta aca 
 
 
…y esto es solo el principio 
INDEX
SUMMARY / RÉSUMÉ
GENERAL INTRODUCTION
1. Apoptosis
 1.1 Mechanisms leading to apoptotic cel death
 1.2 DNA condensation and fragmentation
 1.3 Cel shrinkage and plasma membrane bebbling
 1.4 Nuclear fragmentation
 1.5 The end of the tunnel
2. Inhibitors of apoptosis family (IAPs):the guardians of the cel
 2.1 Survivin: the ugly duckling
3. Caspases: not only inducers of apoptosis
4. RasGAP: the on/off button
 4.1 RasGAP structure
 4.2 RasGAP as a Ras effector and beyond
5. Ras/PI3K/Akt: a signaling cascade important for RasGAP 
derived-fragment N protection
 5.1 5.2 The Ras/PI3K/Akt signaling pathway
6. Skin: a sophisticated barrier against external insults
 6.1 The skin triple layer: epidermis, dermis and hypodermis
 6.2 The sun and the skin: the perfect crime
 6.3 UV-B light: the prize of a beautiful suntan
7. Reference list
OBJECTIVES
RESULTS Part I
 Introduction
 Contribution
 Reference list
 Research article
1
5
7
8
12
12
13
13
14
15
17
22
23
24
27
27
31
31
32
34
37
47
51
53
54
55
57
UNIVERSITÉ DE LAUSANNE
SURVIVAL RESPONSE IN THE SKIN
NIEVES PELTZER
     INDEX
77
79
81
82
85
93
95
97
98
101
125
133
140
141
185
RESULTS Part I
 Introduction
 Contribution
 Reference list
 Research article
RESULTS Part II
 Introduction
 Contribution
   Reference list
 Research article
 Supplementary data
DISCUSSION AND PERSPECTIVES
 Reference list
METHODS
AKNOWLEDGEMENTS
 
UNIVERSITÉ DE LAUSANNE
SURVIVAL RESPONSE IN THE SKIN
NIEVES PELTZER
SUMMARY 
Apoptosis is defined as a programmed cell death process operating in multicellular 
organisms in order to maintain proper homeostasis of tissues. Caspases are among 
the best characterized proteases to execute apoptosis although lately many studies 
have associated them with non-apoptotic functions. In the laboratory an anti-
apoptotic pathway relying on caspase-3 activation and RasGAP has been described 
in vitro. RasGAP bears two conserved caspase-3 cleavage sites. Under low stress 
conditions, RasGAP is first cleaved by low caspase-3 activity generating an N 
terminal fragment (fragment N) that induces a potent anti-apoptotic response 
mediated by the Ras/PI3K/Akt pathway. High levels of active caspase-3, associated 
with increased stress conditions, induce further cleavage of fragment N abrogating 
this anti-apoptotic response. In the present work I studied the functionality of 
fragment N-mediated protection in physiological conditions as well as the mechanism 
by which fragment N induces an anti-apoptotic response, with a focus on survivin, an 
inhibitor of apoptosis.   
During my work in the laboratory I found that mice lacking caspase-3 or unable to 
cleave RasGAP (KI mice) are deficient in Akt activation and more sensitive to 
apoptosis than wild-type mice in response to stress. This higher sensitivity to stress 
led to augmented tissue damage, highlighting the importance of this pathway in 
protection against low stress. In parallel I focused on the study of survivin expression 
in the skin in response to UV-B light and I found that survivin is induced in the 
cytoplasm of keratinocytes in response to stress where it may fulfill a cyto-protective 
role. However fragment N had no effect on survivin expression. In addition, 
cytoplasmic survivin was increased in keratinocytes exposed to UV-B light, whether 
RasGAP is cleaved (WT mice) or not (KI mice), indicating that survivin is not involved 
in fragment N mediated protection. 
Altogether these data indicate that fragment N is pivotal for cell protection against 
pathophysiologic damage and can encourage the development of therapies aimed to 
strengthen the resistance of cells against aggressive treatments. Importantly, this 
finding contributes to the characterization of how caspase-3 can be activated without 
inducing cell death, although further studies need to be conducted in order to 
completely characterize this pro-survival molecular mechanism.   
1
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RÉSUMÉ 
L'apoptose est définie comme un processus de mort cellulaire programmée 
s’exécutant, dans les organismes multicellulaires, afin de maintenir l'homéostasie 
adéquate des tissus et organes. Les caspases sont des protéases qui déclenchent 
l'apoptose bien que de récentes découvertes l’impliquent aussi dans des fonctions 
non-apoptotiques. Il a été démontré dans notre laboratoire que RasGAP était un 
substrat de la caspase-3 comportant deux sites de clivage conservé. Lors d’un faible 
stress, RasGAP est clivée par de faibles niveaux de caspase-3 activée, générant un 
fragment N-terminale qui a des fonctions anti-apoptotique (fragment N) agissant à 
travers l’activation de la voie Ras/PI3K/Akt. Lors d’un fort stress, quand l’activité de la 
caspase-3 est élevée, le fragment N est alors lui aussi clivé ce qui abolit sa réponse 
anti-apoptotique. Dans cette étude, j'ai étudié le rôle du fragment N dans cette 
signalisation en conditions physiologiques, ainsi que les mécanismes moléculaires 
par lesquels le fragment N induit une réponse cyto-protectrice, en me concentrant sur 
la survivine, un inhibiteur de l'apoptose. 
Au cours de mon travail dans le laboratoire, j'ai découvert que des souris dépourvues 
de la caspase-3 ou ne pouvant pas cliver RasGAP sont incapables d’activer Akt et 
sont, de ce fait, plus sensibles à l'apoptose que des souris de type sauvage en 
réponse au stress. Cette plus grande sensibilité se manifeste par une augmentation 
des dommages des tissus, ce qui souligne l'importance de cette voie dans la 
protection contre de faibles stress. 
Parallèlement,  je me suis concentrée sur l'étude de l'expression de la survivine dans 
la peau en réponse aux rayons UV-B. J'ai découvert que l’expression de cette 
protéine était augmentée dans le cytoplasme des kératinocytes en réponse au stress 
ayant vraisemblablement un rôle cyto-protecteur. Néanmoins, étant donné que 
l’expression du fragment N n'a aucun effet sur l'expression de la survivine in vitro, et 
que la survivine cytoplasmique est augmentée dans la peau exposée au rayons UV-
B indépendamment du clivage de RasGAP, nous en déduisons que la survivine n'est 
pas impliquée dans la protection induite par le fragment N. 
 
En conclusion, ces données indiquent que le fragment N est essentiel pour la 
protection des cellules contre les dommages physiopathologiques et pourraient 
3
mener au développement de thérapies visant à renforcer la résistance des cellules 
contre des traitements agressifs. Ces résultats sont aussi très importants car ils 
contribuent à la compréhension du mécanisme d’activation de la caspase-3 
n’induisant pas l’apoptose. Toutefois des études complémentaires sont nécessaires 
afin de décrypter ce signal de survie.  
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  “LIFE	  IS	  PLEASANT.	  	  DEATH	  IS	  PEACEFUL.	  IT’S	  THE	  TRANSITION	  THAT	  IS	  TROUBLESOME”	  
	  Isaac	  Asimov	  
 
1. Apoptosis 
Apoptosis is a genetically encoded program leading to cell death that is involved in 
normal development of tissues during embryogenesis, for example removal of 
superfluous cells for hollowing ducts or deletion of interdigital cells during limb 
formation, and, in adults, to maintain homeostasis in rapidly renewing tissues, such 
as the intestine epithelium or hematopoietic cells. Apoptosis plays also an important 
role in the elimination of old or irreparably damaged cells that could have harmful 
effects on the health of the organism. Programmed cell death was first described by 
the German Scientist Carl Vogt in 1842 but it was not until 1972 when John Foxton 
Ross Kerr (Kerr et al., 1972) was able to distinguish apoptosis from traumatic cell 
death. He was indeed the first to coin the term “Apoptosis” for this kind of cell death 
with the help of a Greek Professor at the University of Aberdeen. This is a citation 
from a footnote in Kerr’s publication. “We are most grateful to Professor James 
Cormack of the Department of Greek, University of Aberdeen, for suggesting this 
term. The word "apoptosis" (ἁπόπτωσισ) is used in Greek to describe the "dropping 
off" or "falling off" of petals from flowers, or leaves from trees. To show the derivation 
clearly, we propose that the stress should be on the penultimate syllable, the second 
half of the word being pronounced like "ptosis" (with the "p" silent), which comes from 
the same root "to fall", and is already used to describe the drooping of the upper 
eyelid” (Kerr et al., 1972). 
Apoptotic cells are equipped with plasma membrane alterations that allow their rapid 
removal from tissues before the release of their cytoplasmic content. Because they 
retain their plasma membrane integrity and are rapidly engulfed by phagocytes, 
apoptotic cells are not followed by inflammation and promote the recycling of cellular 
components (Savill and Fadok, 2000). Other sort of cell death, namely “Necrosis”, is 
accompanied by a rapid loss of membrane integrity and the release of cellular 
contents into the extracellular space, invariably triggering an immune response (Kerr 
et al., 1972). In biological terms necrosis plays the role of an alert to danger since 
7
many pathogens and many types of trauma (burns, cuts, etc) facilitate infection 
(Matzinger, 2002; Chen et al., 2007).  
 
1.1 Mechanisms leading to apoptotic cell death 
Apoptosis typically proceeds through one of two signalling cascades termed the 
intrinsic and the extrinsic pathways (Figure 1), which induce the activation of 
caspases. Caspases are cysteine-dependent aspartate-directed proteases that 
regulate apoptosis through the cleavage of several proteins ultimately leading to cell 
death (Taylor et al., 2008).  Activation of initiator caspases such as caspase-8, -9 and 
-10 by either apoptotic pathway mediate the activation of executioner caspase-3, -6 
and -7 that finally execute apoptosis. 
In the intrinsic pathway diverse cytotoxic insults, including growth factor deprivation 
and DNA damaging agents, initiate apoptosis by activating pro-apoptotic proteins 
(Figure 1). This phenomenon leads to mitochondrial depolarization that finally 
commits the cell to die. The pathway is mainly regulated by a balanced interaction 
between pro and anti-apoptotic members of the B cell lymphoma 2 (Bcl-2) family. 
Within this family, Bcl-2, Bcl-XL and Mcl-1 promote cell survival by preventing the 
apoptosis effectors, Bax and Bak, from damaging the mitochondrial membrane. Upon 
an apoptotic stimulus, pro-apoptotic Bax and Bak activation, although by a 
mechanism highly debated, is essentially based on the activity of the apoptosis 
initiators, the so-called BH3-only proteins. This family comprises Bad, Bik, Bid, Bim, 
Bmf, Noxa and PUMA, which engage and inactivate their prosurvival relatives (Bcl2, 
Bcl-XL and Mcl-1) resulting in Bax/Bak activation. After activation Bax and Bak 
undergo extensive conformational changes leading to mitochondrial targeting of Bax 
and homo-oligomerization of Bax and Bak in the mitochondrial membrane (Strasser 
et al., 2011). These changes initiate the formation of proteinaceous channels 
(Antonsson et al., 1997) that although not yet well understood, may be formed by 
Bax and Bak themselves (Martinez-Caballero et al., 2009). Pore formation induces 
membrane depolarization or mitochondrial outer membrane depolarization 
(MOMP) (Tait and Green, 2010) finally leading to permeabilization and release into 
the cytoplasm of pro-apoptotic proteins from the mitochondrial intermembrane space.  
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Cytochrome c is one of the main pro-apoptotic proteins to be released from the 
mitochondria. Once in the cytoplasm, it binds apoptotic protease activating factor 1 
(Apaf1), inducing its conformational change and allowing the formation of a 
heptametrical wheel like structure that functions as a caspase activating platform, 
termed apoptosome. The apoptosome recruits, dimerizes and activates caspase 9, 
one of the initiator caspases, which in turn activates the effector caspases -3, -6 and -
7. The apoptosome works as a molecular timer since it induces caspase-9 
autoprocessing which greatly diminish its affinity for the apoptosome leading to 
caspase-9 inactivation. Therefore, apoptosome-mediated caspase-9 activation 
depends on the level of intracellular procaspase-9.  
Other pro-apoptotic proteins are released from mitochondria during MOMP such as 
the second mitochondrial-derived activator of caspase (SMAC, also known as direct 
IAP-binding protein with low pI, DIABLO), the stress-activated endoprotease OMI 
(also known as high temperature requirement protein A 2 or HtrA.2) and the 
apoptosis-inducing factor (AIF), while the latter is released in a slower manner. 
Although it has been reported that the release of Smac was caspase-dependent 
(Adrain et al., 2001), later publications sustained that release of the above mentioned 
pro-apoptotic proteins is caspase independent and that it happens simultaneously 
with cytochrome c release (Goldstein et al., 2000; Goldstein et al., 2005). Once the 
mitochondria has been depolarized, the release of pro-apoptotic proteins happens in 
about 5 minutes and the continuous and slow release of AIF suggests that the pore 
formed during MOMP remains open for a few hours (Munoz-Pinedo et al., 2006). 
Smac is an inhibitor of the X-linked inhibitor of apoptosis protein (XIAP), a well-known 
caspase inhibitor (more details in the “inhibitors of apoptosis” section) that upon 
release from the mitochondria cooperates with cytochrome c – mediated caspase-3 
activation through XIAP inactivation. OMI belongs to the family of serine proteases 
that induces apoptosis by inhibiting IAPs in a caspase dependent manner (Suzuki et. 
al. 2001), although it can also function in a caspase-independent fashion directly 
through its serine protease activity (Garrido and Kroemer, 2004). Finally, AIF once 
released from the mitochondria, translocates to the nucleus, interacts with DNA and 
induces chromatin condensation by itself (Ye et al., 2002), triggering apoptosis in a 
caspase-independent manner.  
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The extrinsic pathway is initiated through the engagement of cell surface death 
receptors with intracellular death domain (DD) that belong to the tumor necrosis 
factor (TNF) receptor superfamily, by their specific ligands (Figure 1). Ligation of 
death receptors such as CD95/Fas or TRAIL receptors TRAIL-R1 and TRAIL-R2 by 
their cognate ligands, induce aggregation of trimerized receptors leading to the 
formation of the death inducing signaling complex (DISC). The DISC is composed 
of the receptor, an adaptor molecule such as Fas- associated death domain (FADD) 
and the initiator caspase -8 or -10. Oligomerization of caspase-8 upon DISC 
formation drives its activation, activating in turn its downstream effectors, such as 
caspase-3. In Type I cells the mere activation of caspase-8 is sufficient to trigger 
apoptosis independently of MOMP, directly activating effector caspases. In type II 
cells on the contrary, DISC-induced caspase-8 signaling is amplified though the 
cross-talk with the mitochondrial pathway by the caspase-8 - mediated cleavage of 
BH3  - interacting domain death agonist (BID; a BH3 only protein) leading to BID 
activation and mitochondrial cell permeabilization (Fulda and Debatin, 2006). 
Signaling by death receptors can be negatively regulated by FLICE-inhibitory protein 
(FLIP). FLIP is similar in structure to caspase-8 but lacks active site residues. 
Therefore, FLIP can dimerize with caspases-8 preventing its activation at the DISC 
(Krueger et al., 2001). 
Independently of the pathway leading to cell death, the bottle neck of apoptosis is the 
activation of effector caspases-3, -6 and -7. These proteases are responsible for the 
typical morphological changes exhibited by an apoptotic cell, such as chromatin 
condensation, nuclear fragmentation, cellular shrinkage, and plasma membrane 
blebbing. These series of events culminate with the formation of apoptotic bodies that 
present “eat me” signals at the surface to be finally recognized and engulfed by 
phagocytes. 
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Figure 1: Simplified schematic representation of the intrinsic and extrinsic pathways of 
apoptosis. Dashed arrows represent the transition between normal and stressed conditions in 
either pathway. Grey arrow represents the crosstalk between the extrinsic and intrinsic 
pathways. MOM: mitochondrial outer membrane, IMS: inter-membrane space. 
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1.2 DNA condensation and fragmentation  
DNA condensation and fragmentation are one of the most noticeable features of 
apoptosis. The pattern of DNA fragmentation is the result of endonuclease-mediated 
chromatin cleavage at internucleosomal sites and is therefore accompanied by 
chromatin condensation.  
The caspase-activated DNase (CAD) is the best-characterized nuclease that 
functions exclusively during apoptosis (Widlak and Garrard, 2005). CAD and its 
inhibitory chaperone the Inhibitor of CAD (ICAD) form an inactive complex. The CAD-
ICAD complex can bind DNA but ICAD prevents CAD-mediated DNA digestion by 
blocking its dimerization. Following caspase-3 activation, ICAD is cleaved and then 
CAD is released to form homo- or oligomers that become active (Nagata et al., 
2003). Although CAD was thought to be involved not only in DNA degradation but 
also in chromatin condensation, it has been demonstrated that the kinase MST1 is 
cleaved and activated by caspase-3 (Ura et al., 2001). Once activated, MST1 
migrates to the nucleus were it phosphorylates histone 2B (H2B), which is correlated 
with chromatin condensation (Cheung et al., 2003). 
 
1.3. Cell shrinkage and plasma membrane blebbing 
On activation caspases cleave many of the major constituents of the cytoskeleton 
including actin and actin-binding proteins such as myosine, spectrins, α-actinin, 
gelsolin and filamin (Taylor et al., 2008). Some components of the microtubular 
filaments are also caspase-3 substrates comprising tubulins and microtubule-
associated proteins such as tau, cytoplasmic dynein intermediate chain and 
p150Glued. Proteolysis of these structural components of the cytoskeleton contributes 
to rounding and retraction of the cell observed in the early phases of apoptosis.  
Another feature of apoptosis, which is also a consequence of cytoskeleton 
weakening, is the dynamic membrane blebbing as the cell cytoplasm flows against 
unsupported regions of the plasma membrane. Rho-associated kinase I (ROCK I), a 
caspase-3 substrate, plays an important role in this phase of apoptosis. This kinase 
is a Rho effector and a regulator of actin cytoskeleton dynamics that is activated 
upon removal of the C-terminal region by caspase-3. This activation leads to myosin 
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light chain phosphorylation with the consequent contraction of actin bundles. 
However, in conditions where the cytoskeleton has been disrupted (i.e. in the 
absence of a solid cytoskeleton) the contraction of the actin bundles leads to the 
formation of blebs (Coleman et al., 2001; Sebbagh et al., 2001).  
 
1.4. Nuclear fragmentation 
Nuclear fragmentation relies on the caspase-dependent cleavage of nuclear lamins 
leading to the disintegration of the nuclear membrane (Rao et al., 1996). However, 
lamin cleavage alone is not sufficient to cause nuclear disintegration. Because of the 
attachments between the actin cytoskeleton and the nuclear envelope, this literally 
tears the nucleus apart during apoptosis and therefore ROCK I also plays a role in 
nuclear fragmentation (Croft et al., 2005). 
 
1.5. The end of the tunnel 
The terminal event of the demolition phase is the ingestion of dead cells by 
phagocytes. This is achieved by the formation of apoptotic bodies and the release of 
chemoattractans molecules by the dying cell. The formation of apoptotic bodies is 
probably a consequence of the actin-myosin mediated process of membrane 
blebbing, in which membrane-bound extrusions of cytosol become pinched off into 
independent vesicles (Orlando et al., 2006). Apoptotic cells are not only ready to be 
eaten but they are capable of attracting phagocytes by the caspase-3 dependent 
release of chemoattractants lipids such as lysophosphatidylcholine, or by changes in 
the membrane (Lauber et al., 2003). For instance, phosphatidylserine (PS) is 
normally confined to the inner plasma membrane leaflet but is translocated to the 
outer membrane leaflet in a caspase-3 dependent manner (Martin et al., 1995). 
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2. Inhibitors of Apoptosis Family (IAPs): the guardians of the cell 
Inhibitors of apoptosis (IAP), are among the main caspase inhibitors. Eight human 
IAPs are currently known: XIAP, cIAP1, cIAP2, NAIP, ML-IAP, TS-IAP, BRUCE and 
the smallest of all, survivin. The feature that defines this family is the presence of the 
baculovirus IAP repeat (BIR) domain, a zinc binding domain of approximately 70 
amino acid residues that mediates protein–protein interactions, and is essential for 
the anti-apoptotic potential of most IAPs. BIR domains are protein interacting 
modules and most of them (except BIR1) bind the extreme N-terminus of short 
peptides of defined sequence named IBM (IAP-binding motif). IBM is found in 
proteins like caspase-9, -3 and -7 (Scott et al., 2005), Smac/DIABLO and others 
(Vaux and Silke, 2003). The mammalian IAPs, XIAP, cIAP1 and cIAP2, contain three 
such domains in their aminoterminal portion (Figure 2). These IAPs also harbor 
additional domains such as the carboxyterminal RING finger domain that provides 
them with Ubiquitin ligase (E3) activity (Yang et al., 2000) and a Ub-associated 
domain (UBA) domain through which they interact with ubiquitylated proteins (Gyrd-
Hansen and Meier, 2010). Finally cIAP1 and 2 contain a caspase-recruitment domain 
(CARD) that, unlike all known CARD domains, it does not interact with CARD-
containing proteins. Instead, cIAP 1/2 CARD domain keeps cIAP1/2 into a closed 
conformation preventing its E3 activity (Lopez et al., 2011). 
IAPs counteract apoptosis in different manners. XIAP is the only one able to directly 
inhibit caspases (Figure 1). Inhibition of caspase-9 requires an essential interaction 
between a groove on its BIR3 domain and a conserved four-residue IBM of the small 
subunit of caspase-9. Caspase-3 and -7 are inhibited in a different way. The linker 
region between BIR1 and BIR2 of XIAP interacts with the activated caspase in a 
revers orientation relative to the substrate, while the BIR2 domain contributes to 
inhibition by direct interaction with the N-terminus of the small subunits of activated 
caspase. Binding of XIAP to caspases is antagonized by the mitochondrial protein, 
Smac (Rumble and Duckett, 2008; Dubrez-Daloz, 2009).  
The other well-characterized IAPs are c-IAP1 and 2, although they inhibit apoptosis 
in a more indirect fashion. cIAPs maintain survival through induction of the canonical 
pathway of NK-κB activation. Basically the Ub-dependent formation of complex-I, 
consisting of the adaptor protein TNFRSF1A-associated via death domain (TRADD), 
14
the Ub ligases TRAF2, TRAF5, cIAP1 and cIAP2, and the protein kinase RIPK1, is 
recruited to the membrane after TNFα binding to its receptor (TNFR1) (Gyrd-Hansen 
and Meier, 2010). cIAP1/2-mediated K63 ubiquitylation of some components of 
complex-I, such as RIPK1 and it-self, stimulates Ub-dependent recruitment of trimeric 
linear ubiquitin chain assembly complex (LUBAC), which promote NK-κB activation 
and the induction of pro-survival signals (Haas et al., 2009; Gerlach et al., 2011). 
Additionally, cIAP1/2 block cell death by preventing the formation of a RIPK1-
dependent, caspase-8 activating complex (complex-II) by keeping RIPK1 in complex-
I by ubiquitylation (Varfolomeev, 2008). Also cIAP1/2 is able to modulate the non-
canonical pathway of NK-κB, through ubiquitylation and degradation of NIK, a well-
known inducer of NK-κB (Darding and Meier, 2012).  
The role of other IAPs, such as NAIP or Survivin on apoptosis inhibition is not very 
well understood. NAIP appears to be involved in activation, rather than inhibition, of 
the pro-inflammatory caspase-1 therefore having a role in inflammation (see section 
3). Survivin, bears only one BIR domain and the absence of a structural equivalent to 
the linker between BIR2 and 3 of XIAP makes survivin not able to bind directly to 
caspases in the same manner as XIAP (Wheatley and McNeish, 2005). Even though 
many anti-apoptotic functions have been attributed to this IAP, its role as an 
antiapopotic protein is controversial (Yue et al., 2008).  
 
2.1. Survivin: The Ugly Duckling 
The exception within the IAP family, Survivin (also called BIR containing protein-5, 
BIRC5) is a 16.5 kDa protein that functions simultaneously at cell division and 
apoptosis inhibition. Structurally, Survivin bears only one BIR domain in its N-terminal 
end that contributes to its function in apoptosis inhibition. In its C-terminal domain, 
survivin contains an extended carboxy-terminal alpha-helical coiled-coil which is 
thought to be important for its interaction with microtubules, hence its role in cell 
division (Li and Altieri, 1999) (Figure 2).  
In active proliferating cells, Survivin regulation is cell cycle dependent, being almost 
undetectable at G1 and S phases and peaking at G2/M (Li et al., 1998). Survivin is a 
chromosomal passenger (CP) (Uren et al., 2000; Wheatley et al., 2001), and is hence 
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found in the inner centromere during prophase where they remain until the 
chromosomes have converged to the metaphase plate. At the metaphase-anaphase 
transition, survivin relocates to the newly forming microtubules that develop between 
the separating chromosomes to finally migrate to the cell cortex during anaphase, 
where it delineates the cleavage plane.  
 
 
 
 
Figure 2: Domain structure of human IAPs. All IAPs are characterized for the presence of at 
least one BIR domain. BIR: baculovirus IAP repeat. RING: Ub-ligase activity domain. UBA: Ub-
associated domain. UBC: Ub-conjugating domain. CARD: caspase recruitment domain. 
NOD/LRR: nucleotide binding oligomerization domain. LRR: carboxyl-terminal leucine-rich 
repeat domain. CC: alpha-helical coiled-coil domain.  
 
 
Endogenous survivin exists in different subcellular pools. Nuclear survivin is only 
involved in mitosis and has no anti-apoptotic properties. In fact the cytoprotective 
activity of survivin depends on its active nuclear export through the nuclear export 
receptor chromosome region maintenance (Crm1) (Rodriguez et al., 2002). 
Moreover, Dohi and collaborators reported that there is a pool of survivin that 
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localizes to the mitochondria in tumor cells and that it is translocated into the 
cytoplasm when cells are subjected to stress (Dohi et al., 2004a; Dohi and Altieri, 
2005). Even though survivin is not a direct caspase inhibitor, there are three 
proposed mechanisms for the survivin anti-apoptotic effect and all of them take place 
in the cytoplasm (Figure 3). One of the mechanisms relies on survivin direct 
interaction with Smac/DIABLO (Song et al., 2004; Song et al., 2003), which prevents 
the neutralizing effects of Smac over XIAP, allowing it to maintain a suppression 
effect on the effector caspases. The second mechanism proposed is survivin direct 
binding with XIAP. This interaction leads to the stabilization of XIAP against 
proteasome degradation. Moreover, the survivin-XIAP complex synergistically inhibits 
apoptosis induced by Bax expression, whereas survivin has no effect by it-self if 
XIAP is not present in the cell (Dohi et al., 2004b). A third proposed mechanism is the 
inhibition of caspase-9. This inhibition only takes place when survivin is bound to the 
hepatitis B – X interacting protein (HBXIP). Once the complex is formed, survivin is 
able to sequestrate caspase-9 and thus interfere with the apoptosome assembly 
(Marusawa et al., 2003).  
Survivin anti-apoptotic function is controversial. Yue and collaborators support the 
idea that cells lacking survivin are more sensitive to apoptosis because of an 
aberrant mitosis and not because of a role as an IAP (Yue et al., 2008). However, by 
dissociating survivin mitotic function from anti-apoptotic-survivin it was shown that 
cells lacking anti-apoptotic survivin are more sensitive to apoptosis, even though 
mitosis proceed normally (Barret et al., 2010; Colnaghi et al., 2006), suggesting that 
survivin has indeed anti-apoptotic properties per se. 
 
 
3. Caspases: not only inducers of apoptosis 
As described above, caspases are cysteine proteases that cleave many substrates in 
an aspartate residue to trigger apoptotic cell death or inflammation. A total of 14 
caspases have been identified in mammals. They are synthesized as zymogens 
(inactive proenzymes) and can be classified in 3 groups according to the length and 
function of their N-terminal prodomain.  
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Figure 3: Different anti-apoptotic mechanisms proposed for survivin cytoprotective effect. 
Dashed arrow represents the transition between normal and stressed condition. MOM: 
mitochondrial outer membrane, IMS: inter-membrane space. 
 
 
Caspases with a large prodomain are referred to as inflammatory caspases (group I) 
and initiator of apoptosis (group II), while those with a short prodomain are called 
effector caspases (group III) (Figure 4). The large prodomain of procaspases contain 
a death effector domain (DED), or a caspase recruitment domain (CARD) (Figure 4). 
Theses domains are mostly responsible for recruiting initiator caspases into death- or 
inflammatory- inducing complexes, resulting in proteolytic auto-activation. For 
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activation, caspases require proteolysis at internal aspartate residues resulting in the 
formation of a heterotetramer p202-p102. The activation mechanism of caspases from 
groups I and II relies on the dimerization and interdomain cleavage, as well as 
cleavage and release of their prodomains (Figure 4). Executioner caspases are 
present as dimers in the cell and are activated by cleavage of the interdomain which 
leads to intramolecular rearrangements and the formation of enzymatically active 
dimers.   
Although caspases have largely been associated with apoptosis induction as 
described in the previous section, apoptosis can occur independently of caspase 
activation and vice versa the activation of caspases can be involved in non-apoptotic 
pathways, including inflammatory responses, immune cell proliferation, differentiation 
of various cell types, and others.  
A subfamily of caspases, referred to as group I comprises caspases-1, -4, -5, and -
13 (a bovine homolog of caspase-4) and mouse caspase-11 (homolog of caspse-4) 
and -12. These caspases play a role in neuronal cell death. Their main function 
though is the regulation of inflammatory responses. Indeed caspase-1, the first 
caspase to be described, is responsible for processing pro-interleukin-1β into active 
IL-1β. Mature IL-1β is implicated in various immune reactions including the 
recruitment of inflammatory cells to the site of infection (Launay et al., 2005). 
Caspase-5 is involved in IL-1β maturation by interacting with caspase-1 in a 
multiprotein complex called the inflammasome. Caspase-11, being first described as 
a caspase-1 activator, triggers caspase-1 independent macrophage death and 
caspase-1 dependent IL-1β and IL-18 production in response to a subset of non-
canonical inflammatory activators (Kayagaki et al., 2011). Additionally, caspase-11 
can interact with actin-interacting protein 1 (Aip1), an activator of cofilin-mediated 
actin depolimerization, contributing to actin cytoskeleton dynamics (Li et al., 2007) 
and also to the fusion of phagosomes containing non-pathogenic bacteria with 
lysosomes (Akhter et al., 2012). 
The second group, group II, is composed of caspases- 2, -8, -9 and -10 and are 
known as initiator caspases. Caspase-2 is the most evolutionary conserved caspase 
although its role in apoptosis remains controversial. It is known, however that this 
caspase is indeed required in stress-induced apoptosis acting upstream the 
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mitochondria by inducing cytochrome c release (Lassus et al., 2002). Additionally it 
has been proposed that caspase-2 is recruited to a platform called PIDD (p53-
induced death domain) to form a large multiprotein complex involving the adaptor 
molecule RAIDD. This platform, called the PIDDosome spontaneously activates 
caspase-2 and, although it is not sufficient to trigger cell death, it sensitizes cells 
against genotoxin-induced apoptosis (Tinel and Tschopp, 2004; Jang et al., 2010). 
On the other hand, the PIDDosome most resembles the inflamasome complex 
having apoptosis-independent related roles such us activation of the DNA repair 
machinery (Tinel and Tschopp, 2004). Caspase-8 can have pleiotropic effects since it 
may promote cell motility mediated by calpain activation (Helfer et al., 2006) and 
macrophage differentiation by cleavage of the receptor-interacting protein (RIP), 
resulting in a downregulation of NFκB required during differentiation (Rebe et al., 
2007). Moreover, caspase-8 activation together with cFLIP (the short FLIP isoform) 
can prevent cells from undergoing programmed necrosis or necroptosis, by cleaving 
RIP Kinase 1 (RIPK1) (Oberst et al., 2011; Feoktistova et al., 2011).  
Caspase-10 is implicated in the activation of NFκB-dependent prosurvival signaling 
pathways by a mechanism that is independent of its catalytic domain (Shikama, 
1998; Sprick et al., 2002). 
The group III is composed of caspase-3, -6 and -7 and is the so-called effector 
caspases. Caspase-3, the well characterized executioner caspase, possesses many 
apoptosis-independent functions. Cell cycle regulators are substrates for caspase-3. 
Cleavage of cyclin-dependent kinase inhibitor (CKI) p27 by caspase-3 promotes 
proliferation of lymphoid cells (Frost, 2001). Another non-apoptotic function of 
caspase-3 is the cleavage of protein kinase C-δ (PKC-δ) which stimulates 
keratinocytes differentiation (Okuyama et al., 2004). Active caspase-3 alone or in 
combination with caspase-9, can induce embryonic stem cells (ESC) differentiation 
by cleavage and inactivation of Nanog, a transcriptional factor involved in ESC 
renewal (Fujita et al., 2008). Additionally, caspase-3 activation by pro-inflammatory 
stimuli can induce microglia activation through the cleavage and activation of the 
kinase PKCδ dependent pathway, leading to the activation of NF-κB (Burguillos et al., 
2011). 
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Figure 4: Structure and activations of fourteen characterized caspases. A_ Domain structure of 
caspases grouped according to their functions. CARD: caspase recruitment domain. DED: 
death effector domain. B_ Mechanism of proteolytic activation of caspases of group II (left 
panel) and group I (right panel). Red dots represent the cleavage sites.  
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Not only this caspase has roles different from apoptosis induction but paradoxically it 
can induce anti-apoptotic responses in certain conditions. Caspase-3 has been found 
to activate the B-cell receptor which triggers the cleavage of the kinases Fyn and Lyn 
generating fragments that inhibit apoptosis (Luciano et al., 2003). In addition, we 
have demonstrated that RasGAP, a regulator of Ras signaling pathway, when 
cleaved by caspase-3 generates a potent anti-apoptotic signal in vitro in response to 
diverse stressful stimuli (Yang and Widmann, 2001). 
Finally, caspase-14 is an exception within this family of proteases since it is not 
ubiquitously expressed and it is processed differently presumably in a caspase 
independent manner (Denecker et al., 2008). Caspase-14 has been associated with 
the terminal differentiation of human keratinocytes and cornification (Eckhart et al., 
2000) and more recently it has been reported to be involved in filaggrin catabolism 
and maintenance of hydration in the skin (Hoste et al., 2011). 
 
4. RasGAP: the on/off button 
Small monomeric G-proteins (guanosine nucleotide - binding proteins) function as 
molecular switches that control a wide range of cellular processes by coupling cell 
surface receptors to intracellular effectors at the inner plasma membrane. Monomeric 
G proteins are a superfamily of GTP binding proteins with intrinsic GTPase activity 
and based on their sequence homology and function similarity they are classified into 
five major subfamlies: Ras, Rho, Rab, Ran and Arf (ADP ribozilation factor) 
(Pamonsinlapatham et al., 2009; Wittinghofer A., 1998). Within these small GTPases, 
Ras (p21Ras) controls cell proliferation, differentiation, migration and apoptosis. In 
humans, three RAS genes encode for 3 homologous Ras proteins: HRAS, NRAS, 
KRAS4A and KRAS4B (alternative splice variants of KRAS). Several members of the 
Ras superfamily cycles between an active conformation in which they bind GTP and 
an inactive GDP-bound form (Donovan et al., 2002), resulting in the tracking of 
internal vesicles, nuclear import, cell cycle progression, cytoskeletal reorganization, 
and protein translation. Under physiological conditions, the transition between the 
two states is controlled by Guanine nucleotide exchange factors (GEFs), which 
promote the activation of Ras proteins by stimulating the GDP/GTP exchange, and 
by GTPase activating proteins (GAPs), which accelerate RAS-mediated GTP 
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hydrolysis (Figure 5A). Inactivation of Ras hydrolysis activity induction by GAPs is 
indeed the predominant target of most common somatic mutations found in the 
oncogenic variants of RAS alleles (Pylayeva-Gupta et al., 2011). p120-Ras GTPase 
activating proteins (p120-RasGAP or RasGAP) has been identified as the essential 
negative regulator of the Ras-signalling pathway (Bos et al., 2007). RasGAP, is a 
multi-domain protein and apart from being a regulator of Ras, its N-terminal domain 
contains a number of signalling modules that mediate interaction with other proteins 
(see section 4.1 and 4.2) indicating that RasGAP bears functions independent of Ras 
(Pamonsinlapatham et al., 2009). 
 
4.1. RasGAP structure 
RasGAP is a 120 kDa cytosolic protein (Figure 5B). In the amino-terminal region it 
contains a Src Homology 3 (SH3) domain flanked by two SH2 domains. The SH3 
domain is essential for Ras downstream signaling since it can bind several effector 
targets. For instance, RasGAP is able to control Rho-mediated cytoskeletal 
reorganization through its SH3 domain. Calpain small subunit 1 (Capns 1), a 
regulator of adhesive complex dynamics, has been reported to be a RasGAP SH3 
binding partner. Aurora kinases can similarly interact with RasGAP through this 
domain. RasGAP SH3 binding protein 1 (G3BP1) is an endoribonuclease that has 
been characterized as a RasGAP SH3 binding protein (Parker et al., 1996), however 
a recent study has shown that no interaction exists between these two proteins 
(Annibaldi et al., 2011). The conserved SH2 domains, on the other hand, have 
important dynamic roles in specific signals associated with phosphorylated tyrosine 
kinase receptors such as PDGF and EGF, as well as with the non-receptor tyrosine 
kinase, v-Scr (Pamonsinlapatham et al., 2009). Both SH2 RasGAP domains are 
individually capable of binding p190-RhoGAP (a GAP protein specific for the Rho 
family of small GTPases). Members of the elongation factors family (eEF1A1 and 2), 
involved in cell proliferation, were also shown to interact with RasGAP SH2 domains 
(Panasyuk et al., 2008).  
The second SH2 domain is followed by a pleckstrin homology (PH) domain that can 
bind to the GAP domain of RasGAP and interfere with Ras/RasGAP interaction. 
Furthermore, the expression of isolated RasGAP PH domain specifically inhibits Ras-
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mediated signalling and transformation without affecting cellular growth (Drugan et 
al., 2000).  
A calcium-dependent phospholipid-binding domain (CaLB/C2) follows the PH domain 
which binds Anexin-A6, a Ca+2-regulated protein that forms a complex with RasGAP 
and induce Ras inactivation (Grewal and Enrich, 2006). 
In the carboxy-terminal region of RasGAP is located the catalytic GAP domain. The 
main mechanisms by which GAPs catalyze GTP hydrolysis comprise the direct 
chemical contribution of the GAP protein to the active site of Ras; and the 
immobilization of G-proteins switch regions. RasGAP stabilizes the catalytically 
important glutamine 61 of Ras and thus the transitional state of the Ras/RasGAP 
complex, which in turns coordinates the attacking water molecule required for the 
GTP hydrolysis to take place. Arginine 789 of RasGAP is positioned into the 
phosphate-binding site neutralizing the emerging negative charge of the α-­‐phosphate 
during hydrolysis of the GTP to GDP. Oncogenic mutations at positions 12 and 13 of 
Ras sterically block the proper orientation of the Arg789 of RasGAP and the Glu61 of 
Ras preventing GTP hydrolysis. RasG12V, RasG13V and RasG61V have therefore 
oncogenic activity.  
 
4.2. RasGAP as a Ras effector and beyond 
Ras is activated through the stimulation of tyrosine kinase/growth factor receptors 
(Lowy and Willumsen, 1993) and regulates diverse cellular responses through 
distinct signaling pathways such as Raf/MAPK/ERK, PI-3K/Akt and 
RASSF/MST1/0032, which are mainly involved in cell survival and proliferation. 
RasGAP binds to activated Ras (Ras-GTP) through its catalytic GAP domain and it is 
sufficient to favour Ras GTPase activity. Moreover RasGAP has an amino-terminal 
region similar in structure to “adaptor” proteins, which may indicate that RasGAP can 
have other functions related or unrelated to its function as a regulator of Ras.  
Aurora Kinase has been identified as a binding partner of RasGAP SH3 domain 
(Gigoux et al., 2002). The human Aurora kinase orthologs (HsAIRK-1 and HsAIRK-2) 
are proteins involved in proper cell division and are thus cell cycle-dependent. The 
activation, de-activation and degradation of these proteins are regulated by 
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phosphorylation (cAMP-dependent protein kinase) and de-phosphorylation (protein 
phosphatase 1) (Walter et al., 2000). Gigoux and collaborators have proposed a  
model in which RasGAP regulates Aurora kinase orthologs by facilitating their 
association with kinases and phosphatases necessary for their regulation, indicating 
that RasGAP can be implicated in proliferation.  
RasGAP and p190-RhoGAP are believed to be implicated in the actin cytoskeleton 
remodelling (Kulkarni et al., 2000). Constitutive association between these two 
GTPases has been reported to be required for turnover and reorganization of stress 
fibers and focal adhesions, independently of Ras activation. In addition RasGAP 
knock out fibroblasts have dramatically reduced cell migration (Bos et al., 2007), 
which implies that RasGAP, although by mechanisms not clearly understood, is 
implicated in cell migration and cytoskeleton remodelling.  
RasGAP plays also a pivotal role in the onset of apoptosis. As mentioned in the 
previous section, p120-RasGAP possesses two conserved caspase-3 cleavage sites 
(Yang and Widmann, 2001). The sequential cleavage of RasGAP in these two sites 
by active caspase-3 will determine cell fate (Figure 5C). At low levels of caspase 
activity, RasGAP is first cleaved at position 455. The N-terminal fragment (fragment 
N) generated by this cleavage induces a protective response against apoptotic 
induced cell death. The signaling pathway that mediates this response is the 
Ras/PI3K/Akt signaling pathway (Yang and Widmann, 2002), which is crucial for cell 
survival in low stress conditions (Yang et al., 2004). However, when activated 
caspase-3 level increases due to a stronger stress condition, fragment N is further 
cleaved at position 157 into fragments N1 and N2, abrogating its anti-apoptotic 
activity (Yang et al., 2005). The capacity of RasGAP to sense the level of stress 
within a cell through caspase-3 activity led us to propose this GTPase as cell death 
versus survival molecular switch (Yang et al., 2004). 
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Figure 5: RasGAP function and structure. A_ Ras cycle of activation and inactivation by the 
Ras-specific Guanine Exchange factor (GEF), SOS, and the Ras GTPase Activating Protein 
(GAP), RasGAP, respectively. B_ RasGAP domain structure. SH2/3: Scr Homology 2 or 3 
domain. PH: pleckstrin homology domain. C2: calcium-dependent phospholipid domain. C_ 
Caspase-3 - dependent sequential cleavage of RasGAP. The level of stress and of caspase-3 
activation is represented by the yellow bar on the left of the figure. Cleavage positions at low or 
high levels of active caspase-3 are represented by the small and big red dots, respectively. The 
numbers indicate the cleavage position 
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 5. Ras/PI3K/Akt: a signaling cascade important for RasGAP derived-fragment 
N induced protection 
The cleavage of RasGAP by caspase-3 at position 455 and the resulting N-terminal 
fragment (hereafter referred to as fragment N) generation are crucial events in the 
protection of cells against apoptotic cell death in vitro (Yang and Widmann, 2001). 
Several evidences indicate that this protective response requires the activation of 
Ras, Phosphatidylinositol-3-kinase (PI3K) and Akt since their corresponding 
dominant negative mutants abrogate completely the inhibitory effect of fragment N on 
apoptosis. Furthermore, constitutively active forms of Ras, PI3K or Akt mimic 
fragment N-mediated protective effects. A further indication comes from the 
overexpression of a caspase-3 insensitive mutant form of fragment N (N-D157A), 
which is able to induce the activation of the aforementioned proteins (Yang and 
Widmann, 2002). 
 
5.1. The Ras/PI3K/Akt signaling  
The activation of Ras/PI3K/Akt signaling cascade is triggered by the engagement of 
the tyrosine kinase receptor to their cognate ligands, which induces the dimerization 
and autophosphorylation at tyrosine residues. Once the receptor has been 
stimulated, PI3K and Ras are recruited to the membrane where they activate a 
number of signaling cascades.  
PI3K is a heterodimeric protein with an 85-kDa regulatory subunit containing two SH2 
domains and a 110-kDa catalytic subunit. Phosphorylated tyrosine residues interact 
with the SH2 domains of the p85 subunit, recruiting PI3K to the membrane together 
with the adaptor protein Grb2. Consequently, Grb2 recruits and activates SOS (GEF 
specific for Ras) inducing the activation of Ras, also recruited to the membrane. 
Finally Ras determines the activation of p110 of PI3K. Activated p110 transfers 
phosphate groups to the membrane phospholipid phosphatidylinositol 3,4-
biphosphate (PIP2) thereby generating the second messenger lipids 
phosphatidylinositol 3,4,5-triphosphate (PIP3). These lipids attract a series of kinases 
bearing PH domains to the plasma membrane such as Akt (or protein kinase B, 
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PKB), phosphoinositide-dependent kinase 1 (PDK1) (Steelman et al., 2011) and 
maybe also mTORC2 (Gan et al., 2011), both kinases responsible for Akt activation 
(Figure 6). 
Akt is a 57 kDa enzyme belonging to the ACG protein kinase family. The Akt family 
includes three isoforms that are highly conserved: Akt1/α, Akt2/β, and Akt3/γ. 
Whereas Akt1 and 2 are ubiquitously expressed, Akt 3 displays a more restrictive 
tissue specific pattern of expression, being found abundantly in the nervous tissue 
(Brazil et al., 2004). All three Akt isoforms share structural homology and contain 
three domains: an N-terminal pleckstrin (PH) domain, a C-terminal regulatory domain 
(RD), and a central kinase domain (KD) (Thomas et al., 2002) (Figure 6). At least two 
residues within Akt are rapidly phosphorylated, including Threonine 308 (T308) which 
lies within the KD and the Serine 473 within the RD. Akt recruitment to the membrane 
promotes its phosphorylation by both PDK1 and mTORC2, the latter being a protein 
complex bearing Rictor, GβL and the mammalian taget of rapamycin (mTOR), a 
conserved Ser / Thr protein kinase (Sarbassov et al., 2005).  
Recent data suggests that not only PIP3 can interact with Akt but also 
phosphatidylserine (PS), another phospholipid highly enriched in the inner leaflet of 
the plasma membrane. The interaction of the RD with either PIP3 or PS induces an 
open conformation of the RD that exposes S473 for phosphorylation by mTORC2. 
Both localization of Akt to the membrane and phosphorylation at S473, promote the 
ability of PDK1 to phosphorylate T308, leading to full activation of Akt (Huang et al., 
2011).	   
After activation, Akt leaves the membrane to phosphorylate up to 100 substrates 
thereby modulating a variety of cellular functions. Akt may translocate to the nucleus 
(Martelli et al., 2006) where it affects either directly or indirectly the activity of various 
transcriptional factors such as CREB (Du and Montminy, 1998), E2F (Brennan et al., 
1997) and NF-κB  (Cheng et al., 2011). Akt stimulates cell proliferation by inactivating 
p27 (Fujita et al., 2002) and preventing the glycogen synthase kinase-3β (GSK3β) - 
mediated Myc and cyclin D1 inhibition (Vivanco and Sawyers, 2002). Additionally Akt 
is one of the main regulators of a complex involved in protein translation and 
ribosome biogenesis; the mTORC1 complex (Guertin et al., 2006). mTORC1 is 
comprised of mTOR and Raptor and is sensitive to rapamycin (in contrast to the 
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mTORC2 complex). Akt positively regulates this complex by phosphorylating two 
different substrates, the GAP TSC2 and PRAS40 (proline-rich Akt substrate of 40 
kDa) leading to inactivation of their functions. TSC2 inhibits the small GTPase, Rheb 
(Ras-homolog enriched in brain), which activates mTORC1. On the other hand 
PRAS40 negatively regulates mTORC1 through competition with Rheb and thus its 
phosphorylation leads to inactivation and release of competition. This dual regulation 
makes Akt the main promoter of the activation of mTORC1 pathway, which turns on 
the translational machinery to produce ribosomes and increases the protein 
synthesis rate (Carracedo and Pandolfi, 2008). Conversely, mTORC1 has been 
shown to inhibit Akt activation by a negative feedback loop mechanism (Carracedo et 
al., 2008).  
Last, but not least, Akt signaling exerts a strong anti-apoptotic effect through the 
phosphorylation of several targets such as the forkhead transcription factors 
(FOXO1/3/4) family and BAD. Phosphorylation causes the association of these pro-
apoptotic proteins with 14-3-3 proteins in the cytoplasm, which induces the export 
from the nucleus (van der Horst and Burgering, 2007) or blockage of mitochondrial 
translocation (del Peso L. et al., 1997), respectively. Another anti-apoptotic Akt target 
is the murine double minute 2 (MDM2), which antagonizes p53-mediated apoptosis 
(Steelman et al., 2011).  
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Figure 6: Akt activation mechanism. Akt is activated in the plasma membrane by a series of 
phosphorylating events. After activation p-Akt detaches from the membrane and activates or 
inhibits a series of proteins leading to various cellular responses. P: phosphate group. Grey 
dashed arrow represents the transition between the inactivated and activated state of Akt. 
Black dashed arrow represents the detachment of already activated Akt from the plasma 
membrane. Downstream Akt targets are highly simplified and represent an example of the wide 
downstream signaling cascade triggered by Akt. 
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6.  Skin: a sophisticated barrier against external insults	  	  
The skin is a sophisticated and dynamic organ that basically serves as a barrier 
between the internal environment and the world outside. Yet, the skin plays many 
important roles in homeostatic and temperature regulation, prevention of loss of 
fluids, electrolytes and proteins, sensory reception and immune surveillance. In fact 
without the skin we would literally evaporate.  
 
6.1.   The skin triple layer: Epidermis, Dermis and Hypodermis.  
The epidermis is the most external surface of the skin and contains mostly 
keratinocytes plus a smaller population of Langerhans cells and melanocytes (Elias, 
2007). The epidermis is composed of 4 to 5 layers in humans (2 to 4 layers in 
mouse), where the outermost one is the stratum corneum (Figure 7). This layer is 
composed of enucleated corneocytes, which are the very last differentiated state of 
keratinocytes. The following layer is the stratum lucidum and, similarly to the stratum 
corneum, is composed of anucleated corneocytes, although this layer is only found in 
palms and soles. The granular layer (stratum granulosum) is just below and is 
composed of keratinocytes containing keratohyalin granules, which promote 
hydration and crosslinking of keratin. The middle layer is the spinous layer (stratum 
spinosum) with desmosomal connections between keratinocytes. Langerhans cells, 
which are immunologically active cells, can be found in this layer. Finally the basal 
layer (stratum basale) is composed mainly of proliferating and non-proliferating 
keratinocytes attached to the basement layer by hemidesmosomes and integrins. 
Most cells within the basal layer are the rapidly dividing progeny of stem cells and are 
referred to as transit amplifying cells which undergo a limited number of divisions 
before they escape the cell cycle and commit to terminal differentiation, detach by 
asymmetric cell division from the basement membrane and begin their way towards 
the surface of the skin	   (Barrandon and Green, 1987; Jones et al., 2007). 
Melanocytes, which are the cells that produce melanin and therefore determine the 
color of the skin, are present in this layer and are connected to keratinocytes through 
dendrites. Merkel cells are also found and are involved in touch sensation (Farage et 
al., 2007).  
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The dermis, separated by the epidermis by a basement membrane, is composed 
mainly of connective tissue and blood vessels (Figure 7). This tissue supports the 
epidermis and contains elastin and collagen, which give the skin its characteristic 
elasticity and tensile strength, respectively. The dermis also contains nerve fibers, 
sensory receptors, hyaluronic acid, responsible for the normal turgor of dermis 
because of its water-holding capacity, and supportive glycosaminoglycans (GAG).  
The hypodermis is located below the dermis and is composed of loose connective 
tissue and subcutaneous fat (Figure 7). It functions as a thermoregulator and 
provides cushioning and stability to the skin connecting the dermis with internal 
organs (Martini F. Fundamentals of Anatomy and Physiology. San Francisco: 
Benjamin-Cummings, 2004).  
 
6.2.    The sun and the skin 
The epidermis is a stratified epithelium in which balanced proliferation, differentiation, 
and cell death are essential for the maintenance of skin organization and function 
(Fuchs and Raghavan, 2002). The epidermis is constantly exposed to external insults 
such as ultraviolet radiation (UVR). UV light is electromagnetic radiation with a 
shorter wavelength than that from visible light (400-780 nm) ranging from 200 nm to 
400 nm and is composed of three fractions (Figure 8A).  
The shorter one is the UV-C light ranging from 200-290 nm, the longer one is the UV-
A light from 320-400 nm and the UV-B that stands midways ranges from 290-320 nm. 
Even though UV-C photons cause the most striking effects and it is used as 
germicidal, they are not relevant for human health since they are absorbed by 
atmospheric layers of oxygen and stratospheric layers of ozone. On the other hand 
UV-A and B radiations do traverse these layers and can elicit acute and chronic 
biological effects (Matsumura and Ananthaswamy, 2004). While the longer but less 
energetic UV-A reaches the basal layer and the deeper dermal compartments 
(Lavker et al., 2003), UV-B light, being more energetic, is scattered and absorbed 
faster within the superficial epidermal layers. A biological effect of UVR is established 
within the skin when chromophores absorb energy that matches their absorption 
maxima. When UV photons strike the skin part of the energy is reflected, but another 
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part is transmitted and finally absorbed. Chromophores are molecules that absorb the 
light energy, resulting in the transition of their electron from the ground state to the 
excited state. Since the depth of penetration through the epidermis varies with the 
different wavelengths, the chromophores affected by UV-A and UV-B are different. In 
this project I was most interested in the keratinocyte response to stress and thus I will 
focus on UV-B light effects.  
 
 
 
 
 
Figure 7: Graphic representation of the skin with a detailed illustration of the epidermis 
composition. Within the epidermis the cells are well interconnected: green structures are 
desmosomes, dark gray represents hemidesmosomes, white coloured are focal adhesions and 
light grey, adherent junctions. This figure was adapted from (Fuchs and Raghavan, 2002). 
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6.3.    UV-B light 
UV-B is one of the main causes of DNA damage in the skin since its main 
chromophores include purine and pyrimidine bases in DNA and RNA with an 
absorption maximum of 200-290 nm. The most common photo-induced reactions in 
DNA bases, called photoproducts, are the (6-4) pyrimidine-pyrimidone [(6-4)PP] and 
cyclobutane pyrimidine dimers (CPD) (Figure 8B). CPDs are the result of a covalent 
linkage between CC or TT bases where UV-B light is absorbed by a double bond in 
pyrimidine bases (thymidine -T- and cytosine -C- in DNA), opening the bond and 
allowing it to react with neighboring molecules. If the neighboring molecule is another 
pyrimidine base they may form a covalent bond resulting in a tight four-membered 
ring (TT or CC dimer) (Figure 8B). Alternatively, (6-4)PP arise from the formation of a 
single bond between the C6 position of the 5’-pyrimidine in an adjacent pair, to the 
C4 position of the 3’-pyrimidine (Friedberg, 2003) (Figure 8B). The presence of these 
lesions in the DNA double helix drastically alters processes such as replication and 
transcription, since they not only represent a physical blockage but can also lead to a 
misspelling of information and apparition of mutations (Batista et al., 2009).  
CPDs and (4-6)PPs are mainly repaired by the Nuclear Excision Repair System 
(NER) machinery that is orchestrated by around 15 proteins. NER first recognizes the 
damage or distortion in the double-helix and a helicase unwind the strand at the site 
of damage. This unwinding is followed by an incision at the 3’ and 5’ ends of the DNA 
strand and removal of around 25-30 nucleotides. The double strand break is then 
filled-in by the DNA polymerase δ or ε resulting in a repaired damage (Fuss and 
Cooper, 2006; Nouspikel et al., 2009). In order to have adequate time for DNA repair, 
cells are arrested at G1 or G2 phases of the cell cycle, both events being modulated 
by the tumor suppressor protein p53 or, the so called “guardian of the genome”. If the 
damage has not been correctly repaired, p53 induces apoptosis or senescence to 
prevent cells with severely damaged DNA from becoming cancerous (Latonen and 
Laiho, 2005) 
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Figure 8: A_ The electromagnetic spectrum. UVR are depicted in light blue. B_ Most common 
photoproduct lesions in the DNA caused upon exposure to UV-B light. This figure was adapted 
from (Batista et al., 2009). 
 
 
 
Other levels of cellular damage induced by UV-B are the so-called “photosensitizers”, 
which are proteins targeted by UV-B. Excitation of these chromophores results in 
their conversion into excited and highly unstable molecules which can transfer the 
energy of the absorbed photon to adjacent molecules (lipids, proteins and nucleic 
acids) or and/or to molecular oxygen, leading to the formation of reactive oxygen 
species (ROS). ROS can then initiate and propagate a complex signal transduction 
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network dictating the fate of keratinocytes (Batista et. al., 2009; Van Laethem et al., 
2005). The skin counteracts with numerous antioxidant defense mechanisms that 
consist of enzymes, such as catalase and gluthatione, and natural antioxidants, like 
the ascorbic acid and α- tocopherol, that will minimize the deleterious effects of ROS. 
Following exposure to UV-B light, if the NER machinery fails to repair excessive DNA 
damage or the endogenous antioxidant defense systems become overwhelmed by 
high production of ROS, cells will become sunburn cells (SBC) (Van Laethem et al., 
2005). SBC exhibit morphologic characteristics of apoptotic cell death with a pyknotic 
(condensed) nuclei and eosinophilic cytoplasm and are basically keratinocytes 
undergoing apoptosis (Saskia Lippens, 2009).   
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OBJECTIVES 
 
Professor Widmann’s laboratory has been studying the role of RasGAP cleavage by 
caspases for many years since they discovered that it has a pivotal role in the 
protection against apoptosis in low stress conditions. In the past few years, they have 
identified that the N-terminal fragment (fragment N) of RasGAP is responsible to 
trigger this protective response by inducing the Ras/PI3K/Akt signaling pathway. At 
present there are two main objectives in the laboratory, which consist of determining 
whether this anti-apoptotic pathway characterized in vitro also plays a role in vivo in 
pathophysiological conditions and to further study the molecular mechanism 
underlying this protective response by deciphering which of the various Akt 
downstream targets could be implicated. 
During my thesis I undertook the following research projects: 
I. Using a mouse model unable to generate fragment N (KI mice), together with a 
caspase-3 knock-out model I have studied the role of the caspase-3 dependent 
RasGAP cleavage-derived fragment N in mouse skin exposed to UV-B light and 
contributed to the study of heart and intestine exposed to doxorubicin and DSS, 
respectively. Understanding the role of fragment N protection in vivo may 
contribute to the discovery of novel anti-apoptotic responses in 
pathophysiological conditions as well as to the characterization of active 
caspase-3 in situations where it does not trigger apoptosis. 
II. Survivin is a member of the IAP family of inhibitors of apoptosis and several 
mechanisms has been proposed for its cyto-protective effect, the majority 
relying on its cytoplasmic localization. In this work, I have characterized the 
localization of survivin induction in the skin upon UV-B exposure within cells and 
within the epidermal layers. Moreover I have studied whether survivin induction 
in the skin was a mere consequence of cell death or if it was an attempt of the 
cells to cope with, and prevent apoptosis. These findings contribute to 
unraveling the role of survivin in cyto-protection in the skin in response to UV-B 
light. 
III. It has been reported that survivin expression is induced by Akt. Considering this 
finding together with results obtained during my work (points I and II) I centered 
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my interest in survivin as a putative Akt target mediating fragment N-dependent 
anti-apoptotic response. I have therefore studied whether fragment N regulated 
survivin expression and function as well as its involvement in fragment N-
mediated protection in the skin using KI mice exposed to UV-B light. This 
research contributes to deciphering the downstream targets of Akt that mediate 
fragment N induced protection. 
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INTRODUCTION 
 
Role of Caspase-3 and RasGAP cleavage in vivo. 
 
As detailed in the general introduction, RasGAP acts as a molecular switch within the 
cells due to it sequential cleavage by active caspase-3 in response to different levels 
of stress. The N-terminal fragment derived from RasGAP first cleavage by low active 
caspase-3 induces a potent anti-apoptotic response that relies on the activation of 
Akt. Further cleavage of the RasGAP N-terminal fragment (fragment N), by high 
levels of active-caspase-3, abrogates this protective signal and the cell eventually 
dies by apoptosis (Yang et al., 2004; Yang and Widmann, 2002; Yang and Widmann, 
2001).  
The overexpression of an uncleavable form of fragment N in vitro protects various 
cell types against different stress stimuli (Yang et al., 2004). Protection induced by 
fragment N was also demonstrated in vivo, using a mouse model in which fragment N 
was overexpressed specifically in pancreatic β-cell (RIP-N transgenic mice). These 
cells were protected against apoptosis without affecting their ability to appropriately 
secrete insulin in physiological conditions and without favoring excessive proliferation 
(Yang et al., 2009). On the other hand, Akt activation has been reported in response 
to UV-B irradiation (Ibuki et al., 2010) and therefore it is attractive to postulate that 
Akt activation in the skin in response to UV-B light depends on fragment N 
generation.  
With the aim of assessing the physiological role of RasGAP cleavage we investigated 
whether mice lacking caspase-3 or unable to cleave RasGAP exposed to diverse 
pathophysiological insults, particularly in the skin exposed to UV-B light, were able to 
activate this potent anti-apoptotic response, relying on Akt activation, described in 
vitro.  
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CONTRIBUTION 
 
This work has been sent for publication to Molecular and Cellular Biology (MCB) and 
it is currently under revision. I performed all the experiments concerning the skin and 
contributed with immunohistochemistry and analysis of phosphorylated Akt in the 
heart and with immunohistochemistry, analysis and quantification of phosphorylated 
Akt in the colon. I contributed with the writing of the manuscript   
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Caspase-3 Protects Stressed Organs against Cell Death
Hadi Khalil,a Nieves Peltzer,a Joël Walicki,a Jiang-Yan Yang,a Gilles Dubuis,a Noémie Gardiol,b Werner Held,b Paul Bigliardi,c*
Benjamin Marsland,d Lucas Liaudet,e and Christian Widmanna
Department of Physiologya and Ludwig Center for Cancer Research of the University of Lausanne,b Faculty of Biology and Medicine, University of Lausanne, Lausanne,
Switzerland, and Department of Dermatology,c, Department of Pneumology,d and Department of Intensive Care Medicine,e Centre Hospitalier Universitaire Vaudois and
University of Lausanne, Lausanne, Switzerland
The ability to generate appropriate defense responses is crucial for the survival of an organism exposed to pathogenesis-inducing
insults. However, the mechanisms that allow tissues and organs to cope with such stresses are poorly understood. Here we show
that caspase-3-knockout mice or caspase inhibitor-treated mice were defective in activating the antiapoptotic Akt kinase in re-
sponse to various chemical and environmental stresses causing sunburns, cardiomyopathy, or colitis. Defective Akt activation in
caspase-3-knockout mice was accompanied by increased cell death and impaired survival in some cases. Mice homozygous for a
mutation in RasGAP that prevents its cleavage by caspase-3 exhibited a similar defect in Akt activation, leading to increased
apoptosis in stressed organs, marked deterioration of their physiological functions, and stronger disease development. Our re-
sults provide evidence for the relevance of caspase-3 as a stress intensity sensor that controls cell fate by either initiating a
RasGAP cleavage-dependent cell resistance program or a cell suicide response.
Executioner caspases mediate cell death during apoptosis (45).Of these, caspase-3 has the ability to cleave the majority of the
caspase substrates (43), and its activity is required for the induc-
tion of cell death in response tomany apoptotic stimuli (1).While
executioner caspases are indispensable for apoptosis, there are sit-
uations when their activation does not lead to death. For example,
healthy dividing cells can weakly activate caspase-3 in response to
mild stresses (47). Caspase-3 also participates, in an apoptosis-
independent manner, in T and B cell homeostasis (35, 46), in
microglia activation (6), in long-term depression (26), and in
muscle (17), monocyte (44), embryonic stem cell (18), and ery-
throid cell (13) differentiation. However, it remains unclear how
activation of caspase-3 under these conditions does not eventually
lead to cell death (1, 24). Cells could have an intrinsic ability to
tolerate low caspase activity by constitutively expressing antiapo-
ptotic molecules, such as members of the inhibitors of the apop-
tosis protein family, or may stimulate antiapoptotic pathways in
parallel to caspase activation (24). Alternatively, the caspases
themselves might activate prosurvival pathways, in particular,
when they are mildly stimulated. Indeed, there is evidence in cul-
tured cells that caspase-3 mediates neuroprotection after precon-
ditioning (30) and that caspase-3 activity turns on the antiapop-
totic Akt kinase following partial cleavage of the RasGAP protein
(47). Other caspase substrates that could potentially induce pro-
tective signals once cleaved include p27kip1 (14), Lyn (28), synphi-
lin-1 (19), and Rb (42), yet the physiological importance of these
cleaved substrates has not been evaluated to date.
In the present study, we have investigated the role played by
caspase-3 and its substrate p120 RasGAP in the induction of the
antiapoptotic Akt kinase in stressed tissues in vivo.
MATERIALS AND METHODS
Caspase-3-KO mice. B6.129S1-Casp3tm1Flv/J caspase-3-knockout (KO)
micewere purchased from the Jackson Laboratory (BarHarbor,ME). The
mice were genotyped using a mixture of the following three oligonucleo-
tides: wild-type sense (GCG AGTGAGAATGTGCAT AAA TTC), wild-
type antisense (GGGAAACCAACAGTAGTCAGTCCT), and caspase-
3-knockout antisense (TGC TAA AGC GCA TGC TCC AGA CTG). The
sizes of the amplified fragments are 320 bp for the wild-type allele and 300
bp for the caspase-3-knockout allele.
Generation of RasGAPD455A-knock-in (KI)mice.The strategy and
methods used to create the targeting vector are presented in Fig. S1 in the
supplemental material.
UV-B exposure and isolation of skin samples.Mice were shaved on
both flanks, followed by depilationwith depilatory cream (Veet), and 48 h
later were anesthetized and illuminated with a Waldmann UV801 KL
apparatus equippedwith a PhilipsUV21UV-B lamp (TL 20W/12RS). The
doses of UV-B illumination were 0.05 and 0.3 J/cm2 (i.e., 50 mJ/cm2
and 300 mJ/cm2, respectively), which were measured with a Waldmann
Variocontrol dosimeter. In each case, only one side of the mouse was
illuminated and the other side was used as a control (i.e., nonexposed
skin). Mice were sacrificed 24 h after illumination. The lateral skin biopsy
specimens (approximately 2 by 2 cm)were excised fromeachmouse, fixed
in phosphate-buffered saline (PBS) and 4% Formol solution, and embed-
ded in paraffin. The paraffin-embedded skin was cut into 4-m sections,
deparaffinized, and stained with hematoxylin-eosin for histological ob-
servation.
Doxorubicin injection and hemodynamic measurements using left
ventricular PV microcatheters. Eight-week-old mice were weighed and
injected with a single intraperitoneal doxorubicin dose of 20 mg/kg of
body weight using a 2-mg/ml doxorubicin solution (catalog number
733857-01EBEWE; Pharma) or injected with an equal volume of saline
(catalog number 534534; B. Braun Medical AG). At 5 days postinjection,
the animals were weighed again (the weight loss at that time was between
10 and 15%). The animals were anesthetized with an intraperitoneal in-
jection of 75 mg/kg ketamine and 10 mg/kg xylazine (the volume of in-
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jection was 10 l per g of mouse). A pressure-volume (PV) SPR-839
catheter (Millar Instruments, Houston, TX) was inserted into the left
ventricle (LV) via the right carotid artery. After stabilization for 20 min,
heart rate, LV systolic and end-diastolic pressures, and volumesweremea-
sured, and stroke volume, ejection fraction, and cardiac output were cal-
culated and corrected according to in vitro and in vivo volume calibrations
with a cardiac PV analysis program (PVAN3.2; Millar Instruments) (38,
39). End-systolic LV PV relationships were assessed by transiently reduc-
ing venous return by compressing the inferior vena cava, and LV contrac-
tility was assessed from the slope of the LV end-systolic PV relationship
(end-systolic elastance), calculated using PVAN3.2, as detailed previously
(21, 38). Hearts were isolated, cut into two pieces, and then either snap-
frozen or fixed in 4% formalin for histology studies.
DSS-induced colitis and clinical score. Eight-week-old mice were
given acidified water supplemented with 5% (wt/vol) dextran sodium
sulfate (DSS; molecular weight, 400,000 to 600,000; MP Biomedicals,
Illkirch, France) for 72 h and then given normal drinking water for four
additional days. Mice were examined daily, and body weight, water con-
sumption, occult blood, and diarrhea weremeasured. At day 7, mice were
sacrificed, the colon length was measured, and a clinical score was esti-
mated according to the procedure described by Ohkawara et al. (36).
Percentage of weight loss was calculated by comparing the weight at day 0
and the weight of the mice at sacrifice. Scores were given according to
the extent of weight loss: 0, no weight loss; 1, 1 to 5%; 2, 5 to 10%; 3, 10
to 15%; 4, 15%. Diarrhea was scored using a scale with values rang-
ing from 0 to 4: 0, normal; 1, slightly loose feces; 2, loose feces; 3, semi-
liquid stool; and 4, liquid stool. Fecal occult blood was detected using
guaiac paper (ColoScreen Hemocult kit; Helena Labs, Beaumont, TX),
and the associated scores were as follows: 0, none; 2, positive Hemocult
result; and 4, gross bleeding. Colons were cut into three equal portions
(proximal,middle, and distal), and each portionwas further cut into three
equal parts, two of which were snap-frozen in liquid N2 and stored at
80°C for subsequent protein and RNA analysis, and the third portion
was fixed in 4% formalin for histology analysis (paraffin sections).
Quantitation of active Akt- and active caspase-3-positive cells in
heart, skin, and colon. Sections stained as described in the previous sec-
tions were scanned using an automated Nikon Eclipse 90i microscope
equipped with Apo Plan 20 (0.75 pH 2 PM) and Apo Plan 40/1.0
DIC-H objectives and piloted with NIS-Elements Advance Research soft-
ware (Nikon Instruments Inc., Melville, NY).
Three whole-heart sections were scanned at different levels, and the
corresponding whole-section images were generated. The number of
pAkt-positive cells was scored manually by counting the number of cells
stained with the anti-phospho-Akt antibody (the samples were random-
ized prior to examination, and the person performing the counting was
not aware of the experimental conditions). The total number of cells was
determined by automatically scoring the number of nuclei (stained with
the Hoechst 33342 dye) using the NIS-Elements AR program (Nikon). In
order tominimize errors, all images were acquired with the same contrast
(high), size and quality (1280 960), exposure time (4=,6-diamidino-2-
phenylindole [DAPI], 40 ms; fluorescein isothiocyanate [FITC], 300 ms),
and gain (1). The quantification threshold in the automated measure-
ment menu was set at L32 for low and H236 for high, and the area was
restricted to 0 to 0.5m2out. In the imagemenu, the local contrast was set
to 30, and in the image-background option, the background was set to 40
forDAPI and to 999 for FITC.Using the binarymenu, the holeswere filled
using the fill holes option. This was performed to avoidmultiple counting
of the same nucleus. Touching nuclei were separated using the morpho
separate objects option. The number of nuclei was displayed under auto-
matedmeasurement results—object data. Skin sectionswere scanned and
analyzed similarly. Fifteen different fields were randomly taken from the
proximal, middle, and distal sections of the colon and processed and
analyzed as described above.
Apoptosis scoring. Apoptosis on histological slides was assessed by
terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end la-
beling (TUNEL) assay (DeadEnd Fluorometric TUNEL system; catalog
number G3250; Promega Switzerland), as per the manufacturer’s proto-
col, and quantitated as described for the Akt staining in the previous
section. Apoptosis in vitro countingwas assessed by scoring the number of
cells with pycnotic or fragmented nuclei after Hoechst 33342 staining
(48).
Chemicals and antibodies. The Q-VD-OPh caspase inhibitor was
from MP Biomedicals (catalog number OPH109). Hexameric FasL (fu-
sion protein between the Fas ligand and the Fc portion of IgG1) (20) was
a kind gift from Pascal Schneider (University of Lausanne). The mono-
clonal and polyclonal anti-phospho-Ser473 Akt antibodies and the
cleaved caspase-3-specific antibody were from Cell Signaling Technology
(catalog numbers 4051, 9271, and 9664, respectively). The monoclonal
anti-phospho-Ser473 Akt antibody was used on skin and colon sections as
well as for Western blot assays, while the polyclonal anti-phospho-Ser473
Akt antibody was used on heart sections. The antibody recognizing total
Akt was from Santa Cruz (catalog number sc-8312). The anti-RasGAP
antibody was from Enzo Life Science (catalog number ALX-210-860-
R100). Secondary antibodies (Cy3-coupled donkey anti-rabbit, horserad-
ish peroxidase [HRP]-coupled donkey anti-rabbit, and HRP-coupled
donkey anti-mouse antibodies) were from Jackson Immunoresearch (cat-
alog numbers 711-165-152, 715-035-150, and 715-035-150, respectively).
Protein extraction. Snap-frozen skin (0.3-cm2 biopsy specimens),
heart, and intestine tissue samples were crushed into powder in liquid
nitrogen-dipped mortar and pestle and then suspended in 700 l lysis
buffer (Tris-HCl, 50mM; EDTA, 1mM; EGTA, 1mM; Triton X-100, 1%;
dithiothreitol, 1 mM; sodium pyrophosphate, 5 mM; NaF, 50 mM; pro-
tease inhibitor cocktail tablet [1 tablet/40 ml buffer; catalog number 04
693 132 001; Roche; phenylmethylsulfonyl fluoride, 1 mM; glycerol,
10%; pH 7.4). The samples were sonicated (amplitude, 80%; 5 s; twice).
Protein concentration was measured by the Bradford assay using bovine
serum albumin (BSA) as a standard. Lysates were mixed with an equal
volume of sample buffer (62.4 mM Tris-HCl [pH 6.8], 10% glycerol, 5%
[vol/vol] -mercaptoethanol, 2% [wt/vol] sodium dodecyl sulfate [SDS],
and 0.01% bromophenol blue) and boiled for 5 min at 95°C before load-
ing on SDS-polyacrylamide gels.
Western blotting.Western blottingwas performed and quantitated as
described previously (31).
Preparation of tissue section and immunohistochemistry. Mice
were euthanized by cervical dislocation. The isolated organs (heart, skin,
or intestine) were stored in PBS–4% Formol solution and embedded in
paraffin. Four-micrometer sections were deparaffinized in toluene (cata-
log number 488555; Carlo Erba, Milan, Italy) and rehydrated using
graded alcohol and distilled water. Antigen retrieval was performed by
immersing sections in sodium citrate buffer (10 mM sodium citrate, pH
6), followed by heating in a microwave oven for 20 min (8 min at 800 W
and 12 min at 400 W). Sections were cooled to room temperature and
blocked using a 50 mM Tris-HCl, pH 7.6, 0.5% Tween 20, 0.2% BSA
solution. The primary antibody was diluted (pAkt, 1/100; cleaved
caspase-3, 1/200) in 50 mM Tris-HCl, pH 7.6, 0.5% Tween 20, 0.2% BSA
and incubated with the slides for 1 h. Slides were washed 2 times for 10
min each time in 50 mM Tris-HCl, pH 7.6, 0.5% Tween 20. The fluoro-
chrome-conjugated secondary antibody (Jackson Laboratory), diluted
1:300 in 50 mM Tris-HCl, pH 7.6, 0.5% Tween 20, 0.2% BSA, was incu-
bated with the slides for another hour in the dark. Slides were then exten-
sively washed (at least 6 times with one overnight washing step). The
nuclei in the sections were then stained with 10 g/ml Hoechst 33342.
Finally, the slides were mounted in Mowiol (catalogue number 81381;
Fluka) at a concentration of 0.1mg/ml in a solutionmade of 20% glycerol
and 0.1%DABCO (diazobiciclo-octane; catalogue number 33480; Fluka).
Immunohistochemistry with tyramide signal amplification. Tyra-
mide amplification of immunohistochemical signals using phospho-Akt-
specific antibodies was performed as described earlier (4). The primary
antibody and the secondary HRP antibody were diluted 1/100 and
1/1,000, respectively.
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Ethics statement. Experiments on the mice were carried out in strict
accordance with the Swiss Animal Protection Ordinance (OPAn). The
protocol was approved by the Veterinary Office of the state of Vaud,
Switzerland (permit numbers 2055, 2056, and 2361).
MEF preparation.Mouse embryonic fibroblasts (MEFs) from KI and
wild-type mice were initially prepared as described earlier by digesting
embryonic day 14 embryos for 1.5 h in 0.05% trypsin (5). Using this
protocol, MEFs could be generated from wild-type embryos, but none
were obtained from the KI embryos (Fig. 5C). Reducing the incubation
time in trypsin to 15 min, which presumably lessened a stressful situation
on cells, however, allowed production of both wild-type and KI MEFs in
more or less similar numbers (Fig. 5C).
Statistics. SAS/STAT (version 9.1) software (SAS Institute Inc., Cary,
NC) was used to perform the statistical analyses. Unless otherwise stated,
one-way analyses of variance were performed to determine the signifi-
cance of the observed differences presented in the figures. Asterisks and
NS in the figures indicate significant differences (P 0.05) and no signif-
icant differences, respectively.
RESULTS
Mice lacking caspase-3 are impaired in their capacity to activate
Akt in response to stress. Akt (also called PKB) is a downstream
effector of phosphatidylinositol 3-kinase (PI3K) thatmediates the
survival responses of many cell types and tissues (40) and as such
could be involved in stress survival responses across most, if not
all, tissues. To determine whether Akt is activated in various tis-
sues and organs in response to pathology-inducing stresses, mice
were exposed to three different challenges: exposure of the skin to
UV-B, injection of doxorubicin (an anticancer drug inducing car-
diomyopathy), and administration of dextran sulfate sodium
(DSS) via drinkingwater to induce colitis. In control skin, very few
keratinocytes (0.25%) expressed the active phosphorylated
form of Akt (Fig. 1A). In response to mild UV-B exposure (0.05
J/cm2), more than 10% of the keratinocytes had active Akt in their
cytoplasm (Fig. 1A). In the hearts of untreatedmice, cells express-
ing activated Akt were readily observed. Virtually all of these cells
were cardiomyocytes, as determined by their shape and nucleus
location (Fig. 1B). Under basal conditions (i.e., no treatment), the
percentage of cardiomyocytes with active Akt was much higher
(6%) than that in the epidermis. Doxorubicin increased this
percentage in a statistically significant manner to10% (Fig. 1B,
gray bars). Akin to the situation encountered in the skin, very few
cells in the colon epithelium (0.7%) were found to be positive
for active Akt (Fig. 1C). This percentage significantly increased to
1.2% when colitis was induced by DSS (Fig. 1C, gray bars).
To determine whether Akt activation was dependent on
caspase-3, we analyzed caspase-3-KO mice on the C57BL6 back-
ground that had reached adulthood and bred (25). When the skin
of these mice was exposed to UV-B, the number of keratinocytes
with active Akt increased (Fig. 1A, lower right), suggesting that a
caspase-3-independent mechanism can participate in the induc-
tion of protective signals in the epidermis. However, the UV-B-
induced increase in the percentage of active Akt-positive kerati-
nocytes in caspase-3-KOmicewasmuch reduced compared to the
situation observed in wild-type mice, and the increase was not
statistically significant (Fig. 1A, black bars). This indicates that
caspase-3 is required for a maximal Akt response in keratinocytes
subjected to UV-B illumination. When caspase-3-KO mice were
treated with doxorubicin or DSS, the percentage of cells with ac-
tive Akt in the targeted organs did not change compared to the
nonchallenged situation (compare the gray and black bars in
Fig. 1B andC), indicating that caspase-3 is strictly required for Akt
activation in these tissues exposed to stress. To determine if stim-
ulation of caspase-3 activity and not some other noncatalytic
functions of the protease is necessary for stress-induced Akt acti-
vation, wild-type mice were injected with Q-VD-OPh, a broad-
spectrum caspase inhibitor (10). Figures 2A and B show that this
compound inhibited UV-B-induced caspase-3 activation in the
skin. Q-VD-OPh was found to significantly decrease the ability of
epidermal cells to stimulate Akt in response to UV-B (Fig. 2C),
indicating that activation of caspases is required for the induction
of the antiapoptotic Akt kinase in response to stress.
Increased stress-induced cell death and cell damage in mice
lacking caspase-3. Impaired Akt activation in caspase-3-knock-
FIG 1 Defective stress-induced Akt activation in mice lacking caspase-3. The
indicated numbers of wild-type (WT) and caspase-3-knockout (C3 KO) mice
were subjected or not to illumination of their skin with 0.05 J/cm2 UV-B (A; 2
independent experiments), injection of 20mg/kg doxorubicin (DOXorDoxo)
(B; 2 independent experiments), or exposure to 5%DSS in the drinking water
(C; 3 independent experiments) (seeMaterials andMethods for details). (A to
C) Histological sections of the organs and tissues targeted by these stresses
were then stained with an antibody recognizing the active phosphorylated
form of Akt, and the percentage of phospho-Akt (pAkt)-positive cells was
quantitated. Results correspond to themean	 95%CI. The images shown are
representative examples of sections labeled with the anti-phospho-Akt anti-
body (red or green staining) and with Hoechst 33342 (blue staining of the
nuclei). Bars, 20 m.
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out mice may not lead to visible damage of the targeted tissues if
the absence of caspase-3 prevents implementation of a cell death
response. There are indeed situations where caspase-3 is manda-
tory for cell death. For example, beta cells from caspase-3-KO
mice are fully resistant against streptozotocin-induced death,
while beta cells from wild-type mice are not, leading to the devel-
opment of diabetes (27). In other situations, cell death may still
occur in the absence of caspase-3, either as a result of a nonapop-
totic type of death or because apoptosis is mediated by other exe-
cutioner caspases (e.g., caspase-7). In such cases, the absence of a
caspase-3-mediated Akt activationmight have detrimental conse-
quences. To assess this point, we monitored the extent of stress-
induced cell death in the skin and the heart of caspase-3-KO and
wild-type mice.
In the skin of wild-typemice, UV-B induced the appearance of
keratinocytes with a pycnotic nucleus and densely staining glassy
cytoplasm—the so-called sunburn cells (see the inset in the lower
left-hand panel in Fig. 3A)—which are apoptotic cells character-
istic of those in damaged skin following UV exposure (12). The
percentage of sunburn cells generated by UV-B in the skin of
caspase-3-KOmice was significantly reduced compared to that in
the skin of wild-type mice (Fig. 3A). Similarly, there were fewer
TUNEL-positive keratinocytes in the UV-B-illuminated skin of
caspase-3 mice than in the skin of wild-type mice (Fig. 3B). This
indicates that caspase-3 is a main mediator of UV-B-induced
keratinocyte apoptosis. Cells can also die in a necrosis-like, nonapo-
ptotic manner, in particular, when apoptosis pathways are altered
(41). Keratinocytes dying in this way are characterized by their
irregular shape, an eosinophilic cytoplasm, and hyperchromatic,
condensed, and partly fragmented nuclei (3) (see the inset in the
lower right-hand panel in Fig. 3A). UV-B dramatically increased
the percentage of keratinocytes undergoing this type of death in
the skin of caspase-3-KO mice compared to the skin of wild-
type mice (Fig. 3A). When accounting for both apoptosis and
necrosis-like deaths, there was more UV-B-mediated death re-
corded in the skin of caspase-3-KO mice than in the skin of
wild-type mice (8.1 	 2.5% versus 4.9 	 1.2%; mean 	 95%
confidence interval [CI]).
Doxorubicin is a DNA-intercalating drug that induces both
caspase-dependent and -independent cell death in various cell
types (29), including cardiomyocytes (51). In response to doxo-
rubicin injection, the percentage of cardiomyocytes undergoing
apoptosis, as assessed with the TUNEL assay (see a representative
example on the left-hand side of Fig. 3C), was significantly higher
in caspase-3-KO mice than wild-type mice (Fig. 3C). It therefore
appears that apoptosis induced by doxorubicin can be efficiently
mediated by executioner caspases other than caspase-3, which is
consistent with the observation that doxorubicin efficiently acti-
vates caspase-7 (11).
The increased susceptibility of caspase-3-KO mice to doxoru-
bicin-induced cardiomyocyte apoptosis raised the possibility that
the lack of caspase-3 affects survival of mice treated with doxoru-
bicin. Figure 3D shows that caspase-3-KOmice survived doxoru-
bicin treatment less efficiently than wild-type mice. This suggests
that caspase-3 mediates a protective response in doxorubicin-
treated animals that is required to counteract tissue damage in-
duced in a caspase-3-independent manner.
In conclusion, the results presented in Fig. 1 to 3 show that,
upon stress exposure, mice lacking caspase-3 are defective in the
activation of the prosurvival Akt kinase and that this correlates
with increased cell death, tissue damage, and even death of the
animals.
Generation ofmice expressing a caspase-3-resistant RasGAP
mutant. In vitro, low caspase-3 activity leads to the cleavage of the
RasGAP protein into an amino-terminal fragment, called frag-
mentN, that stimulates Akt in aRas/PI3K-dependentmanner (47,
50), preventing further caspase-3 activation and apoptosis (47). In
the presence of high caspase-3 activity, fragment N is further
cleaved into two additional fragments (fragmentsN1 andN2) that
are unable to activate Akt (48).Notably, this second cleavage event
does not take place if the first cleavage is prevented (49). Further,
in the absence of caspase-3 in cells, other executioner caspases,
such as caspase-6 and caspase-7, cannot cleave RasGAP (47).
RasGAP is therefore a specific caspase-3 substrate. To assess the role
of fragment N in Akt stimulation in stressed organs, we generated
a KI mouse in which the first RasGAP cleavage site recognized by
caspase-3 was destroyed by an aspartate-to-alanine substitution at
position 455 (DTVA[455]G) (Fig. 4A and B); the construction of
the targeting vector is shown in Fig. S1 in the supplemental mate-
rial, and genetic analyses of the resultingmice are shown in Fig. 4B
and C. This mutation does not affect the function of full-length
RasGAP (47). Mice homozygous for the RasGAPD455A allele (KI
mice) are viable and fertile, grow normally (Fig. 4D), and show no
obvious morphological alterations (Fig. 4E), histologic defects
(data not shown), or hematologic abnormalities (see Table S1 in
the supplemental material). Expression of RasGAP, caspase-3,
Akt, and actin was similar in given tissues and cells derived from
wild-type and KI mice (Fig. 4F). The transmission of the mutated
alleles occurred with normal Mendelian ratios (among 317 off-
FIG 2 Pharmacological inhibition of caspases hampers UV-B-induced Akt
activation in the epidermis.Wild-typemice were injected or not with 50mg of
the Q-VD-OPh caspase inhibitor per kg of mouse 15 min prior to UV-B ex-
posure of the skin (0.3 J/cm2 [A and B] and 0.05 J/cm2 [C]). (A) Levels of
cleaved active caspase-3, full-length inactive caspase-3, and actin were assessed
by Western blotting. This experiment was repeated once with similar results.
(B) Levels of active caspase-3 in situ were also visualized by immunofluores-
cence. Bar, 20 m. The pictures are representative images of data obtained
with three mice per condition. (C) Levels of phosphorylated Akt were assessed
as described in Fig. 1. Results correspond to the mean	 95%CI of 3 indepen-
dent experiments (n 3).
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spring obtained from breeding heterozygote 
/D455A mice,
22.4%were
/
, 54.3%were
/D455A, and 23.7%were D455A/
D455A).
As expected, fibroblasts derived from KI embryos were unable
to cleave RasGAP in response to various apoptotic stimuli
(Fig. 5A) and were more prone to apoptosis in response to these
stimuli than control MEFs (Fig. 5B). Additionally, in contrast to
what was observedwithwild-type embryos, cells fromKI embryos
did not survive long-term trypsin digestion (Fig. 5C). MEFs from
KI embryos were also impaired in their capacity to activate Akt in
response to stress (Fig. 5D). The increased susceptibility of KI cells
to death in response to stresses is consistent with the known ability
of fragment N to stimulate Akt and inhibit apoptosis in cultured
cell lines (47, 49, 50).
Mice that cannot cleaveRasGAPatposition455 areunable to
activate Akt in response to stress, and they experience increased
apoptosis, tissue damage, and organ dysfunction. The KI mice
were thenused to assess the importance of RasGAP cleavage inAkt
activation and in the protection of tissues and organs upon expo-
sure to the pathophysiological challenges described for Fig. 1. In
response to low UV-B exposure (0.05 J/cm2), Akt was activated in
about 10% of keratinocytes of wild-type mice (Fig. 6A). Akt acti-
vation was, however, not observed when the skin was exposed to
higher UV-B doses (0.3 J/cm2) (Fig. 6A) that led to strong
caspase-3 activation (Fig. 6B). It is known that low caspase-3 ac-
tivity leads to fragmentN generation, while high caspase-3 activity
induces fragment N cleavage into fragments that are no longer
able to activate Akt (48). In skin samples, all the RasGAP antibod-
ies that we have tested lit up bands in the 35- to 55-kDa range,
precluding visualization of fragment N (52 kDa) (Fig. 6C). These
bands may be nonspecifically recognized by the RasGAP antibod-
ies, but it is more likely that they correspond to RasGAP degrada-
tion products that are generated in keratinocytes en route to their
final differentiation stage in the cornified layer, a process that is
known to be associated with massive activation of epidermal pro-
teases (8). Fragment N2, one of the caspase-3-generated products
of fragment N (49), was, however, seen in samples derived from
skin exposed to 0.3 J/cm2 UV-B but not in samples derived from
skin exposed to 0.05 J/cm2 UV-B (Fig. 6C). These results indicate
that Akt is not activated under conditions where fragment N2 is
produced, i.e., when fragment N is degraded. In contrast to what
was observed inwild-type skin, lowdoses ofUV-Bonlymarginally
and nonsignificantly activated Akt in keratinocytes from KI skin
(Fig. 6A). This correlated with increased numbers of cells express-
ing active caspase-3 (Fig. 6B) and cells undergoing apoptosis (Fig.
6D). When the skin was exposed to higher UV-B doses (0.3
FIG3 Increased stress-induced cell death and cell damage inmice lacking caspase-3. (A)Histological assessment of sunburn (black arrow) and necrotic-like (red
arrows) cells in the epidermis (left and middle) of UV-B (0.05-J/cm2)-irradiated mouse skin. Results correspond to the mean 	 95% CI of measurements
performed on 3 and 8 control and irradiated animals, respectively. Bar, 20m. (B) Quantitation of TUNEL-positive keratinocytes following UV-B (0.05-J/cm2)
irradiation. Results correspond to the mean	 95% CI (3 animals per condition). (C) Apoptosis assessment by the TUNEL assay in cardiomyocytes from mice
injected with 20mg/kg doxorubicin 5 days earlier. A representative example of an apoptotic cardiomyocyte is shown on the left. Bar, 10m. Results correspond
to the mean	 95% CI (3 animals per condition). (D) Survival curves of 6 wild-type and 7 caspase-3-KOmice injected with 20 mg/kg doxorubicin (8 wild-type
and 11 caspase-3-KO mice were used in the control noninjected groups). A Wilcoxon test of equality over strata (life-test procedure) was used to assess the
significance of the observed difference.
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J/cm2), the extent of apoptosis in the skin ofwild-type andKImice
was not significantly different, although there was a trend of a
stronger apoptotic response in KI mice (Fig. 6D) that correlated
with a tendency of KI mice to activate less Akt (compare the last
two bars in Fig. 6A) but more caspase-3 (Fig. 6B) at high UV-B
doses. Sunburn cells (see the example in Fig. 6E) were significantly
augmented in the epidermis of 0.05-J/cm2 UV-B-exposed KI skin
compared to wild-type skin (Fig. 6E). The observed difference at
higher UV-B doses (0.3 J/cm2) was, however, not statistically sig-
nificant.
Doxorubicin induced the cleavage of RasGAP into fragment N
in the heart of wild-type mice (Fig. 7A). As expected, this was not
observed in KI mice (Fig. 7A). Following doxorubicin injection,
the number of cardiomyocytes with activated Akt did not increase
in KI mice (Fig. 7B). This was also associated with an increase in
the number of apoptotic cells in the heart (Fig. 7C). In response to
doxorubicin, KImice hadmore impaired cardiac function asmea-
sured by hemodynamic parameters (see Table S2 in the supple-
mental material). Specifically, end-systolic elastance, which is de-
rived from end-systolic pressure volume curves (Fig. 7D) and
which is a direct (load-independent) measure of the heart con-
tractile activity, was significantly decreased inKImice treatedwith
doxorubicin (Fig. 7D and E).
Finally, enterocytes from KI mice were also affected in their
capacity to activate Akt in response to DSS (Fig. 8A), and this was
accompanied by an increased apoptotic response compared to
FIG4 Generation of RasGAPD455A/D455A knock-inmice. (A) The targeting vector consists ofmouse RasGAP exons 9, 10, and 11. Exon 10 (indicated in red) bears
the RasGAPD455Amutation. E, X, and B. EcoRV, XhoI, and BamHI, respectively; gray bars below the alleles, length of the BamHI/EcoRV fragments recognized
by the probe (black bar) when genotyping by Southern blot is performed. (B) Detection of the D455A allele by PCR. The D455A allele bears a new NgoMIV
restriction site encompassing the aspartate-to-alanine mutation (in red) within the caspase recognition site in RasGAP (in green). Genomic DNAwas subjected
to PCR amplification using primers flanking exon 10. The amplified fragments, after digestion with NgoMIV or not, were separated on a 1.5% agarose gel. The
presence of theD455Amutation results in cleavage of the600-bpPCR fragment into two comigrating300-bp fragments. (C) Tail-purified genomicDNAwas
digested with EcoRV and BamHI and tested by Southern blotting using the probe shown in panel A. (D) The body weight of wild-type and RasGAPD455A/D455A
knock-inmales wasmonitored at the indicated time points. Results correspond to themean	 95%CI of at least 9 determinations per condition. (E) Images from
anesthetized 10-week-old mice. (F) The expression of RasGAP, caspase-3, Akt, and actin in the indicated cell type and tissues was assessed by Western blotting.
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what was seen in wild-type mice (Fig. 8B). At the clinical level,
DSS-induced colon damage was more pronounced, as assessed by
colon shortening (Fig. 8C) and a more severe DSS-mediated coli-
tis development in KI mice than wild-type mice (Fig. 8D).
DISCUSSION
The role of caspase-3 in the induction of the antiapoptotic Akt
kinase was investigated in adult caspase-3-knockout mice in rela-
tion to three different pathophysiological conditions: UV-B skin
exposure, doxorubicin-induced cardiomyopathy, andDSS-medi-
ated colitis. Each of these stresses led to Akt activation in the tis-
sues affected by the stress. This was, however, blocked or strongly
compromised in mice lacking caspase-3. This impaired Akt acti-
vation correlated with augmented cell death, tissue damage, and
even lethality. A similar defect inAkt activationwas observed inKI
mice that expressed a caspase-3-resistant form of p120 RasGAP,
and this was accompanied by increased apoptosis and stronger
adverse effects: increased number of sunburn cells in UV-B-ex-
posed skin, decreased heart function upon doxorubicin injection,
and strongerDSS-mediated colitis development. This study there-
fore identifies a physiological protective mechanism against stress
that relies on the activity of an executioner caspase.
Caspase-3 is now known to mediate many nonapoptotic func-
tions in cells (15, 23, 24). It is involved in B cell homeostasis by
negatively regulating B cell proliferation following antigen stimu-
lation (46). Caspase-3 is also activated during T cell stimulation
(32), and this may participate in T cell proliferation (2, 22). Addi-
tionally, caspase-3 is required for erythropoiesis (9). There is thus
evidence that caspase-3 plays important functional roles in non-
dying hematopoietic cells, but it remains unclear how these cells
counteract the apoptotic potential of caspase-3. Cleavage of
RasGAP could have been one of the mechanisms allowing these
cells to survive following caspase-3 activation. However, T and B
cell development occurs normally in the D455A RasGAP KI mice
(see Table S1 in the supplemental material). Similarly, the devel-
opment of mature myeloid and erythroid lineage cells in the bone
marrow proceeds normally in the KI mice (see Table S1 in the
supplemental material). Therefore, hematopoietic cells use pro-
tective mechanisms other than those activated by the cleavage of
RasGAP to inhibit apoptosis if caspase-3 is activated during their
development.
Caspase-3 is necessary for the development of several tissues.
Muscle development and osteoblast differentiation are compro-
mised in the absence of caspase-3 (17, 33, 34). Caspase-3 also plays
FIG 5 MEFs from RasGAPD455A/D455A knock-in mice do not cleave RasGAP and are more sensitive to apoptosis. (A and B)Wild-type (WT) and KI MEFs were
left untreated () or treated with 15Mcisplatin (Cis), 96 J/m2UV-C (UV), 15 ng/ml FasL (F), and 15 nM staurosporine (St). (A) Cells were lysed 24 h later and
analyzed byWestern blotting for the presence of RasGAP and its fragments using an anti-RasGAP polyclonal antibody. (B) Alternatively, apoptosis was scored.
Results correspond to the mean	 95% CI of 3 independent experiments (n 3). (C) Mouse embryonic cells 1 day after their isolation using a trypsinization
period of 1 h 30 min or 15 min (see Materials and Methods for details). (D) Wild-type and KI MEFs were treated with 5 ng/ml FasL for the indicated periods of
time. Cells were then washed twice with PBS and then incubated for an additional hour in Dulbecco modified Eagle medium at 37°C before lysis. Akt activation
and total Akt expression were assessed by Western blotting.
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important functions in neurogenesis, synaptic activity, neuronal
growth cone guidance, and glial development (7, 16, 37). Histo-
logical analyses of muscle, bone, and brain tissues did not reveal
any defect in theKImice (data now shown).Moreover, the growth
curve and size of wild-type and KImice were comparable (Fig. 4D
and E). Hence, the mechanisms allowing tissues and organs to
withstand caspase-3 activation during development do not rely on
RasGAP cleavage and remain to be characterized.
In vitro data provided evidence that low caspase-3 activity in-
duced bymild stress generates fragment N, which was responsible
for Akt activation and promotion of cell survival. At higher
caspase-3 activity induced by stronger insults, fragment N is fur-
ther processed into fragments that can no longer stimulate Akt,
and this favors apoptosis (47). The data obtained in vivo in UV-
B-exposed skin are consistent with thismodel. Low doses of UV-B
induced no further cleavage of fragment N (i.e., no production of
fragment N2) in keratinocytes, and this was accompanied by Akt
activation and absence of an apoptotic response. In contrast, high
UV-B doses generated fragment N2 and Akt was no longer acti-
vated, and this led to keratinocyte cell death (Fig. 6). In vivo, there-
fore, RasGAP also functions as a caspase-3 activity sensor to de-
termine whether cells within tissues and organs should be spared
or die.
The levels of caspase-3 activation that are required to induce
partial cleavage of RasGAP into fragment N are at least an order of
magnitude lower than those necessary to induce apoptosis (48). In
vitro, these low caspase activity levels are not easily detected (47).
In response to the stress stimuli used in the present study that led
to Akt activation, we could not visualize low caspase-3 activation
byWestern blotting in any of the tissues investigated, although in
response to stronger stresses that did not lead to Akt activation
(e.g., 0.3 J/cm2 of UV-B; Fig. 6), caspase-3 activation could be
evidenced (Fig. 2A and B). Nonetheless, blocking caspases with
chemical inhibitors or usingmice lacking caspase-3 preventedAkt
activation induced by low stresses (Fig. 1 and 2). Therefore,
caspase-3 exerts an important protective function in tissues and
FIG 6 Role of RasGAP cleavage in UV-B exposed skin. Skin of wild-type (WT) and RasGAPD455A/D455A (KI) mice was exposed to the indicated doses of UV-B.
Mice were sacrificed 24 h later, and the exposed skin was isolated for biochemical and histological analyses. (A and B) Histoimmunofluorescence detection and
quantitation of active Akt (A) and active caspase-3 (B). Results correspond to the mean 	 95% CI of measurements performed on 4 to 6 animals (three
independent experiments). (C) Western blot analysis of RasGAP cleavage (the blot shown is representative of three independent experiments). (D) Assessment
of apoptosis by the TUNEL assay. Results correspond to the mean	 95% CI of measurements performed on 5 to 9 animals (three independent experiments).
(E) Histological assessment of sunburn cells in the epidermis. Results correspond to the mean	 95% CI of measurements performed on 9 to 11 animals (three
independent experiments). Cells indicated by light blue arrowheads are enlarged in the insets. Bar, 20 m.
FIG 7 Role of RasGAP cleavage in heart of doxorubicin-treated mice. Wild-type (WT) and RasGAPD455A/D455A (KI) mice were injected with doxorubicin and
analyzed 5 days later. (A)Western blot analysis of RasGAP cleavage. This experiment has been repeated once with similar results. (B) Histoimmunofluorescence
detection and quantitation of active Akt. Bar, 100 m. (C) Assessment of apoptosis by the TUNEL assay. (B and C) Results correspond to the mean	 95% CI
ofmeasurements performed on 3 animals per condition (three independent experiments). (D) Representative examples of end-systolic left ventricular pressure-
volume loops. (E)Heart contractility assessed by end-systolic elastance. Results correspond to themean	 95%CIofmeasurements performedon 9 to 11 animals
per condition (three independent experiments).
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organs in a RasGAP cleavage-dependent manner under condi-
tions where caspase-3 activation may be below the detection
threshold of current caspase-3 activation assessment methods.
In conclusion, our study provides the first genetic evidence that
in response to various pathology-inducing stresses caspase-3 itself
activates the antiapoptotic Akt kinase and that this protective re-
sponse is mediated through the cleavage of a given caspase-3 sub-
strate, the ubiquitous p120 RasGAP protein. This defense mech-
anism allows an organism to dampen damage to tissues and
organs induced by diverse pathogenic conditions. Hence, proce-
dures aimed at activating the signaling pathways modulated by
RasGAP cleavage may represent an attractive strategy to increase
the resistance of individuals exposed to environmental or chemi-
cal stresses. Additionally, our work has direct implications for
therapeutic protocols using caspase inhibitors, as inhibition of
caspases could lead to unanticipated adverse effects by decreasing
the ability of an organism to cleave RasGAP and defend itself.
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  Supplemental information 
 
Supplemental Tables 
 
Supplemental table 1: Hematopoiesis and lymphopoiesis in wild-type and 
RasGAPD455A/D455A knock-in mice 
Thymocytes, bone marrow (BM) and spleen cells were exposed to a hypotonic buffer 
to remove erythrocytes. Cells were then incubated with 2.4G2 (anti-CD16/32) 
hybridoma supernatant to block FC receptors before staining for multi-color flow 
cytometry (except for the staining of BM precursors). Dead cells were excluded 
based on 7-AAD uptake. The following antibodies were used CD3ε (17A2), CD4 
(RM4-5), CD8α (53.6.7), CD11b (Mac1, M1/70), CD16/32 (93), CD19 (1D3/6D5), 
CD25 (PC-61), CD34 (Ram34), CD43 (S7), CD44 (IM781), CD45R/B220 (RA3-6B2), 
CD45.2 (104.2), CD71 (R17217), CD117 (2B8), CD127 (A7R34), Sca1 (D7), GR-1 
(Ly6G, RB68C5), Ter119 (Ter119), BP-1 (6C3), IgM (11/41 or R6-60.2), TCRβ (H57), 
TCRγδ, CD24. The antibodies were conjugated to appropriate fluorochromes (FITC, 
PE, PE-Texas red, PE-Cy5, PE-Cy5.5, PerCP-Cy5.5, PE-Cy7, APC, Alexa647, 
Alexa700, APC-Cy7, APC-Alexa780, Pacific blue, efluor450) at the Ludwig Center for 
Cancer Research of the University of Lausanne (LICR) or purchased from 
eBiosciences, Becton Dickinson or Biolegend. A cocktail of PE-Cy7-conjugated anti-
TCRβ, CD3ε, CD4, CD8α, CD11β, GR-1, B220, CD19, Ter119, CD161 (PK136) 
monoclonal antibodies was used to gate out lineage-positive cells. Samples were run 
on a LSRII flow cytometer (Becton Dickinson) and analyzed with FlowJo software 
(Tristar). 
 
  WT KI 
Bone Marrow * x 106 29±3 26±4 
lin- Sca1+ c-kit+ (LSK) x 104 7.7±2.0 7.1±3.3 
lin- Sca1- c-kit+ (LKS-) x 104 57.0±19.6 53.6±10.8 
lin- c-kit+ CD127+ (CLP) x 104 6.0±2.0 5.1±2.8 
    
Ter119+ CD71+ x 106 1.8±0.2 1.7±0.3 
GR1+ CD11b+ x 106 14.1±2.6 13.0±2.5 
GR1- CD11b+ x 106 2.3±0.2 2.2±0.5 
7169
	      
B220+ CD43+ x 106 1.3±0.1 1.1±0.2 
B220+ CD43- x 106 6.2±0.6 5.1±1.0 
    
Thymus x 106 80±20 96±18 
CD4-8- (DN) x 106 2.3±2.2 2.7±1.6 
CD4+8+ (DP) x 106 68.9±16.4 77.7±21.3 
CD4+8- x 106 5.7±1.8 8.0±3.8 
CD4-8+ x 106 2.1±0.8 2.2±0.6 
TCRγδ CD4-CD8- x 106 0.17±0.11 0.26±0.15 
    
Spleen x 106 57±22 70±21 
B220+ x 106 21.8±3.2 29.9±2.6 
CD3+CD4+ x 106 12.3±3.4 13.1±1.5 
CD3+CD8+ x 106 6.2±2.6 7.7±1.1 
CD3-CD122+ x 106 0.9±0.6 1.2±0.5 
Data are the mean absolute number of cells (±SD) from 3-5 different mice. 
* Cell counts refer to one hind leg 
 
Interpretation of the results presented in Supplemental Table 2 
The bone marrow of D445A and control mice contained a comparable population of 
Lin- Sca1+ c-kit+ (LSK) cells that contains haematopoietic stem cells. Further, 
myeloid/erythroid (Lin- Sca1- c-kit+, LKS-) and lymphoid committed common lymphoid 
progenitors (CLP, Lin- c-kitlo CD127+) were also present at comparable numbers. 
Among the LKS- cells there was a normal distribution of CMP (Common myeloid 
progenitors), GMP (Granulocyte monocyte progenitors) and MEP (Megakaryocyte 
erythroid progenitors) (not shown) 
Further, the development of mature myeloid and erythroid lineage cells in the bone 
marrow was not perturbed, as judged by the normal numbers of granulocytes (GR-
1+CD11b+), monocytes (GR1-CD11b+) and erythroblasts (CD71+TER119+). With 
regard to lymphocyte development, the sizes of the B220+CD43+ and the 
B220+CD43- populations were comparable. Among immature B220+ CD43- cells 
there were comparable populations of CD19- BP-1-, CD19+ BP-1- and CD19+ BP-1+ 
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  cells (not shown). Similarly, intrathymic T cell development was also unaffected. This 
was not only true for TCRαβ lineage cells but also for CD4-CD8- cells expressing 
TCRγδ. 
As expected from the normal presence of immature precursors, the periphery of 
D445A mice (spleen) contained comparable numbers of B cells (B220), T cells 
(CD3+, both CD4+ and CD8+ T cells) and NK cells (CD3-CD122+).  
In conclusion, the steady state heamatopoiesis and lymphopoiesis was not perturbed 
in RasGAPD455A/D455A knock-in mice. 
 
Supplemental table 2: Wild-type and RasGAPD455A/D455A knock-in mice 
hemodynamic parameters injected or not with doxorubicin  
Hemodynamic measurements were performed using left ventricular pressure-volume 
micro-catheters as described in the methods. Doxorubicin induced cardiac 
dysfunction as shown by reduced left ventricular (LV) systolic pressure, stroke work 
and dp/dt max, which were related to a depression in contractility, as shown by the 
significant reduction of end-systolic elastance, an ejection phase measure of 
contractility. The hearts were not dilated, which is expected in such a short term 
model of heart failure. Importantly, the reduction of cardiac contractility was 
significantly more pronounced in RasGAP D455A KI mice, as shown by significantly 
greater reduction of LV end-systolic pressure, dp/dt max, Ese, as well as significant 
decrease of dp/dt@edv, an isovolumic phase measure of contractility. Results 
correspond to the mean ± 95% CI of measurements performed on 9-11 mice per 
treatment and genotype. 
 
Variable Sham-WT Sham-KI Doxo-WT Doxo-KI 
HR (bpm) 334±30 294±15 245±14† 255±22 
Esp (mm Hg) 131±7 115±7 93±4† 75±5†* 
Edp (mm Hg) 9.2±1.5 11.7±1.5 9.7±1.3 7.6±1.0 
Esv (µl) 15.4±1.1 18.6±1.4 18.3±2.2 23.5±3.2 
Edv (µl) 31.5±1.6 36.7±1.8 35.3±2.3 41.1±3.9 
SV (µl) 18.5±1.1 20.5±2.0 19.5±1.1 19.8±1.8 
CO (µl min-1) 6173±691 5284±301 4737±370 5130±715 
EF (%) 57±2 55±2 55±4 48±4 
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  SW (mm Hg µl) 1791±102 1837±124 1417±124† 1188±123† 
dp/dt max (mm Hg sec-1) 9372±786 7892±326 6724±436† 5173±495†* 
Ese (mm Hg µl-1) 4.8±0.6 4.0±0.5 2.7±0.2† 1.8±0.1†* 
dp/dt@edv (mm Hg sec-1µl-1) 185±29 143±11 188±24 82±17†*  
† p<0.05 vs sham in the same genotype. *p<0.05 WT vs KI 
HR, heart rate; Esp, end-systolic pressure; Edp, end-diastolic pressure; Esv, end-
systolic volume; Edv, end-diastolic volume; SV, stroke volume; CO, cardiac output; 
EF, ejection fraction; SW, stroke work; dp/dt max, first derivative of LV systolic 
pressure increment; Ese, end-systolic elastance (slope of the end-systolic pressure-
volume relationship); dp/dt@edv , dp/dt max corrected for end-diastolic volume. 
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  Supplemental Figure 
 
Figure S1: Schematic representation of the D455A targeting vector 
construction 
The 3’ and 5’ homology arms of the targeting vector were derived from a RasGAP 
genomic clone (RP22-250D10) obtained by screening the RPCI-22 129S6/SvEvTac 
mouse BAC library from the BACPAC Resource Center (Children's Hospital Oakland 
Research Institute, Oakland, California, USA) (2) with a probe corresponding to 
nucleotides 7137306-7136366 of Mus musculus chromosome 13 genomic contig 
(accession N° NT_039589.2). This led to the identification of three BAC clones 
(RP22-250D10, #452; RP22-268I2, #453; RP22-257P13 #454). The DNA prepared 
from these clones was pooled and digested with SwaI. The resulting ~10 kb fragment 
was sub-cloned in the EcoRV restriction site of pBluescript II SK + (Stratagene). A 
plasmid containing RasGAP exons 9, 10, and 11 was identified by PCR and called 
RasGAP exons 9-10-11.blu (plasmid #419). From this plasmid, a blunt-ended ~6.5 
kb BstXI fragment [nucleotides 7139579-7145879 from the Mus musculus 
chromosome 13 genomic contig (accession n° NT_039589.2)] was sub-cloned in the 
EcoRV restriction site of pBluescript II SK + to generate the 5’ homology arm 
composed of parts of introns 8 and 9 and exon 9 (the resulting plasmid was called 
RasGAP exon 9.blu; plasmid #427). A ~2.6 kb HindIII fragment from RasGAP exons 
9-10-11.blu (nucleotides 7138985-7136418 from the chromosome 13 genomic 
contig) was sub-cloned in the HindIII restriction site of pcDNA3 to generate the 3’ 
homology arm composed of parts of introns 10 and 11 and exon 11 (the resulting 
plasmid was called RasGAP exon 11.dn3; plasmid #421). A 590 bp fragment (called 
the Vital Region [VR] as it encodes amino acid 455 of RasGAP) containing exon 10 
and connecting the 5’ and 3’ homology arms was PCR-amplified from the BAC 
clones described above using the Pwo polymerase (Roche Applied Science, 
catalogue n° 04 340 868 001), sub-cloned into the SmaI and NotI sites of pBluescript 
II SK+, and sequenced twice to confirm that no PCR-generated errors occurred (the 
resulting plasmid was called Lox 66-RasGAP Exon 10.blu; plasmid #427). The 
mutation of the caspase cleavage site in exon 10 was done using the megaprimer 
PCR mutagenesis method(1) using the following primers: 1) a sense primer for the 
first PCR: AA GTA CTG AAC GAC ACT GTG GCC GGC AAG GAG ATC TAT AAC 
ACA AT. This corresponds to sequence 641-685 of the Mus musculus RasGAP 
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  mRNA (gi 21703899) carrying an A to C mutation (underlined) that destroys the first 
RasGAP caspase cleavage site by substituting an aspartate (D) residue for an 
alanine (A) (3) and two additional silent mutations (bold) that, together with the D to A 
mutation, create a new restriction site recognized by the NaeI and NgoMIV 
endonucleases (see also Figure 4B). 2) an anti-sense primer for the first PCR: 
TACCTAGCATGAACAGATTG (a random sequence not found in the plasmid) 
GCGGCCGC (NotI) GTTCTAAAACCCTGGTTATA (3' terminal sequence of the Vital 
Region; sequence 42026-42007 of the Mus musculus BAC clone RP23-222G16 [gi 
29367036]). 3) a sense primer for the second PCR: CGTA CCCGGG (SmaI) 
AGTAGGTGGGTTCAGGAGCAG (sequence 42007-42026 of the Mus musculus 
BAC clone). 4) an anti-sense primer for the second PCR: 
TACCTAGCATGAACAGATTG (the same random sequence found in primer 2). 
The mutated PCR product was digested with SmaI and NotI and subcloned into the 
SmaI/NotI sites of pBluescript II SK + [generating plasmid RasGAP exon 10 
(D455A).blu; plasmid #428]. 
The LoxP targeting vector plasmid (Lox-Neo-Lox.ltv, plasmid #425) is a derivative of 
the LTV plasmid (a gift from Olivier Staub, Lausanne University, Switzlerand) from 
which the third LoxP site was removed. This Lox-Neo-Lox.ltv plasmid was used as a 
backbone to construct the targeting vector. It consists of a neomycin-resistance 
cassette (PGK-Neo) flanked with two LoxP sites and the Herpes Simplex Virus 
thymidine kinase gene (HSV-TK). RasGAP Exon 11.dn3 was digested with HindIII 
and the resulting 2.6 kb fragment was ligated into the HindIII site of LTV (generating 
plasmid Lox-Neo-Lox-RasGAP Exon 11.ltv; plasmid #426). The 0.6 kb SmaI/NotI 
fragment of RasGAP Exon 10 (D455A).blu was ligated into the SmaI/NotI sites of 
RasGAP Exon 9.blu, creating plasmid RasGAP Exons 9-10 (D455A).blu. Finally, the 
SalI/NotI 7 kb fragment of RasGAP Exons 9-10 (D455A).blu was inserted into the 
SalI/NotI sites of LTV-Lox-Neo-Lox-RasGAP Exon 11 plasmid to obtain the final 
D455A targeting vector [plasmid RasGAP Exons 9-10 (D455A)-Lox-Neo-Lox-
RasGAP Exon 11; plasmid #441]. This clone was sequenced to verify that the LoxP 
sites and the D455A mutation were intact. 
The targeting vector electroporation, clone selection and injection into C57/BL6 
blastocysts was performed at the Transgenic Animal Facility of the University of 
Lausanne (http://www.unil.ch/taf). 
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INTRODUCTION 
 
UV-B induces cytoplasmic survivin in mouse epidermis 
 
Survivin is an odd member of the “inhibitor of apoptosis (IAP)” protein family. In 
contrast to the other proteins of this family, such as XIAP or cIAPs, survivin bears 
only one baculovirus inhibitor of apoptosis protein repeat (BIR) domain although no 
function as a direct caspase inhibitor. It neither has the really interesting new gene 
(RING) motif (Wheatley and McNeish, 2005) involved in ubiquitylation of target 
proteins implicated in proliferation and protection against cell death. Therefore, the 
effect of survivin in anti-apoptotic responses is highly debated (Banks et al., 2000; 
Yue et al., 2008; Earnshaw, 2005). 
Besides its function as an inhibitor of apoptosis, survivin but not the other members 
of the family, is a chromosomal passenger that ensures proper chromosome 
segregation (Vong et al., 2005) and that might protect dividing cells from undergoing 
apoptosis (Li et al., 1998). One reason that hampers deciphering the apoptosis 
modulator function of survivin is the involvement of the protein in proper cell division. 
Indeed, inhibition or absence of survivin has profound detrimental effect on cells by 
altering mitosis and cytokinesis that ultimately affects cell survival and embryo 
development (Uren et al., 2000; Speliotes et al., 2000). Nevertheless, there is a 
consensus that, if survivin does have anti-apoptotic functions, this results from its 
expression in the cytoplasm or its association to the mitochondria (Connell et al., 
2008; Fortugno et al., 2002; Dohi et al., 2004a). For example, the capacity of survivin 
to protect cells has been attributed to its binding to and stabilization of the anti-
apoptotic XIAP protein, to inhibition of caspase-9 via cooperation with HBXIP, and to 
binding to and inhibition of the pro-apoptotic Smac/Diablo protein (Dohi et al., 2004b; 
Marusawa et al., 2003; Ceballos-Cancino, 2007). In any case, preventing survivin 
translocation from the nucleus to the cytoplasm, while not affecting cell division, 
renders cells more sensitive to irradiation-induced apoptosis (Colnaghi et al., 2006). 
Therefore, the location of survivin in the cytoplasm seems to be an important factor 
for its anti-apoptotic function. 
79
Survivin has been reported to be induced in response to UV-B light in mouse skin 
(Aziz et al., 2004) however a detailed characterization of survivin expression in the 
various layers of the epidermis and assessment of a potential association of 
keratinocyte survivin expression in situ and cell survival in response to UV-B 
exposure have not yet been provided. The aim of the present study was thus to 
define the mode of survivin expression in the skin in response to UV-B and whether 
there was an association between survivin expression and apoptosis  
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Excessive exposure to ultra-violet (UV) light, the UV-B
component (290–230 nm) in particular, represents the most
harmful DNA damage-inducing condition that keratinocytes have
to face on a regular basis. UV-B exposure induces survivin
expression in keratinocytes in vitro [1] and in vivo [2]. Survivin
(BIRC5) is a member of the ‘‘inhibitor of apoptosis (IAP)’’ protein
family that can directly or indirectly inhibit caspases, the proteases
that mediate apoptosis. Unlike the other members of the family,
survivin is also a chromosomal passenger that ensures proper
chromosome segregation during cell mitosis. Survivin is often
considered as a marker of malignancy, being virtually undetectable
in most normal cells and over-expressed in cancer cells [3]. In vitro
studies indicate that upon stress, survivin may translocate to the
cytoplasm [4]. The proposed anti-apoptotic mechanisms allowing
survivin to protect cells rely on a cytoplasmic location of the
protein where it can either inhibit pro-apoptotic proteins or
stabilize anti-apoptotic proteins. However, the implication of
survivin in anti-apoptotic responses is highly debated [5].
Nevertheless, there is a consensus that, if survivin does have
anti-apoptotic functions, this results from its expression in the
cytoplasm or its association to the mitochondria [6]. Indeed,
preventing survivin translocation from the nucleus to the
cytoplasm, while not affecting cell division, renders cells more
sensitive to irradiation-induced apoptosis [7]. However, no
publication yet has reported the presence of survivin in the
cytoplasm of stressed or damaged cells in vivo in non-pathological
conditions and hence the physiological role of cytoplasmic survivin
is still unclear. The aim of the present study was to deﬁne the mode
of survivin expression in mouse skin in response to UV-B exposure
and determine whether there is an association between survivin
expression and apoptosis.
Only a low percentage (about 2–3%) of keratinocytes and follicle
cells in non-exposed skin expressed survivin (Fig. 1A, left panel;
quantitation shown in Fig. 1C and D; Supplementary Material
including detailed experimental procedures is available online).
The majority of these cells displayed a nuclear survivin expression
(ﬁlled arrowheads in Fig. 1A and B, upper panels; quantitation
shown in Fig. 1C and D). The percentage of survivin-positive cells
increased in a statistically signiﬁcant manner starting 24 h post-
UV-B irradiation in the epidermis (Fig. 1B; quantitation shown in
Fig. 1C) and 48 h post-UV-B irradiation in follicles (Fig. 1D).
Virtually no cells in the dermis were found to express survivin,
whether the skin was exposed to UV-B or not (Fig. 1A). Upon UV-B§ This work was supported by Swiss National Science Foundation grant
31003A_119876 (to CW).
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85exposure, the location of survivin was mostly nuclear in follicle
cells (Fig. 1A, ﬁlled arrowhead in right panel), while it was mostly
cytoplasmic in keratinocytes (Fig. 1A, open arrowhead in right
panel; Fig. 1B, lower panel). Expression of cytoplasmic survivin in
follicle cells and nuclear survivin in keratinocytes was not affected
by UV-B irradiation (Fig. 1C and D).
To assess which layers of UV-B-exposed epidermis express
survivin, co-immuno-staining of survivin with either keratin 5 (a
basal cell layer marker) or keratin 10 (a supra-basal layer marker)
was performed. Nuclear survivin was exclusively found in the
basal cell layer of the epidermis (Fig. 1E). Similarly, cytoplasmic
survivin was expressed in keratinocytes of the basal layer of the
epidermis, and to a limited extent, in keratinocytes of the supra-
basal layer (Fig. 1E). There is evidence that cytoplasmic survivin is
present in a few cells of the basal cell layer in normal human
epidermis [8]. However, in the present study using mouse
epidermis, we did not observe such a cytoplasmic staining for
survivin in normal non-exposed conditions. Our results indicate
that induction of cytoplasmic survivin upon UV-B irradiation
mainly occurs in the proliferative layers of the epidermis, at least
in mice.
To assess if there was a correlation between survivin
expression in keratinocytes and apoptosis, skin sections of UV-
B-irradiated mice were stained with an anti-survivin antibody
and labeled with TUNEL to detect apoptotic cells (Fig. 2A). UV-B
irradiation increased by about 10 fold the percentage of
apoptotic cells (Fig. 2B). Upon UV-B-treatment, about 10% of
the keratinocytes expressed survivin in their cytoplasm and
about the same percentage of keratinocytes were undergoing
apoptosis (Fig. 2C). However, there was limited co-localization of
the survivin and TUNEL signals. Indeed, only about 20% of the
cytoplasmic survivin-positive cells were apoptotic and converse-
ly, only about 20% of the TUNEL-positive cells expressed
cytoplasmic survivin (Fig. 2D). Therefore, the majority of
cytoplasmic survivin-positive cells were not undergoing apo-
ptosis, in agreement with data obtained in catagen-phase human
hair follicles [9], indicating that translocation of survivin to the
cytoplasm is not a consequence of cell death. Rather, UV-B-
induced cytoplasmic survivin expression may exert anti-apo-
ptotic functions. On the other hand, the percentage of apoptotic
cells within the cytoplasmic survivin-positive keratinocyte
population was not decreased (it was in fact higher) compared
to survivin-negative keratinocytes (20% vs 10%). Possibly,
survivin positive keratinocytes are the cells that experienced the
highest damage in response to UV-B irradiation and cytoplasmic
expression of survivin might represent an attempt to cope with
this damage. Further studies would need to be conducted to test
this assumption.
In conclusion, this work demonstrates that UV-B irradiation
leads to the expression of survivin in the cytoplasmic compart-
ment of keratinocytes located in the basal layer of the mouse
epidermis. Earlier work had shown that UV-B can induceplasmic survivin expression in mouse epidermis. J Dermatol Sci
y Elsevier Ireland Ltd. All rights reserved.
Fig. 1. UV-B induces expression of survivin in the cytoplasm of basal epidermal cells. (A) Representative images of control mouse skins (0.0 J/cm2) and mouse skins 24 h post
UV-B (0.3 J/cm2) irradiation. The expression of survivin was visualized by immuno-ﬂuorescence (red staining). Nuclei were stained in blue with the Hoechst 33342 dye. Filled
arrowheads, nuclear survivin; open arrowhead, cytoplasmic survivin; D, dermis; arrow, non-speciﬁc staining of a hair shaft. (B) Representative images of nuclear versus
cytoplasmic survivin expression in epidermal cells 24 h after exposure with the indicated UV-B doses. Insets show enlarged sections with the upper one depicting a cell with
nuclear survivin and the lower one depicting a cell with cytoplasmic survivin. (C) Skins of mice were treated as in panel A for the indicated time periods following UV-B (0.3 J/
cm2) irradiation. The percentage of epidermal cells expressing survivin in the nucleus or in the cytoplasm was then quantitated. Results correspond to the mean  95%
conﬁdence interval (CI) of 3 mice (6, 12, and 48 h-time points) and 8 mice (0 and 24 h-time points). The percentage of keratinocytes expressing cytoplasmic survivin increased
signiﬁcantly over time (conditions with different letters are statistically different), while the percentage of keratinocytes expressing nuclear survivin did not. (D) Alternatively, the
percentage of follicle cells expressing survivin in the nucleus or in the cytoplasm was quantitated and analyzed as in panel C. Results correspond to the mean  95% CI of 3 mice (the
percentages of follicle cells expressing cytoplasmic survivin did not statistically differ over time after UV-B exposure). (E) Mouse skin were exposed or not to UV-B (0.3 J/cm2) and
isolated 24 h later. Survivin (red staining), nuclei (blue staining), keratin 5 (green staining, left panel) and keratin 10 (green staining, right panel) were visualized on skin sections by
immunoﬂuorescence. Insets represent enlargement of the indicated areas. Open arrowheads, nuclear survivin; white-ﬁlled arrowheads, cytoplasmic survivin in basal layer
keratinocytes; orange-ﬁlled arrowheads, cytoplasmic survivin in supra-basal layer keratinocytes. The graph represents the quantitation of cells expressing nuclear or cytoplasmic
(Cyt.) survivin in the basal and supra-basal layers. The results correspond to the mean  95% CI of 4 mice. Scale bar for all images: 20 mm.
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Fig. 2. TUNEL and survivin labeling of UV-B-exposed mouse skin. Mice were treated as in Fig. 1A. (A) Skin sections were labeled with an anti-survivin antibody (red staining),
with TUNEL (green staining), and with Hoechst 33342 (blue staining). An example of an apoptotic cell expressing cytoplasmic survivin is indicated with an arrow and enlarged
in the inset. Scale bar: 20 mm. (B) Quantitation of apoptotic keratinocytes 24 h following UV-B (0.3 J/cm2) exposure or not. The results correspond to the mean  95% CI of 7
mice. (C) Quantitation of cells expressing cytoplasmic survivin or positive for TUNEL labeling. (D) The graph on the left hand side only considers TUNEL-positive cells and whether
these cells express or not survivin. The right-hand side graph only considers cytoplasmic survivin-positive cells and whether they are apoptotic or not. The results correspond to the
mean  95% CI of 4 mice. *statistically different.
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compartment this occurred had not been investigated. Data
shown here provide the ﬁrst demonstration that survivin can be
induced in the cytoplasm of non-cancer cells in conditions
where survivin may exert anti-apoptotic functions (i.e. when
cells are stressed or damaged). Since cytoplasmic survivin has
been shown to counteract apoptosis, this is expected to induce a
protective signal in UV-B-exposed keratinocytes. However, no
evidence for increased resistance to apoptosis in cytoplasmic
survivin expressing keratinocytes could be demonstrated and
the exact role played by survivin in the cytoplasm of
keratinocytes remains to be deﬁned.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jdermsci.2012.
05.007.Please cite this article in press as: Peltzer N, et al. UV-B induces cyto
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Materials and methods 
Mice 
C57/BL6N,129SvEv mice were used in this study. Experiments on mice were carried 
out in strict accordance with the Swiss Animal Protection Ordinance (OPAn). The 
protocol was approved by the Veterinary office of the state of Vaud, Switzerland 
(Permit Number: 2055). 
UV-B exposure and skin sample isolation 
Anesthetized (100 mg/kg Ketarnorkon [Streuli; catalogue n° 0670940 and 20 mg/kg 
Rompum [Bayer; catalogue n° 01259402]) 8-week-old mice were shaved and then 
depilated with Veet depilatory cream on both flanks. Most mice at 8 weeks of age are 
in the resting phase of the hair cycle (telogen phase). The few mice that were not, as 
assessed by the presence of dark skin areas (Stenn and Paus, 2001), were not used. 
Forty-eight hours later, the mice were anaesthetized as described above and 
irradiated with a Waldmann UV801 KL apparatus equipped with a Philips UV21 UV-B 
lamp (TL 20W/12RS). The dose of UV-B irradiation was 0.3 J/cm2, measured with a 
Waldmann Variocontrol dosimeter positioned at the same distance from the UV light 
as the exposed mouse skin. In these conditions, UV-A leakage of this lamp was 1 
J/cm2 [a dose that should have none or negligible biological effects (Zheng and 
Kligman, 1993)]. This UV lamp does not generate UV-C. In each case, only one side 
of the mouse was irradiated and the other side was used as a control (i.e. shaved 
and depilated but non-exposed skin). Mice were laid down on a sterile field with the 
flank to be irradiated (left flank) facing the lamp so that the control flank (right flank) 
was facing down and was thus non-exposed. Mice were sacrificed at the indicated 
times after irradiation. Lateral skin biopsies (approximately 2 x 2 cm) were excised 
from each mouse, fixed in PBS, 4% formol solution, and embedded in paraffin. The 
paraffin-embedded skin was cut into 4 µm sections. 
Immunofluorescence  
Paraffin sections were deparaffinized in two consecutive 5 minute long Xylene 100% 
baths and rehydrated by successive 2 minute long washes in ethanol 100%, 96%, 
75% and 50%. Immunohistochemistry was performed as described (Bulat et al., 
2011). Primary antibodies were rabbit monoclonal anti-survivin (Cell Signaling; 
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catalogue n° 2808), and rabbit polyclonal anti-keratin 5 and anti-keratin 10 (Covance; 
catalogue n° PRB 159P and PRB 160P, respectively). The secondary antibodies 
were fluorescein isothiocyanate (FITC)-conjugated AffiniPure donkey anti-rabbit IgG 
and Cy3-conjugated AffiniPure Fab fragment goat anti-rabbit IgG (Jackson 
ImmunoResearch Europe; catalogue n° 711-094-152 and 711-165-152, 
respectively). The Alexa fluor 594 donkey anti-rabbit IgG antibody was from 
Invitrogen (catalogue n° A21207). All secondary antibodies were used at a 1/300 
dilution. Double immuno-fluorescence labeling procedures (including those involving 
TUNEL staining) were done sequentially over a two-day period. The first day, survivin 
staining was performed using a primary antibody dilution of 1/300. The subsequent 
day, keratin staining (using a 1/300 antibody dilution) was performed. Alternatively, 
after an antigen retrieval step (Bulat et al., 2011), TUNEL (see below) was done first, 
followed by an overnight wash and survivin staining. In all cases, nuclei were stained 
with Hoechst 33342 (Molecular Probes; catalogue n° H1399) for 10 minutes before 
mounting the slides in 0.1 g/ml Mowiol, 0.22% (v/v) glycerol, Tris 0.1 M pH 8.5, 0.1% 
diazobicyclo-octane. Mowiol was from Calbiochem (catalogue n°475904) and 
diazobicyclo-octane was from Fluka (catalogue n° 33480). 
 
Apoptosis detection 
Apoptosis was detected using the DeadEnd Fluorimetric TUNEL system (Promega; 
catalogue n° G3250) according to manufacturer’s instructions. 
 
Quantitation of fluorescent positive cells 
Sections stained as described above were scanned using an automated Nikon 
Eclipse 90i microscope equipped with an Apo Plan 40x / 1.0 DIC-H objective and 
piloted with the NIS-Elements Advance Research software (Nikon Instruments Inc. 
Melville, USA; version 3.10). In order to minimize errors, all images were acquired 
with the same contrast (high), size and quality (1280 x 960), exposure time (40 ms for 
Hoechst detection, 50 ms for MK5 detection and TUNEL; 400 ms for MK10 and 
survivin detection, and 1 s for Alexa fluor detection), and gain (1x for Hoechst 
detection and 2.8x for the rest). Quantification threshold in the “Automated 
Measurement” menu was set as “L32” for Low and “H236” for high, and the area was 
restricted to “0-0.5 µm2 out “. Using the “Binary” menu, the holes were filled using the 
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“Fill Holes” option. This was performed to avoid multiple counting of the same 
nucleus. Touching nuclei were separated using the “Morpho Separate Objects” 
option. The number of nuclei was displayed under “Automated Measurement Results 
– Object Data” and the TUNEL- or survivin-positive cells were counted with the 
“Taxonomy tool”. 
 
Statistics 
The data were analyzed using one-way ANOVA (Figure 1C-D) or student t tests with 
Bonferonni corrections (Figure 1E and Figure 2). 
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INTRODUCTION 
 
Survivin regulation  
 
Survivin is a protein with a dual role in apoptosis and cell division. Its expression and 
function is hence highly regulated at different levels including transcription, splicing, 
translation, degradation and intracellular sequestration. 
The survivin promoter is conserved between human and mouse. It is a TATA less 
promoter and contains multiple specificity protein-1 (sp1) - binding sites, two of which 
are essential for its basal level of transcription. Three cycle-dependent-elements 
(CDEs) and a cell cycle homology region (CHR) are found within the survivin 
promoter indicating that it is a protein regulated in a cell cycle dependent manner.  
The survivin gene is repressed by p53 (Hoffman et al., 2002) and RB and it is 
activated by the transcription factor E2F1 (Jiang et al., 2004), three proteins known to 
regulate cell fate either by negatively regulating cell division (p53 and RB) or 
activating it (E2F1). Additionally transcription of survivin is positively regulated by 
NFκB, which is in turn activated by growth factors via Akt-induced activation of IKK α 
and β (Ozes et al., 1999; Romashkova and Makarov, 1999; Van Antwerp et al., 
1998). Other factors known to induce survivin transcription are members of the Ras 
oncogene family (Sommer et al., 2003), STAT (Gritsko et al., 2006), the anti-
apoptotic factor Wnt-2 and the hypoxia-inducible factor-1 alpha (HIF-1α) (Peng et al., 
2006; Chen et al., 2009). Finally, mTOR positively regulates survivin expression via 
rapid changes in mRNA translation (Vaira et al., 2006).  
Post-translational regulation of survivin mainly involves phosphorylation and 
ubiquitylation. Survivin is phosphorylated by cyclin dependent kinase 1 (CDK1) at 
Threonine 48 (Yang et al., 2005) at the beginning of the M phase. Although CDK-1 is 
a kinase that regulates the cell cycle, in the case of survivin it is also believed to 
regulate cyto-protection since it may mediate survivin interaction with caspase-9 
(O'Connor et al., 2000). This phosphorylation site stabilizes survivin against 
proteasome degradation and increases the binding efficiency with several partners 
such as Heat shock protein 90 (Hsp90) (Fortugno et al., 2003) and aryl hydrocarbon 
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receptor-interacting protein (AIP) (Kang and Altieri, 2006). These proteins bind 
survivin in the cytosol and are important for its cyto-protective function. Aurora B 
phosphorylates survivin at Threonine 117 and although there is no clear evidence of 
the role of this phosphorylation site it is most probably involved in cell division rather 
than in cyto-protection, since Aurora B, together with survivin and others, is 
responsible for proper completion of mitosis. More recently a novel phosphorylation 
site was reported at Serine 20 of survivin by Plk1 (Polo-like kinase 1) (Colnaghi and 
Wheatley, 2010) that is involved in the proper completion of mitosis.  
Survivin is ubiquitylated in two different manners. K48 ubiquitylation of survivin by 
other IAPs targets its proteasomal degradation. K63 ubiquitylation on the contrary, is 
required for survivin centromere targeting and chromosome alignment (Vong et al., 
2005). 
Survivin localization within the cell is highly controlled and it is probably the 
cytoplasmic or even mitochondrial fraction of survivin that dictates the cyto-protective 
role of this peculiar IAP member (more detailed information on this matter is found in 
the general introduction). 
In the context of our study, it has been reported that the PI3K/Akt signalling pathway 
is implicated in the upregulation of survivin in vascular endothelial cells and also in 
tumor cells (Altieri, 2003; Zhao et al., 2010; Papapetropoulos, 2000). These findings 
together with the results described previously in this work, in which fragment N-
dependent Akt activation and cytoplasmic survivin induction were observed in the 
skin in response to UV-B light, lead us to focus on survivin as a putative Akt 
downstream target mediating fragment N induced protection. To elucidate the effect 
of fragment N on survivin, several levels of survivin regulation in the presence of 
over-expressed fragment N were studied as well as its involvement in fragment N 
mediated protection. 
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 Abstract 
 
Partial cleavage of p120 RasGAP by caspase-3 in stressed cells generates an 
N-terminal fragment, called fragment N, which activates an anti-apoptotic Akt-
dependent survival response. Akt regulates several effectors, but which of 
these mediate fragment N-dependent cell protection has not been defined yet. 
Here we have investigated the role of mTORC1, Bad, and survivin in the 
capacity of fragment N to protect cells from apoptosis. Rapamycin, an inhibitor 
of the mTORC1 complex, did not alter the ability of fragment N from inhibiting 
cisplatin-induced death. Cells lacking Bad, despite displaying a stronger 
resistance to apoptosis, were still protected by fragment N from cisplatin-
induced death. Fragment N expression in cells did neither modulate survivin 
mRNA nor its protein expression. Additionally, the expression of cytoplasmic 
survivin, known to exert anti-apoptotic actions in cells, still occurred in UV-B-
irradiated epidermis of mouse expressing a caspase-3-resistant RasGAP 
mutant that cannot produce fragment N. Additionally, survivin function in cell 
cycle progression was not affected by fragment N. These results indicate that, 
taken individually, mTOR, Bad, or Survivin are not required for fragment N to 
protect cells from cell death. We conclude that either other downstream targets 
of Akt mediate fragment N-induced protection or several Akt effectors can 
compensate for each other to induce the pro-survival fragment N-dependent 
response. 
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 Introduction 
Activation of executioner caspases was once believed to represent a point of no 
return in the path to death. However it is now well established that while executioner 
caspases are indispensable for apoptosis, there are situations when their activation 
does not lead to death. For example, healthy dividing cells can weakly activate 
caspase-3 in response to mild stresses [1]. Caspase-3 also participates, in an 
apoptosis-independent manner, in T and B cell homeostasis [2,3], in microglia 
activation [4], and in muscle [5], monocyte [6], bone marrow stromal stem cell [7], and 
erythroid cell differentiation [8]. 
Low caspase-3 activation in stressed cells induces the partial cleavage of RasGAP 
into an amino-terminal fragment, called fragment N, that prevents amplification of 
caspase-3 activation and death in an Akt-dependent manner [9]. Knock-in mice that 
only express a caspase-3-resistant RasGAP mutant, and therefore cannot generate 
fragment N in response to stress, are unable to stimulate Akt and are more sensitive 
to damage induced by various pathophysiological insults (submitted article). 
Fragment N generation can therefore explain why cells having mildly activated 
caspase-3 do not necessarily die. On the other hand, when caspase-3 activity is 
strongly stimulated in cells, fragment N is further processed into smaller fragments, 
called N1 and N2, that no longer have the capacity to activate Akt [10]. The extent of 
caspase-3 activity in a cell can therefore be sensed by RasGAP to either mount an 
efficient Akt-dependent protection when the stress is not too strong [1,11] or to 
abrogate this protective signal in cells faced with strong insults or apoptotic stimuli 
[10]. 
Although Akt can lead to activation of the NF-κB transcription factor, fragment N-
mediated Akt activation does not result in NF-κB stimulation [12]. In fact, fragment N 
is able to block NF-κB activation in response to various stimuli including exposure to 
inflammatory cytokines [13,14]. Hence fragment N does not rely on NF-κB activation 
to protect cells despite that its activation is often promoting cell survival [15,16]. In 
some cell types, such as pancreatic beta cells, sustained NF-κB activation leads to 
apoptosis [17]. In this context at least, the capacity of fragment N to block NF-κB 
activation is beneficial and it has indeed been shown that it contributes to fragment 
N-induced, Akt-dependent anti-apoptotic activity in beta cells [14] [18]. These 
observations rule out activation of NF-κB as an Akt-dependent mechanism used by 
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 fragment N to protect cells. Which of the other Akt effectors are required for fragment 
N to protect cells is not known. 
In the present work we investigated whether mTORC1, BAD and Survivin play a role 
in fragment N-mediated apoptosis inhibition. Mammalian TOR (mTOR) is a protein 
kinase that exists in two different complexes. The mTORC1 complex contains mTOR 
and Raptor and is inhibited by rapamycin. Akt indirectly activates mTORC1 by 
preventing the TSC1/TSC2 GTPase-activating proteins from inhibiting Rheb, the 
small GTP-binding protein that stimulates mTORC1. The mTORC2 complex contains 
mTOR and Rictor, is not sensitive to rapamycin, at least in short-term experiments 
[19], and positively regulates the activation of Akt by phosphorylating it rather than 
being an Akt effector itself [20,21]. The involvement of mTORC1 in cell survival 
responses makes it a possible candidate for fragment N mediated protection against 
apoptosis. 
Another putative player in fragment N-induced protective pathway is Bad, a pro-
apoptotic member of the Bcl-2 family [22,23]. When phosphorylated by Akt, Bad 
binds to 14-3-3 proteins and this prevents its capacity to interact with anti-apoptotic 
Bcl-2 family members. Consequently, phosphorylated Bad loses its pro-apoptotic 
activity [24]. 
Survivin (also called BIRC5), an atypical member of the inhibitor of apoptosis (IAP) 
family of proteins, is also a component of the chromosomal passenger protein 
complex that ensures proper segregation of sister chromatids and cytokinesis 
[25,26], and that mediates many other functions during mitosis [27]. The absence of 
survivin profoundly alters mitosis and cytokinesis and this eventually leads to cell 
death [25,28]. The exact contribution of survivin in anti-apoptotic responses is 
controversial and still not well defined. The evidence supporting a caspase-inhibitory 
function of survivin is consistent with the notion that survivin indirectly affects 
caspases either by binding and stabilizing XIAP [29], blocking Smac-dependent XIAP 
inhibition [19, 24, 30, 33] or inhibiting caspase-9 with cooperation with HBXIP [23]. 
Depending on the cell types and the experimental conditions, activation of Akt can 
lead to increased survivin expression [30,31]. 
In the present work, we have investigated whether mTORC1, Bad, and survivin play 
a role in fragment N-mediated apoptosis inhibition. 
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 Materials and methods 
 
Plasmids 
pEGFP-C1 encodes the green fluorescent protein and is from Clonetech. The .dn3, 
.lti and .cmv extensions indicate that the backbone plasmid is pcDNA3 (Invitrogen, 
Carlsbad, CA), a lentiviral vector and pCMV5 (Promega), respectively. HA-
hRasGAP(D157A).dn3 encodes an amino-terminal HA (MGYPYDVPDYAS)-tagged 
human RasGAP mutant that cannot be cleaved by caspase-3 at position 157 
(plasmid #125; previously called HA-D157A.dn3 [11]). HA-hRasGAP[1-
455](D157A).dn3 encodes a similarly tagged and caspase-3-resistant version of the 
1-455 amino acid fragment of human RasGAP (fragment N) (plasmid #352; 
previously called N-D157A.dn3 in [11]). HA-hRasGAP[1-455](D157A).lti is the 
plasmid used for the production of the lentivirus encoding the caspase-resistant form 
of fragment N (plasmid #353; previously called N-D157A.lti in [1]). GFP-HA-
hRasGAP[1-157] (plasmid #231) encodes a fusion protein between GFP and 
fragment N1 (amino acid 1-157 of human RasGAP). It was generated by subcloning 
the ApaI/HindIII fragment of plasmid HA-hRasGAP[1-158].dn3 (plasmid #147; 
previously called HA-N1.dn3 in [11]) into pEGFP-C3 (Clontech) opened with the 
same enzymes. GFP-HA-hRasGAP[157-455] (plasmid #213; previously described 
as GFP-HA-N2 in [32]) encodes a fusion protein between GFP and fragment N2 
(amino acid 158-455 of human RasGAP). E2F1-SPORT6.1 (plasmid # 675) was 
purchased from Imagenes. Mouse survivin promoter plasmids were obtained by 
cloning the sequences corresponding to the entire sequence of survivin promoter ([-
1296 to +13) or the minimal sequence required for its activation (-283 to +13) (called 
mSurvivin promoter [-1296 to +13].gl3, plasmid number gl3, plasmid number #634, 
and mSurvivin promoter [-238 to +13].gl3, plasmid #633, respectively). The 
extension .gl3 indicates that the backbone plasmid bears a promoter-less luciferase 
gene and it was purchased from Promega (name: pGL3 basic, plasmid #95). pRL-TK 
encodes for renilla luciferase and it was used as a efficiency control (plasmid #402). 
 
Cell Culture and chemicals 
The RasGAP+/+ mouse embryonic fibroblasts (MEFs; clone 12.78), the RasGAP-/- 
MEFs (clone 12.64), and their derivatives stably expressing wild-type RasGAP or the 
caspase-resistant D455A mutant [10,33] were maintained in DMEM (Invitrogen 
105
 catalogue n°61965) containing 10% newborn calf serum (Invitrogen, catalogue n° 
26010-074) at 37°C and 5% CO2. BAD knock-out MEFs were cultured similarly. 
Mouse beta cells (Min-6) cells were maintained in modified DMEM complemented 
with 0.1 mM β-mercaptoethanol and 1 mM sodium pyruvate. HeLa cells were 
maintained in RPMI 1640 (Invitrogen catalogue n°61870) containing 10% newborn 
calf serum at 37°C and 5% CO2. Cisplatin (catalogue n° P4394) and rapamycin 
(catalogue n° R0395) were purchased from Sigma. 
 
Antibodies 
The anti-p70-S6Kianse antibody, the anti-phospho Bad antibody simpler kit and the 
rabbit anti-survivin 71G4 monoclonal antibody were purchased from Cell Signaling 
Technology (catalogue n°9205, 9105 and 2808 respectively). Secondary antibodies 
used for Western blotting were Alexa Fluor 680–conjugated anti-rabbit antibody 
(Molecular Probes, Eugene, OR; catalogue n°A21109) or IRDye 800–conjugated 
anti-mouse antibody (Rockland, Gilbertsville, PA; catalogue n°610-132-121). For 
immunohistochemistry the secondary antibody was Cy3-conjugated AffiniPure Fab 
fragment goat anti-rabbit IgG (catalogue n°711-165-152) and was purchased from 
Jackson ImmunoResearch Laboratories. 
 
Lentivirus 
Recombinant lentiviruses were produced as described [34]. The minimal amounts of 
viruses inducing expression of the protein of interest in more than 95% of the cells 
(as assessed by immunofluorescence) were used. 
 
Transfection and luciferase assay 
HeLa cells were transfected with Lipofectamine 2000 (Invitrogen) as described earlier 
(Yang MCB 2001). Min-6 cells (3x105) were co-transfected using Lipofectamine with 
0.5 ug of pGL3-survivin promoter – luc, 0.5 ug of a Renilla encoding plasmid and 1 
ug of either pcDNA3 plasmid coding for fragment N or pCMV-Sport 6.1 plasmid 
coding for E2F1. pcDNA3 or SPORT6.1 empty vectors were used as negative 
controls. Cells were harvested 36 hours after transfection and luciferase activity was 
measured using Dual-Luciferase® Reporter Assay (Promega). Signals were detected 
with GLOMAXTM 96 Microplate Luminoteter (Promega) and analyzed with Glomax 
version 1.7.0 program. Results were normalized with Renilla luciferase activity. 
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RNA extraction and Reverse Transcription  
RNA was extracted by lysing cells with 500 µl TRI buffer (1.7 M guanidium 
thiocyanate, 0.1 M sodium citrate, 0.25% N-lauryl-sarcosyl sodium, 0.05 M β-
mercaptoethanol, 0.1 M sodium acetate), followed by the addition of 200 µl 
chloroform. The tubes were then vortexed, kept at room temperature for 5 min, and 
spun at maximal speed in an Eppendorf centrifuge for 15 min. After the transfer of 
the aqueous phase in a new tube, 500 µl isopropanol was added and the solution 
was mixed by inversion approximately five times. The samples were then incubated 
o/n at –20°C. After spinning 20 min at maximum speed in an Eppendorf centrifuge, 
the upper phase (isopropanol) was aspirated; the pellet was washed twice with 800 
µl 70% ethanol and dried 5–10 min at 50°C. The pellet was finally resuspended in 50 
µl of water and RNA was quantitated at 260 nm. Half a microgram of RNA was mixed 
with 500 ng of random hexamers (Microsynth, Balgach, Switzerland), and water was 
added to reach a final volume of 11 µl. The samples were incubated 3 min at 70°C 
and then kept on ice. A mix (14 µl) containing 5 µl of 10nM dinucleotide triphosphates 
(Promega catalogue number U120D-123D), 0.5 µl of RNasin (Promega catalogue 
number. N211A), 5 µl of buffer 5x, 2 µl dithiothreitol, 0.5 µl Superscript reverse 
transcriptase, and 1 µl water (the 5x buffer, the dithiothreitol and the transcriptase 
coming from the Superscript II reverse Transcriptase Kit; Invitrogen catalog no. 
18064–014) was added to the RNA-hexamer mix. After incubation at 39°C for 1 h 
followed by 15 min at 70°C, the cDNA was diluted 1:3 in water.  
 
Real Time PCR  
Quantitative PCR assays were carried out on a real-time PCR detection system (iQ5; 
Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad catalog no. 170-8862), with 500 
nmol/liter primers, 1 µl of template per 20 µl of PCR, and an annealing temperature of 
59°C. Melting curve analyses were performed on all PCR to rule out nonspecific 
amplification. Reactions were carried out in triplicate. The primers used in real-time 
PCR are: Fw 5’-GCGGAGGCTGGCTTCA-3’ and reverse 5’-
AGAAAAAACACTGGGCCAAATC-3’ 
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 Propidium iodide (PI) staining and flow cytometer analysis  
HeLa (3 x 105) cells were seeded in 3.5 cm dishes and infected with either an empty 
virus or an HA-N enconding virus. 72 hours after infection, cells were synchronized in 
G1-S boundary with 400 µM of mimosine for 18 hours. Cells were release from 
mimosine blockage by changing the medium, and harvested at different time points. 
Cells were washed twice with 1x PBS and fixed with ethanol 100% for 15 minutes at -
20°C. After fixation cells were spinned down at 2000 rpm at 4°C and washed once 
with 1x PBS. Cells were resuspended in 1 ml of PI staining buffer (100 mM Tris pH7, 
150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% NP-40, 20 µg/ml RNAse A, 
1mg/ml propidium iodide diluted 1/500) and put into sorter tubes. After 15 minutes 
incubation at room temperature in the dark, the cells were ready for analysis. Cells 
were scanned in a Flow Cytometer Beckman Coulter FC500 with the following 
parameters: FSC 95 Volts-1 Gain, SSC 519 Volts-1Gain, FL3 lin 313 Volts-1 Gain.  
The population of cells to analyze was gated according to their size (FSC forward 
scatter) and granulosity (SCC side scatter) to exclude dead cells and clumps. Within 
this cell population cells were gated according to the peak of intensity versus the 
integrated signals to exclude debris and doublets. The number of cells considered to 
be representative of the total cell population for DNA content analysis was 10.000 
cells. 
 
Western blot analysis  
Cells were lysed in monoQ-c buffer [11] and protein quantification was performed by 
Bradford technique. Equal amounts of protein were migrated in a polyacrylamide gel 
and transferred onto a Trans-Blot nitrocellulose membrane (Bio-Rad reference 
n°10484060). Membranes were blocked with 0.5% non-fat milk and incubated for 1 
hour at 4°C with specific primary antibodies. Blots were washed with TBS/Tween 
0.1%, incubated with specific secondary antibodies and visualized with the Odyssey 
infrared imaging system (LICOR Biosciences, Bad Homburg, Germany). 
Quantification was performed using the Odyssey infrared imaging software. 
 
Apoptosis measurements 
Apoptosis in Hela cells was determined by scoring the number of transfected cells 
(i.e. cells expressing GFP) displaying pycnotic or fragmented nucleus [32]. Apoptosis 
in infected MEFs was similarly assessed but in all cells. 
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 Immunocytochemistry 
HeLa cells were seeded in coverslips. 24 hours later coverslips were transferred to a 
clean dish and the immunocytochemistry was performed. Cells were fixed with 2% 
paraformaldehyde diluted in 1x PBS for 15 minutes at room temperature. After 
washing thrice with PBS cells were permeabilized with 0.2 % Triton X diluted in 1x 
PBS for 10 minutes at room temperature. After washing with PBS unspecific binding 
sites were blocked using DMEM culture medium complemented with 15% newborn 
calf serum. After 20 minutes at room temperature, primary antibody anti-HA (1/100) 
was added and incubated for 1 hour at room temperature in a dark and humid 
chamber. Secondary antibody was added after three washes in PBS for 1 hour at 
room temperature in a dark and humid chamber. After extensive washes in PBS 
nuclei were stained with Hoechst 33342 (Molecular Probes; catalogue n° H1399) for 
10 minutes before mounting the slides in 0.1 g/ml Mowiol, 0.22% (v/v) glycerol, Tris 
0.1 M pH 8.5, 0.1% diazobicyclo-octane. Mowiol was from Calbiochem (catalogue 
n°475904) and diazobicyclo-octane was from Fluka (catalogue n° 33480) 
 
Mice and UV-B irradiation 
C57 BL6/sv129 wild type (WT) and RasD455A/D455A knock in (KI) mice were described 
in [Khalil, Peltzer et al., 2012; MCB (accepted)] and were treated as described in [35]. 
 
Immunofluorescence in skin sections 
Paraffin sections were deparaffinized in two consecutive 5 minute long Xylene 100% 
baths and rehydrated by successive 2 minute long washes in ethanol 100%, 96%, 
75% and 50%. Immunohistochemistry was performed as described [21]. Nuclei were 
stained with Hoechst 33342 (Molecular Probes; catalogue n° H1399) for 10 minutes 
before mounting the slides in 0.1 g/ml Mowiol, 0.22% (v/v) glycerol, Tris 0.1 M pH 
8.5, 0.1% diazobicyclo-octane. Mowiol was from Calbiochem (catalogue n°475904) 
and diazobicyclo-octane was from Fluka (catalogue n° 33480). Quantitation of 
fluorescent positive cells was performed as previously described [35]. 
 
Data presentation and statistics 
Results are expressed as the mean ± 95% confidence intervals (CI). The statistical 
tests used were one way ANOVAs unless otherwise stated. Normality of the data 
was verified with the Shapiro-Wilk test. 
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 Results and discussion 
 
To prevent cleavage of fragment N into the smaller N1 and N2 fragments, which can 
potentially generate confounding results, the experiments described below were 
performed with a form of fragment N that has its caspase-3 cleavage site destroyed 
[1,11].  
 
mTOR does not mediate fragment N-induced protection 
S6 kinase, an mTORC1 substrate, was phosphorylated in HeLa cells cultured in the 
presence of serum (Figure 1A, first lane). This phosphorylation was fully blocked by 
rapamycin (Figure 1A, second lane) indicating that mTORC1 is the sole kinase 
mediating S6K phosphorylation in serum-cultured HeLa cells. In starved conditions 
(Figure 1A, third lane), mTORC1 was no longer activated as indicated by the 
absence of S6K phosphorylation. As expected from its ability to stimulate Akt, 
fragment N activated mTORC1-dependent S6K phosphorylation (Figure 1A, last two 
lanes). However, the ability of fragment N to protect cells from cisplatin induced 
apoptosis was unaffected by rapamycin (Figure 1B), suggesting that mTORC1 
activation is redundant or plays no role in fragment N-mediated protection. 
 
Phosphorylation of Bad does not play a major role in fragment N-mediated 
protection 
Bad is a pro-apoptotic protein that is blocked from triggering apoptosis by Akt-
mediated phosphorylation on serine 136 [24]. Bad can be phosphorylated by other 
kinases, such as PKA, on serine 112 [36]. As expected from its ability to stimulate 
Akt, fragment N expressed in HeLa cells induced Bad phosphorylation on serine 136 
but not on serine 112 (Figure 2A). Fragments N1 and N2, the fragment N cleavage 
products generated by high caspase-3 activity that are unable to stimulate Akt [10], 
did not induce Bad phosphorylation (Figure 2A). 
The potential contribution of Bad in fragment N-mediated cell protection was 
assessed in MEFs derived from wild-type and Bad knock-out mice. Figure 2B 
displays the possible outcome of experiments using these cells expressing or not 
fragment N and stimulated with increasing concentrations of cisplatin. As Bad 
mediates part of the apoptotic response to cisplatin [37], reduced cisplatin-induced 
death is expected in Bad KO MEFs (orange lines). If Akt-induced Bad 
110
 phosphorylation does not play any role in the protection mediated by fragment N, the 
latter should decrease the extent of apoptosis to similar extent in wild-type and Bad 
KO MEFs (Figure 2B, left graph). In other words, the maximal percent decrease in 
apoptosis induced by fragment N should be similar in both MEF types as shown in 
the inset above the left graph in Figure 2B. In contrast, if Bad phosphorylation is the 
sole mechanisms by which fragment N protects cells, the sensitivity of Bad KO MEFs 
to cisplatin should be unaffected by the presence of fragment N (Figure 2B, right 
graph). In this case, for Bad KO cells, the difference between the apoptosis curves in 
the presence or in the absence of fragment N should be minimal (orange lines in the 
inset above the right graph in Figure 2B). The middle graphs in Figure 2B display a 
situation where Bad phosphorylation is partially contributing to fragment N-mediated 
cell protection. The actual experiment (Figure 2C) generated a pattern that 
corresponded to the scenario presented on the left of Figure 2B. Therefore, Bad 
phosphorylation plays no or only minimal role in fragment N-induced cell protection, 
or if it does contribute, then this can be fully compensated by other Akt effectors. 
 
Fragment N does not regulate survivin 
There is evidence that Akt can induce survivin expression [31,38,39]. As survivin may 
display anti-apoptotic activity in some conditions [29–31,40,41], it could be one of the 
main targets of fragment N that mediates its survival effects. We therefore assessed 
whether fragment N can regulate survivin by determining if it modulated its 
expression in vitro and in vivo and whether it affected survivin capacity to regulate 
cell division. 
The effect of fragment N on survivin transcription was assessed by luciferase assay 
in which either the minimal or the entire sequence of the mouse survivin promoter 
were used. Fragment N expression in cells had no significant effect on either 
promoter activities (Figure 3A). As a positive control for this experiment, cells were 
transfected with an E2F1-expressing vector that is known to mediate survivin 
transcription [42] and this resulted, as expected, in an increase in survivin promoter 
activity (Figure 3A). To further confirm these results, real time PCR was performed to 
measure survivin mRNA in cells expressing or not fragment N. Figure 3B shows that 
fragment N did not induce an increase in the mRNA coding for survivin. Furthermore, 
survivin protein levels were not affected by fragment N (Figure 3C). 
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 We have recently demonstrated that UV-B exposure of the epidermis leads to Akt 
phosphorylation in a caspase-3 and RasGAP cleavage-dependent manner 
(submitted article). Moreover it has also been shown that survivin expression and 
relocalization to the cytoplasm, where it is supposed to induce its anti-apoptotic 
response [43], is induced in mouse skin in response to UV-B light [35]. Given that 
fragment N induces Akt in the epidermis of UV-B-irradiated mice (submitted article) 
and that cytoplasmic survivin expression is augmented in this same tissue [35], we 
tested whether survivin expression in the skin is affected in knock-in (KI) mice that 
cannot generate fragment N because of a mutation in the first caspase-3 cleavage 
site of RasGAP. Control and KI mice were exposed to UV-B light 24 hours prior to 
biopsy and survivin levels were monitored in the skin by immunofluorescence. The 
percentage of keratinocytes expressing cytoplasmic survivin was increased by UV-B 
in a dose-dependent manner. This increase was similar in wild-type and KI mice 
(Figure 3D). This indicates that even though mice unable to generate fragment N are 
more sensitive to apoptosis (submitted article), they are still able to induce 
cytoplasmic survivin expression to levels that are observed in wild-type mice (Figure 
3D). These results suggest that cytoplasmic-survivin is not involved in fragment N-
mediated protection, at least in mouse skin. Of note, the percentage of keratinocytes 
expressing nuclear survivin was not affected by UV-B light (Figure 3D). 
Survivin is a protein with an important role in mitosis, with a peak of expression at 
G2/M phase and is therefore highly regulated in a cell cycle dependent manner 
[42,44]. Even though fragment N does not appear to affect survivin levels, it may 
regulate its well-described function during mitosis. In order to study whether fragment 
N affects cell cycle, cells expressing or not fragment N were synchronized in G1 
using a mimosine block and then released from this block to resume cell cycling. 
Figure 4 shows that ectopic expression of fragment N did not alter the cell cycle of 
HeLa cells. There is thus no evidence that fragment N regulates survivin in vitro or in 
vivo. 
In conclusion, the results presented in this work did not point to a crucial role of a 
given Akt effector in fragment N-mediated cell protection. Fragment N-mediated 
protection was not affected by mTOR inhibition or in BAD KO cells. Furthermore, 
survivin expression was neither modulated by fragment N nor was its function 
impaired in cells unable to generate fragment N upon stress. Possibly, fragment N 
relies on several Akt downstream targets to mount an efficient cell survival response. 
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 Alternatively, Akt effectors that we have not tested in the present work may fulfill most 
of the anti-apoptotic response induced by fragment N. Further studies need to be 
conducted to determine the exact contribution of Akt targets that mediate the 
capacity of fragment N to protect cells. 
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 Figure legends 
 
Figure 1: mTORC1 is not involved in fragment N-induced cell survival 
HeLa cells were transfected with a GFP-expressing plasmid together with empty 
pcDNA3 or with pcDNA3 encoding the D157A caspase-resistant form of fragment N. 
Twenty-four hours later, the cells were incubated or not 90 min with 20 ng/ml 
rapamycin. A. The cells were lysed after an additional 24-hour period and the extent 
of S6K phosphorylation was assessed by Western blot. B. Alternatively, after the 
rapamycin pre-incubation period, the cells were treated or not with 10 µM cisplatin for 
24 hours and, apoptosis was scored (mean ± 95% CI of 5 independent experiments 
performed in monoplicate). Means with different symbol (# or &) are significantly 
different. 
 
Figure 2: Bad modulation plays little role in fragment N-induced cell survival 
A. MEFs were infected with an empty lentivirus or with lentiviruses encoding 
fragments N, N1, and N2, as indicated. Alternatively, HeLa cells were transfected 
with empty pcDNA3 or with pcDNA3 encoding the fragments N. The cells were lysed 
24 hours later. The extent of Bad phosphorylation was assessed by Western blot 
using antibodies specific for Bad phosphorylated on serine 112 or serine 136. 
Triangles indicate non-specific bands. B. Predicted apoptotic response in cells 
lacking or not Bad in the presence or in the absence of fragment N. See text for 
details. C. MEFs expressing or not Bad were infected with an empty lentivirus or with 
a fragment N-encoding lentivirus. Forty-eight hours later, the cells were incubated 
with the indicated concentrations of cisplatin. Apoptosis was assessed after an 
additional 24 hour-period. The inset depicts the reduction in the percentage of 
apoptosis induced by the expression of fragment N in wild-type or Bad KO cells at the 
indicated doses (using the values of the main figure). The results correspond to the 
mean ± 95% CI of sextuplets derived from 4 independent experiments. Statistics 
were done by repeated measures ANOVA tests. 
 
Figure 3: Fragment N does not regulate survivin expression 
A. Min6 cells were co-transfected with a luciferase expressing vector under the 
control of either a minimal promoter sequence required for survivin activity (left 
graph) or the entire survivin promoter sequence (right graph) with increasing amounts 
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 of fragment N- (closed circles) or E2F1- (open circles) encoding plasmids. The 
results correspond to the mean ± 95% CI of 6 (left panel) and 3 (right panel) 
independent experiments performed in triplicate. Repeated measures ANOVA tests 
were performed to determine if there was significant increase in luciferase activity 
induced by the E2F1- or fragment N-encoding plasmids (normality was verified with 
the Shapiro-Wilk test). B-C. MEFs were infected with an empty virus or with a 
lentivirus encoding the HA-tagged version of the D157A fragment N mutant. Survivin 
mRNA levels were analyzed 24 hours later by quantitative RT-PCR (panel B). The 
location of the 672FW and 672RV primers (red arrows), used for the amplification of 
the survivin mRNA, is depicted on top of the graph. Alternatively, cells were lysed 
and the protein expression of HA-fragment N and survivin was assessed by Western 
blotting (panel C). The results correspond to the mean ± 95% CI of 3 independent 
experiments. D. Skins of mice were irradiated with low (0.05 J/cm2) and high (0.3 
J/cm2) doses of UV-B light. Expression of nuclear and cytoplasmic survivin was 
assessed by immunofluorescence in situ (left panel). The quantitation shown on the 
right-hand side corresponds to percentages of keratinocytes displaying nuclear or 
cytoplasmic survivin (mean ± 95% CI of 6 and 10 mice for the low and high UV-B 
dose exposure, respectively). No cells were found to display both cytoplasmic and 
nuclear survivin expression. 
 
Figure 4: Fragment N does not affect cell cycling 
HeLa cells, infected with an empty virus or with a lentivirus encoding the HA-tagged 
version of the D157A fragment N mutant, were synchronized at G1 by treatment with 
mimosine for 18 hours. The cells were then washed and cultured in fresh medium for 
the indicated periods of time. A. Representative histograms obtained at different time 
points after release from the mimosine block (NT, not synchronized cells). B. 
Immunocytochemistry-based detection (gold staining) of fragment N in the infected 
cells. The nuclei are colored in blue (Hoechst staining). C. Percentage of cells in 
each phase of the cell cycle as determined by PI staining (DNA content). Results 
represent the mean ± 95 % CI of 4 independent experiments. 
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SUPPLEMENTARY DATA 
 
Supplemental materials and methods  
 
Cell fractioning 
At least 1x106 cells were harvested with hypotonic lysis buffer (HEPES pH 7.4 10 
mM, MgCl2 10 mM, KCl 42 mM) and incubated at 4°C for 20 minutes. Cells were 
homogenized using a dounze and spinned down at 300 x g for 5 minutes at 4°C. 
After two washing steps with hypoptonic buffer cells were resuspended with 
hypotonic buffer complemented with 1% Triton X100. The lysate was sonicated 4 
times 15 seconds followed by a centrifugation at 10.000 g for 10 minutes at 4°C. The 
obtained pellet was resuspended in lysis buffer (0.5% Triton X-100, 500 mM Tris-HCl 
pH 7.5, 137 mM NaCl, 10% glycerol, 0.5% Triton X-100) complemented with 0.5% 
SDS and the nuclear fraction was recuperated. The supernatant was centrifugated at 
10.000 x g for 10 minutes at 4°C. The supernatant represented the the cytoplasmic 
fraction. 
 
Mitochondria purification  
MEF cells were harvested in PBS and centrifuged 10 minutes at 1000 x g. After 
resuspending the cells in isotonic mitochondrial buffer (10mM HEPES pH 7.4, 210 
mM mannitol, 70 mM sucrose, 1 mM EDTA, 1 tablet/50ml EDTA-free protease 
inhibitor (Roche)), cells were broken by twenty passages through a 25G1 0.5- by 25-
mm needle fitted on a 2 ml syringe and centrifuged at 1500 x g for 5 minutes. This 
procedure was repeated twice and supernatants from each step were pooled and 
centrifuged 5 minutes at 1500 x g. Supernatant was collected, centrifuged 5 minutes 
at 2000 x g and further centrifuged 10 minutes at 9000 x g. Supernatant was 
conserved and represented the cytoplasmic content. Pellet was then resuspended in 
mitochondrial buffer (MB), centrifuged 10 minutes at 7000 x g and the pellet 
(mitochondrial fraction) was finally resuspended in MB. Protein content was 
quantitated by Bradford.  
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SUPPLEMENTARY RESULTS 
 
Posttranscriptional regulation of Survivin  
As previously mentioned, survivin is targeted to proteasomal degradation by 
ubiquitylation. Moreover, phosphorylation of survivin plays a role in its subcellular 
localization but also in its stability. Connell and collaborators have shown that the 
cytoplasmic fraction of survivin has an increased half-life as compared to the nuclear 
pool (Connell et al., 2008). In order to assess whether fragment N has an effect on 
survivin protein stability, either MEFs or HeLa cells were treated with cycloheximide 
to block translation and harvested at different time points after blockage (Figure 1). 
This allowed us to follow the degradation of Survivin in a time dependent manner and 
to decipher if fragment N could extend the half-life of the protein in two different cell 
types. Surprisingly even if the presence of fragment N slightly induced survivin 
protein levels, its turnover was accelerated as compared to control conditions 
independently of the cell type used (Figure 1A and B). We exclude the possibility that 
the fragment N is degraded during the experiment since its half-life is of 10.5 hours 
(Bulat et al., 2011) and as observed by western blot fragment N protein levels did not 
decrease upon translation blockage (Figure 1A). These results suggest that fragment 
N does not induce survivin stabilization. 
 
Fragment N does not affect survivin subcellular localization 
Survivin exists in different subcellular compartments and nuclear or cytoplasmic 
fractions of survivin bear different functions. Survivin is translocated to the cytoplasm 
of keratinocytes of mouse skin in response to stress and apparently this relocalization 
is related to cytoprotection (Peltzer et al., 2012). Furthermore cytoplasmic fraction of 
survivin has an increased half-life as compared to the nuclear pool of survivin and 
sending survivin to the nucleus abolishes its antiapoptotic effect (Connell et al., 
2008). So far we did not observed an effect on survivin expression by fragment N but 
since its localization is essential for protection in vitro we tested the effect of fragment 
N on survivin translocation to the cytoplasm in response to stress. To answer this 
question we treated MEFs from either WT or KI mice with a low concentration of 
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cisplatin (10 M) that induce a mild stress and analyzed the induction of survivin in 
different cellular compartments (Figure 2A). Low concentration of cisplatin resulted in 
an increase in the levels of survivin expression both in the nucleus and cytoplasm, 
although a more pronounced effect was observed in the nuclear pool of survivin 
(Figure 2A and B). However there was a slight or no difference in the levels of 
cytoplasmic survivin expression in response to cisplatin in WT and KI cells, 
suggesting that survivin translocation does not need a functional RasGAP cleavage, 
and fragment N generation, in vitro, in agreement with data obtained in keratinocytes. 
 
Mitochondrial pool of survivin  
Dohi and collaborators have reported the existence of a mitochondrial pool of survivin 
that is rapidly discharged in the cytosol in response to a cell death stimulus (Dohi et 
al., 2004). In order to assess if fragment N is able to increase the levels of this 
particular pool of survivin we purified mitochondria from cells overexpressing or not 
fragment N and assessed the levels of survivin. As shown in Figure 3, fragment N did 
not affect the mitochondrial levels of survivin in MEFs and thus this pool of survivin is 
not regulated by fragment N. The survivin non-mitochondrial content (cytoplasm plus 
nuclei), was not affected by fragment N, confirming the results presented earlier in 
this section (Figure 5_Results) 
. 
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Figure 1: Survivin stability in the presence of fragment N. A_B_ MEFs were infected with an 
empty virus (Co), or an HA-N enconding virus (N) and treated for 0, 30, 60 and 90 minutes with 
cycloheximide (CHX 50 μg/ml). Representative image of protein lysates analysed by Western 
blot (A) and quantification of survivin band intensities normalized to actin (B, left panel). B 
(right panel)_ HeLa cells were transfected with pcDNA 3 (Co) or with an HA-N encoding plasmid 
(N) and treated for 0, 30, 60, 120, 180 and 240 minutes with cycloheximide. Only quantifications 
are shown. Values correspond to 3 independent experiments ± 95 % CI except for points 180, 
210 and 240 that were performed just once 
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Figure 2: Survivin localization in response to mild stress. Both wild type (WT) and 
RasGAPD455A/D455A (KI) MEFs were treated with a low concentration of cisplatin (15 M) and 
16hs later cell fractionation was performed. A_ Representative western blot depicting survivin 
protein levels in different cell compartments in control or cisplatin treated cells. Purity of the 
fractions was confirmed by tubulin (for cytoplasmic fraction) and Histone 3 (for nuclear 
fraction).  B_ Quantitation of band intensities shown in A. The results represent the average of 
4 independent experiments ± 95% CI. TL: total lysate, Cyt: cytoplasmic fraction, Nc: nuclear 
fraction. 
 
 
 
 
Figure 3: Mitochondrial survivin levels in the presence of fragment N. MEFs were infected with 
an empty virus (Control), or an HA-N enconding virus (HA-N). Mitochondrial protein content 
was isolated and survivin levels were detected by western blot. Mitochondria-free protein 
content is shown as control (left panel). Quantitation of band intensities are shown (right 
panel). The results represent the average of 3 independent experiments ± 95% CI.  
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DISCUSSION AND PERSPECTIVES 
 
Caspase-3 being one of the major proteases involved in cell death is usually linked to 
induction of apoptosis. In the last few years though, many functions different from 
execution of apoptosis have been proposed for this protease. In our laboratory, we 
have previously shown that low levels of caspase-3 induce an anti-apoptotic 
response in vitro through the cleavage of RasGAP and the consequent activation of 
the Ras/PI3K/Akt signaling pathway. This finding explains how cells undergoing a 
mild stress do not die despite the activation of caspases.  
In the present work I have shown that the protective pathway initiated by caspase-3 
activation and fragment N generation is important for the protection of keratinocytes 
of mouse skin exposed to UV-B light, cardiomyocytes of mouse heart injected with 
doxorubicin, and enterocytes in mouse colon treated with DSS. In all the 
experimental conditions studied, I have found that abrogation of the anti-apoptotic 
pathway induced by fragment N either by blocking caspases (caspase-3 KO mouse 
model and caspase inhibitor injection in WT mice), or preventing RasGAP cleavage 
(RasGAP KI mouse model where the first caspase-3 cleavage site of RasGAP has 
been destroyed), resulted in a deficiency of Akt activation which was translated in a 
higher sensitivity to apoptosis. This data suggests that RasGAP cleavage- induced 
anti-apoptotic response is essential to prevent cell death in low stress conditions in 
vivo. Most interestingly, blocking RasGAP cleavage and therefore fragment N 
generation rendered mice prone to an overall dysfunction of the organs where the 
stress stimulus was applied. The relevance of fragment N generation in this response 
was highlighted when WT mice were challenged with a high UV-B dose. Interestingly 
in this condition, there is a reduction of Akt activation and an increase in apoptosis as 
compared to the low UV-B exposed skin. Remarkably, phosphorylated Akt levels and 
percentage of apoptotic cells in WT mice exposed to a high dose of UV-B were 
comparable to those observed in KI mice exposed to the same dose. These 
observations indicate that not only RasGAP cleavage is important for protection, but 
it is specifically the presence of fragment N, since if not generated or destroyed (KI 
mice or WT mice in response to high stress) the protective response is turned off.  In 
these conditions, active caspases-3 levels in the skin are almost undetectable. This is 
not the first evidence of the importance of the levels of caspases in the decision of 
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cell fate. Caspase-8 has anti-necroptosis functions, favoring apoptosis by cleaving 
RIPK1 (Darding et al 2012), however low activation of caspases-8 allows RIPK1 
activation and association with RIPK3, triggering necroptosis and inflammation 
(Bonnet et al. 2011; Declercq et al., 2011). 
Other systems in the cell function as molecular switch determining cell fate in 
response to the level of stress present in the cell. The well-known tumor suppressor, 
p53 has different functions according to the type and level of stress suffered by the 
cell. A wide variety of stressful conditions (DNA damage, hypoxia, heat shock, 
nutrient deprivation and oncogene activation) result in the accumulation and 
activation of p53 and, despite all these stresses converge in the activation of p53, the 
expression pattern of downstream genes appears to be specific for each stress and 
therefore the physiological output is different (apoptosis, senescence or survival). 
p53 can either block cell division and induce DNA repair, sparing  the cell from death 
when damage is mild or transient. However, when damage is extensive or stress 
continues persistently, p53 switches to drive the elimination of affected cells (Gottlieb 
and Vousden, 2010; Hunziker et al., 2010). RasGAP, as p53, regulate cell fate 
according to the level of stress in the cell, indicating that indeed cells can use the 
same proteins to protect or sacrifice themselves. Furthermore, a recent work has 
demonstrated that the ability of p53 to behave differently according to the stress is 
not due to the level of p53 itself, but to the dynamics of p53 expression (Purvis et al., 
2012). Whether RasGAP cleavage also behaves in pulses or in a sustained manner, 
or whether a chronic or an acute stress would affect RasGAP cleavage or fragment N 
mediated response remains to be determined.  
The targeting of the signaling pathway relying on RasGAP cleavage can potentially 
be developed into therapies, aimed to increase resistance of sensitive cells exposed 
to environmental or chemical stresses, or to prevent death in pathological conditions 
such as Parkinson disease (Lev et al., 2003), heart failure (Gill et al., 2002) and 
diabetes (Mathis et al., 2001; Thomas et al., 2009) that are characterized by 
excessive apoptosis in the brain, heart and pancreatic beta cells, respectively. On the 
contrary, it would be stimulating to assess whether mice unable to cleave RasGAP 
into fragment N are more resistant to tumor incidence, postulating RasGAP cleavage, 
and particularly fragment N, as a new target for the study of cancer development.  
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In parallel with this work, I have studied another survival response in the skin relying 
on the previously reported induction of survivin in keratinocytes exposed to UV-B 
light. By studying the expression of survivin in vivo, in mouse skin exposed to UV-B 
light, I have observed an induction of survivin takes place specifically in the 
cytoplasm of keratinocytes of the basal cell layer, which are actively proliferating 
cells. This induction and redistribution of survivin to the cytoplasm is not a 
consequence of cell death but rather of cellular damage. However, our data indicate 
that survivin function as an anti-apoptotic protein is not very potent since the 
percentage of apoptotic cells in the cytoplasmic survivin positive population was 
greater than in the population of cytoplasmic survivin negative population. Further 
studies would need to be conducted in order to assess for instance, if the population 
of cytoplasmic survivin positive cells received the highest damage in response to UV-
B and the expression of cytoplasmic survivin is an attempt to cope with this stress. 
DNA photoproducts generation would be an interesting approach to study the level of 
damage in each individual cell within the epidermis and it would help us determine 
whether there is a correlation between cellular damage and survivin expression in the 
cytoplasm. 
Altogether, this is the first time that survivin has been reported to translocate to the 
cytoplasm in response to an apoptogenic stress in vivo in a non-pathological 
condition and in normal mouse skin. This finding is important in the context of cancer 
biology since cytoplasmic survivin is usually associated with cancer with little or no 
expression in normal cells. Here, I demonstrate that non-tumor cells are able to 
activate cytoplasmic survivin with no effect on nuclear survivin that is linked with 
proliferation.  The presence of survivin in damaged keratinocytes and also in cancer 
or disease, may indicate that survivin is expressed when cells are undergoing a 
stressful condition. 
The discovery that cytoplasmic survivin is induced in the skin together with the 
observation that Akt is also activated in skin in response to UV-B light in a caspase-3 
and fragment N dependent manner, lead me to investigate whether the induction of 
cytoplasmic survivin was a consequence of fragment N-dependent Akt activation. 
However, cytoplasmic survivin was induced in UV-B exposed keratinocytes 
independently on RasGAP cleavage. Moreover, the maximal cytoplasmic survivin 
expression was observed at a high UV-B dose, which does not correlate with 
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fragment N generation and Akt activation. These results indicate that survivin is not 
an important player in fragment N mediated protection at least in keratinocytes 
exposed to UV-B light. Further, this observation suggests that survivin is not 
regulated by Akt in high stress conditions and the effect of Akt on survivin expression 
should be re-evaluated, at least in keratinocytes. 
Other Akt targets were studied for their involvement in this protective pathway such 
as mTOR and BAD but none of them play major roles in fragment N-mediated 
protection, even though induction of mTOR activity and phosphorylation of BAD were 
observed in response to fragment N overexpression. Albeit the existence of many 
other Akt targets that could be involved in this pathway, it is also possible that 
fragment N elicits a pleiotropic effect, initiating a cooperative network to prevent cell 
death through the activation of Akt. Hence one of the main issue that remains to be 
established in the future is whether fragment N affects directly Akt post-translational 
modifications leading to its final activation, such as phosphorylation or ubiquitylation, 
or if it is an indirect mechanism relying upstream of Akt.  
For instance, fragment N could prevent RasGAP from inhibiting Ras- induced 
signaling, by physical interaction with the GAP domain of RasGAP or by stabilizing 
Ras-GTP and therefore recruitment to the membrane and activation of PI3K and Akt. 
The effect of fragment N on the Akt activators mTORC2 and PDK1 activity as well as 
their recruitment to the membrane should also be clarified. Similarly, the importance 
of the different isoforms of Akt implicated in this protective response could contribute 
to elucidate the molecular mechanism underlying RasGAP cleavage.  
Preliminary data performed in HCT116 cells suggests that Akt1, but not Akt2 is 
important for fragment N-mediated protection given that only Akt1 Knock out (KO) 
cells are not protected by overexpressed fragment N in response to FasL-induced 
apoptosis. Akt2 KO cells, on the contrary are still protected by fragment N, 
suggesting that specifically Akt1 plays an essential role in this pathway. Interestingly, 
it has been reported that the absence of Akt2, but not of Akt1, impaired NF-kB 
activation in prostate cancer cells (Dan et al., 2008) indicating that indeed different 
isoforms of Akt can have different effects on downstream targets. Notably, fragment 
N was shown to block NF-kB activation despite the fact that it activates Akt (Bulat et 
al., 2011), (Yang et al., 2009). The fact that specifically Akt2, but not Akt1, blocks NF-
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kB, correlates with our preliminary results suggesting that Akt1, but not Akt2, may be 
specifically involved in this protective response, and may explain how fragment N can 
block NF-kB even though it activates Akt (i.e in an Akt1 independent manner). These 
preliminary results also correlate with the activation of Akt in the skin observed in this 
work, since it has been reported that Akt1 is the predominant isoform expressed and 
activated in the skin in wound healing experiments (Di-Poi et al., 2002). The specific 
role of Akt1 in fragment N-mediated protection and how does fragment N selectively 
activates Akt1 is still a matter of future research. The importance of the different Akt 
isoforms implicated in this response need to be deeply studied and can contribute to 
elucidate the molecular mechanism underlying RasGAP cleavage.  
Taken together, in this work I have discovered a new anti-apoptotic pathway 
operating in vivo in response to different pathophysiological stresses which 
encourages a new line of research in the development of therapies aimed to prevent 
massive cell death, as well as contributing to our basic knowledge of how caspase-3 
can be activated without inducing apoptosis. A more profound research on the 
mechanism of fragment N induced protection is required for the understanding of this 
paradoxical but potent anti-apoptotic response. 
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Reagents 
 
1. HEPES buffer  (2X) pH 7.05 (23°C): 
 
1.1. Important note: always calibrate the pH meter before starting preparing the Hepes buffer. 
1.2. Composition. 
Chemicals Final concentration Source/Company Code/quantities 
    
NaCl 280 mM Fluka 71380 (1 kg) 
KCl 10 mM Fluka 60130 (1 kg) 
Na2HPO4 1.5 mM Merck 1.06586.0500 (500 g) 
D-glucose H2O 12 mM Merck 1.08342.1000 (1 kg) 
HEPES 50 mM Fluka 54461 (250 g) 
    
 
1.3. Recipe. 
Chemicals For 500 ml 
  
NaCl 8 g 
KCl 0.38 g 
Na2HPO4 0.1 g 
D-glucose H2O 1.1 g 
HEPES 5 g 
Adjust pH with NaOH (1 N, then 0.1 N) to 
7.05 (23°C) 
See 1.4 
  
 
1.4. Add ddH2O to about 450 ml, then adjust to pH 6.8-6.9 with 1 N NaOH, and finally to pH 
7.05 with 0.1 N NaOH. Complete to 500 ml with ddH2O. Control that the pH is still at 7.05. 
1.5. Sterilize through a 0.22 m 500 ml Stericups (Millipore #SCGPU05RE). Under a sterile 
hood, aliquot in 50 ml tubes (40 ml per tube). Write the lot number and the date on the tubes 
(the lot number should be indicated in your laboratory book). Store at –20°C.  
 
2. Others 
 
Chemicals Source/Company Code/quantities Solvent [stock] Storage Sterile 
       
NaOH Fluka #71690 (500 g) ddH2O 10 N Room temp. no 
Chloroquine Sigma C6628 (25g) PBS 25 mM -20°C yes 
CaCl2 2H2O (MW 
147.02) 
Acros 207780010 (1 kg) ddH2O 2.5 M 4°C yes 
Gelatin Fluka 48722 (500 g) PBS 0.1% 4°C yes 
DMEM, glutamax I, 
4.5 g/l glucose, sans 
sodium pyruvate 
Gibco 61965026 (500 ml)     
Newborn calf serum 
(NBCS), heat 
inactivated 
Gibco 26010041 (500 ml)     
       
 
2.1. Preparation of NaOH solutions. 
NaOH can cause irreversible damage to the eyes. It is thus mandatory to wear glasses when 
preparing or using NaOH solutions. The preparation of 10 N NaOH involves a highly 
exothermic reaction, which can cause breakage of glass container. Prepare this solution with 
extreme care in plastic beakers. To 80 ml of H2O, slowly add 40 g of NaOH pellets, stirring 
continuously. As an added precaution, place the beaker on ice. When the pellets have 
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dissolved completely, adjust the volume to 100 ml with H2O. Store the solution in a plastic 
container at room temperature (plastic containers are to be used because NaOH slowly 
dissolves glassware). Sterilization is not necessary. 
 
2.2. Preparation of a 25 mM chloroquine solution. 
In a 50 ml Falcon tube, add 0,645 gr of chloroquine and complete to 50 ml with ddH2O. 
Transfer to a 50 ml syringe and sterilize through a 0.22 m filter (Millex – GV filters 
[Millipore #SLGV025LS]). Under a sterile hood, aliquote in 15 ml tubes (10 per tube). Write 
the lot number and the date on the tubes (the lot number should be indicated in your 
laboratory book). 
 
2.3. Preparation of a 2.5 M CaCl2 solution. 
In a 50 ml Falcon tube, add 18.4 g of CaCl2 2H2O and complete to 50 ml with ddH2O. 
Transfer to a 50 ml syringe and sterilize through a 0.22 m filter (Millex – GV filters 
[Millipore #SLGV025LS]). Under a sterile hood, aliquote in 15 ml tubes (10 per tube). Write 
the lot number and the date on the tubes (the lot number should be indicated in your 
laboratory book). 
 
2.4. Preparation of a PBS/0.1% gelatin solution (500 ml). 
Add 0.5 g gelatin and 50 ml PBS 10X to 450 ml ddH2O in a glass bottle. Autoclave and store 
at 4°C. 
 
___________________________________________________________________________________ 
 
 
Procedure 
 
Day 0. 
1. Plate cells in appropriate medium (use gelatinized dishes if required). 
 
Cells Number per 10 
cm dish 
Number per well (6 
well-plates) 
medium Gelatinized 
dish 
     
HEK 293 and 
derived cell lines 2
.
10
6
 350’000 DMEM; 10% NBCS yes 
 
1.1. Gelatinization of the dishes. 
Place the indicated volume of PBS/0.1% gelatin in the dish (tilt the plate to cover the entire 
surface with the solution). Wait at least 10 min. Just before adding the cells to the plates, 
aspirate the PBS/0.1% gelatin (do not allow the plates to dry). 
1.2.  
Dish size Volume of PBS/01% gelatin 
  
10 cm 2-5 ml 
6 well plates 0.5 ml 
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Day 1. 
2. Prewarm the HEPES 2X buffer in a 37°C water bath (at least 20 min). In case the buffer is thawed, 
mix very well before using. 
 
3. Add the DNA in the indicated volume of H2O. Add the corresponding volume of 2.5 M calcium 
solution. Mix 10 times by pipetting the solution up and down. Allow 20-30 min the solution to 
equilibrate. 
4.  
Cells Dish size Volume of 
medium in the 
dish 
DNA 
amount 
Volume of water in 
which the DNA is 
added 
Volume of 2.5 M 
calcium to be added 
      
HEK293 10 cm 10 ml 5-20 g 450 l 50 l 
 6 well plate 2 ml 2 g 90 l 10 l 
 
5. Add 25 M chloroquine to the cell culture medium (not necessary to change the medium). 
Note: if the cells are grown in RPMI medium (e.g. HeLa cells), you have to replace it with DMEM 
because RPMI medium is not compatible with the present transfection technique. 
6.  
Dish size Volume of medium Volume of stock 
   
10 cm 10 ml 10 l 
6 well plates 2 ml 2 l 
 
7. Place the plates back in the incubator for at least 10 min. 
 
8. Add the indicated volume of prewarmed (37°C) 2X HEPES buffer to the DNA/calcium solution, 
mix 5 times by pipetting the solution up and down. Incubate for 1 minute exactly (starting from the 
moment the HEPES has been added to the DNA; not from the time when the mixing is finished). 
Put the DNA-HEPES mix in the culture medium (rock the plate left to right and up and down 2 
times). 
 
Dish size Volume of HEPES 2X to be added 
  
10 cm 500 l 
6 well plate 100 l 
  
 
 
9. Incubate the cells at 37°C for 8-16 hours (always mention this time of incubation in your 
laboratory book). Replace the transfection medium with normal culture medium containing 
penicillin and streptomycin [use a 1:100 dilution of a Penicillin-Streptomycin Glutamine 100X 
solution (10’000 units/ml penicillin G; 10 mg/ml streptomycin sulfate; 29,2 mg/ml L-glutamine; 
10 mM sodium citrate; 0.14% NaCl {GibcoBRL #10378-016})] to avoid contamination (the DNA 
used for the transfection is generally not sterile!). 
 
10. Expected transfection efficiencies (count at least 500 cells). 
 
Cells Transfection efficiency 
  
HEK293 30-80% 
COS 30-40% 
  
 
11. In your laboratory book, always mention how long after step 7 were the cells analyzed. 
___________________________________________________________________________________ 
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Reagents 
 
Chemicals Source/Company Code/quantities 
   
Lipofectamine 2000 (1 mg/ml) Gibco/Invitrogen 11668-019 (1.5 ml) 
RPMI1640 Medium SIGMA R8758 (500 ml) 
DMEM SIGMA D5796 (500 ml) 
Newborn calf serum, heat inactivated SIGMA N4637 (500 ml) 
15 ml polystyrene round-bottom tube Becton Dickinson 352057 
   
 
___________________________________________________________________________________ 
 
Procedure 
 
Day 0. 
1. Plate cells in appropriate medium according to Table I. 
 
Table I 
Cells Number per 10 cm dish Number per well of 6 
well-plates 
medium 
    
HeLa cells 0.5-2
.
10
6 
(use 0.5
.
10
6 
cells for P-Akt assay) 
4 10
5
 RPMI, 10% 
NBCS 
    
 
Day 1. 
a. Add the required DNA amounts at the bottom of sterile Eppendorf tubes (see column 3 of 
Table II). Using a 2 ml plastic pipette, add the serum-free medium (for the volume of medium 
to be used, please refer to column 3 of Table II). Using the same plastic pipette, transfer the 
required volume of serum-free medium to the 15 ml polystyrene round-bottom tubes (for the 
volume of medium to be used, please refer to column 4 of Table II). 
b. Mix the Lipofectamine 2000 stock solution gently before use, centrifuge quickly to pellet the 
drops to the bottom of the tube, and then add the Lipofectamine 2000 to the serum-free 
medium that has been placed in the 15 ml tubes (for the volume of Lipofectamine 2000 to be 
used, please refer to the column 4 of table II). Mix gently and incubate 5 minutes at room 
temperature. 
c. Using 1 ml tips, add the diluted DNA drop by drop to the diluted lipofectamine2000. Mix 
gently and incubate 20 min at room temperature. 
d. Just before the next step, wash the plates twice with serum-free culture medium (see column 5 
of Table II for the volumes to be used). 
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e. Add serum-free culture medium to the DNA + lipofectamine mix with a 5 ml plastic pipette 
and, using the same plastic pipette, add this mixture to the cells (refer to column 6 of Table II 
for the volumes to be used). 
f. Incubate 5 hours at 37°C in a CO2 incubator 
g. After 5 hours replace the medium with serum-containing medium (use twice as much as the 
volumes indicated in column 5 of Table II). The cells can then be processed according to the 
experimental design. 
 
 
Table II 
1 2 3 4 5 6 
Cells Dish size Total DNA 
amount ( g) and 
Dilution 
Volume ( l) 
Lipofectamine 
2000 ( l) and 
Dilution Volume 
( l) 
Washing 
steps 
(volume to 
be used) 
Volumes of 
serum-free 
medium to be 
added to the 
Lipofectamine-
DNA mix 
      
HeLa 10 cm dish 7 g in 600 l 8-10 l in 600 l 5 ml 3.8 ml 
HeLa 6 well-plate 4 g in 250 l 4 l in 250 l 2 ml 1.5 ml 
      
 
_________________________________________________________________________________ 
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Apparatus 
Transfer tank located in the drawers next to Christian’s office door. It is the transparent tank containing 
red-black electrode module inside. Gel cassetes and sponges are either in the drawer above the one containing 
the tanks or above the sink in the middle of the lab.  
 
Materials and reagents 
1. Plastic sheets, commercial Enhanced chemiluminescence (ECL) solution and other reagents. 
1.1. Materials and reagents. 
 
Materials and reagents Source/Company Code/quantities 
   
Plastic sheets 
Kapak Tubular Roll Stock 
[9.5’’x250’ #5 Scotchpak (2 
Mil)]. 
Kapak Parkdale Drivewe, 
Minneapolis, Minnesota 55416 • 
1681 
 
Tris Sigma T1503 5Kg 
Tween Acros p7949 100ml 
Milk   
ECL reagent 
Supersignal West Femto 
Substrate 
Pierce #34095 
Ponceau S Acros 161470250 (25 g) 
   
   
 
 
1.2. Ponceau S Staining Solution [0.1%(w/v) Ponceau S in 5% (v/v) acetic acid] 
 1g Ponceau S  
 50ml acetic acid  
 Make up to 1 liter with ddH2O  
Store at 4
o
C. Do not freeze. 
 
Alternative recipe:0.2% (w/v) Ponceau S in 3% (v/v) acetic acid. 
 
1.3. Tris-buffer saline (TBS; 18 mM HCl, 130 mM NaCl, 20 mM Tris pH 7.2) 
 30ml HCl 
 152g NaCl 
 48g Tris base 
 Up to 1L dH2O 
 
 
1.4. TBS/tween 
 19L dH2O 
 1L 20X TBS 
 0.1% Tween (final concentration) 
 
 
1.5. TBS/milk 
 5% powdered milk (25g for 500ml of TBS/tween) 
 TBS/tween 
 Alternatively some primary antibodies work better if they are diluted in 5% BSA (5%BSA in 
TBS/tween) 
 
2. Home-made ECL solution. 
 
2.1. Composition of the stocks. 
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Chemicals Stock 
concentration 
Final concentration Source/Company Code/quantities 
     
Luminol (3-
aminophthalydrazid
e) 
250 mM (1 g in 
22.7 ml DMSO). 
Make 1.5 ml 
aliquotes 
1.25 mM Sigma A-8511 (1 g) 
P-coumaric acid 90 mM (0.5 g in 
33.3 ml DMSO). 
Make 660 l 
aliquotes. 
0.2 mM Acros 12109-0250 (25 g) 
Tris 1 M pH 8.5 100 mM Boehringer 
Mannheim 
708976 (1 kg); IBCM 
stock 
H2O2 30% 30% 0.01% Merck 1.07210.0250 (250 ml) 
     
Solution 1: 2.5 mM luminol and 0.4 mM coumaric acid in 100 mM Tris pH 8.5. 
Solution 2: 0.02% H2O2 in 100 mM Tris pH 8.5. 
 
 
3. Home-made enhanced ECL solution Note: for the moment this is not working (use the above recipe 
instead). 
 
3.1. Composition of the stocks. 
Chemicals Stock 
concentration 
Final concentration Source/Company Code/quantities 
     
Luminol (3-
aminophthalydrazid
e) 
250 mM 1.25 mM Sigma A-8511 (1 g) 
p-iodophenol (in DMSO) 50 M   
Tris 1 M pH 8.5 100 mM Boehringer 
Mannheim 
708976 (1 kg); IBCM 
stock 
H2O2 30% (8.82 M) 30% 2 mM Merck 1.07210.0250 (250 ml) 
     
 
 
___________________________________________________________________________________ 
Procedure 
 
1. General remarks. 
1.1. The conditions of incubation of the blots have to be adapted for each antigen and each antibody used. 
Therefore, the procedures presented in the following sections have to be considered as general 
guidelines and should not be assumed to work in all cases. Indications of possible improvements when 
the conditions are not found optimal will be mentioned. 
1.2. Always centrifuge the tubes containing the antibodies before usage. 
1.3. In principle, do not incubate two blots in the same bag. 
1.4. Never touch the blot with bare hands. Use gloves and move the blots with tweezers. 
1.5. The following procedure should be considered only for the small gels (see SOP12.1). 
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2. Migration on gels. 
 
Percentage of acrylamide Separation 
  
8% 40-200 kDa 
10% 30-200 kDa 
12% 20-200 kDa 
4-20% 7-250 kDa 
8-16% 15-250 kDa 
  
 
 
3. Transfer to membranes. 
3.1. After migration, proteins are transferred to nitrocellulose filters (Schleicher and Schuell, BA83 0.2,µm, 
no. 401380) or PVDF membranes. Instruction on how to do this can be found in the same drawer as the 
material used for the transfer and for the SDS-PAGE (see SOP 12.1). 
3.2. Transfer buffers. 
David has recently tested the two following buffers. According to him, transfer buffer II works better. 
 
Composition of transfer buffer I. 
Chemicals Stock solution Final 
concentration 
Source/Company Code/quantities 
     
CAPS 1M pH11 10 mM Acros 172621000 (100 g) 
Methanol  10% Fluka 65543 (5 l) 
     
CAPS 1M stock solution (500 ml): 110 g CAPS (MW 221.3) and 20 g NaOH in water. The pH should be 11. 
Store in the dark at 4°C. 
Prepare the transfer buffer (5 liters) directly in the transfer tank (50 ml CAPS 1M, 500 ml methanol, and water 
up to 5 liters). 
Methanol evaporation ensures that the buffer does not heat too much. Therefore the transfer buffers cannot be 
used too many times. Without methanol, the buffer would boil during the transfer! 
Transfer o/n at 600 mA. 
 
Composition of the transfer buffer II. 
Chemicals 10X stock (1 liter) Final concentration 
(1X transfer buffer) 
Source/Company Code [quantities] 
Tris 30.2 g 1 mM Biosolve ltd 20092388 [4 kg] 
Glycine 144 g 8 mM ACROS 120070050 [5 kg] 
SDS 10 ml of a 10% 
solution in water 
0.001% Biosolve ltd 19822359 [0.5 kg] 
Prepare the transfer buffer 1X (5 liters) directly in the transfer tank. 
Add 500 ml of the 10X buffer, 1 liter of methanol and water up to 5 liters. 
Transfer 5 hours at 660 mA. 
 
Currently the situation with the transfer buffers is like this: they are located above the sink were other materials 
for the transfer can also be found (sponges, etc.), There are several bottles of 10x transfer buffer. In order to 
make 1x transfer buffer, mix 100 ml of the 10X preparation with 700ml of water and 200ml of some alcohol 
(methanol or ethanol). 
 
 
3.3  After preparing the transfer tank, place the top on and plug it into a power supply machine (make 
sure that the plus and minus plugs are connected right: you do not want your proteins to be released 
on the wrong side directly into the transfer buffer). Transfer is usually preformed at 250 mA (constant 
amperage) for one hour or one hour and twenty minutes. 
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3.4 Check if the protein markers have been transferred (one should see the markers on the membrane and 
not on the gel). 
 
 
 
4. This protocol should be used when there are no particular problems to get a strong signal 
 
4.1. Ponceau S Stain for Western blots. 
Background. This is a rapid and reversible staining method for locating protein bands on Western blots.  Sensitivity is somewhat 
less than Coomassie blue and produces reddish pink stained bands; minor components may be difficult to resolve.  The stain is 
useful because it does not appear to have a deleterious effect on the sequencing of blotted polypeptides and is therefore one 
method of choice for locating polypeptides on Western blots for blot-sequencing.  The stain binds strongly to nylon-based filter 
media but is fine for nitrocellulose and PVDF membranes.  Incubate the membrane for up to an hour in staining solution with 
gentle agitation.  Rinse the membrane in distilled water until the background is clean.   The stain can be completely removed from 
the protein bands by continued washing.  Stain solution can be re-used up to 10 times.  
How we use it in the laboratory. Incubate the blot in Ponceau for 2-3 min to visualize the proteins and 
to determine whether the transfer was homogeneous. With a pen, mark the position of the molecular 
weight markers. The blots are then subjected to the following incubations. 
4.2. wash 3x 20 min at room temperature with TBS/0.1% Tween 20 (TBS/Tween; found in the big tank next 
to the sink near the entrance of the laboratory). 
4.3. 45-60 min at room temperature with TBS/5% powdered milk (TBS/milk). 
4.4. overnight with the primary antibody (in TBS/milk) at 4°(in a cold room). 
4.5. 3x 20 min at room temperature with TBS/Tween. 
4.6. 45 min at room temperature with TBS/milk. 
4.7. 45 min with the secondary antibody (in TBS/milk) at room temperature (if the secondary antibody bears 
a fluorochrome sensitive to light [e.g. antibodies required for the odyssey detection; see SOP 17], make 
sure that incubation is performed in a black box ). 
4.8. 3x 20 min at room temperature with TBS/tween (in the dark). 
 
5. Detection of the secondary antibodies on films. 
5.1. This method should be used only for antibodies and antigens that do not generate strong signals. If this 
is not the case, detect the secondary antibodies with the BioRad Fluor-S imager (refer to SOP 2.0) or 
even better with the Odyssey apparatus (see SOP 17). 
5.2. Check that the developer has been turned on and is ready to be used. 
5.3. Prepare a cassette that should contain a fluorescent ladder (to position your film on the blot later on). 
5.4. Wash a glass plate thoroughly (first with soap, rinse with water and finally with ethanol). 
5.5. Prepare the ECL reagent by mixing equal volumes of solutions I and II. You need about 1 ml for each 
10 cm
2
 of your blot. 
5.6. Cut some Kappak plastic sheet that will be used to contain your blot during the exposure to films. Seal 
it but leave one side open. 
5.7. Take the blot with tweezers and touch some absorbing paper with one of its corner to remove the liquid 
in excess. Place the blot on the glass plate with the transferred proteins up. Pour the ECL reagent on the 
blot. Check that the whole surface is covered and wait one minute. 
5.8. With tweezers, transfer the blot in the Kappak bag. Remove the bubbles and seal the bag. Using 
absorbing paper, remove the liquid on the exterior of the bag. Place the bag in the cassette as close as 
possible to the fluorescent ladder. Tape the bag on one side. 
5.9. Immediately, go to the dark room with the sealed blot, the films and a cassette. Place a film on the blot. 
Close the cassette. Wait one minute. Remove the first film that you insert in the developer. While the 
first film develops, place a second one on the blot and close the cassette. When the first film comes out, 
check the intensity of the signal. If it is weak, expose the second film for 5-15 min. If it is too strong, 
develop the second film immediately (it will of course be too dark too) and expose a third film to 5-15 
seconds. If the film has to be exposed for 1-2 seconds, tape it on the other side of the cassette. This will 
ensure that when you close the lids, the film will not move. Note again that if the signal is strong, you 
should not use this technique (see point 3.1). 
5.10. Keep all the films (the overexposed ones are often used to position the molecular weight markers). All 
the films should be labeled (do it immediately) with the date, the experiment number, the exposure 
time, the type of ECL used, and the experimental conditions for each lane. Also try (when possible) to 
identify the bands on your blots. 
 
6. Detection of the secondary antibodies with the BioRad Fluor-S imager. 
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6.1. Refer to SOP 2.0. 
6.2. In this case also, the images obtained should be labeled: date, the experiment number, the exposure 
time, the type of ECL used, and the experimental conditions for each lane. Also try (when possible) to 
identify the bands on your blots. 
 
7. Quantitation of the ECL signal. 
7.1. In principle, quantitation should not be performed using films because the signal on films is not linear 
(you need more that one photon to active the silver grains) and saturates rapidly. 
7.2. If possible, quantitation should be performed using the BioRas Fluor-S imager. Please refer to SOP 2.0. 
 
8. Detection of the secondary antibodies using the Odyssey system (Licor). 
8.1. Refer to SOP 17. 
 
9. No signal 
9.1. Increase the incubation with the antibodies: o/n incubation with the first antibody and 2-4 hours with the 
secondary antibody. Perform the incubations at 4°C. 
9.2. Reduce the “stringency” of the incubation buffer. Milk containing buffer can possibly quench a fraction 
of the antibody. The following buffers are ranked from highest to lowest stringency: milk-containing 
buffer, BSA containing-buffer, tween-containing buffer, PBS or Tris buffer. 
 
10. How to store antibodies. 
10.1. It is possible to reuse antibodies many times and this should be done whenever the antibody is rare and 
not available commercially. The solution containing the antibody needs to contain 0.05% azide (NaN3) 
and 10 mM EDTA. 
 
11. Very important: after completion of the Western blot procedure, always store the nitrocellulose membranes 
in Kappak bags at -20°C for further potential use. 
 
___________________________________________________________________________________ 
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Reagents 
 
 
 
Chemicals/medium Source/Company Code/quantities 
   
JETstar maxi Genomed 20 prep (#220020) 
Isopropanol   
Glycerol   
Tris   
EDTA   
 
TE: Tris 10 mM pH 7.4, EDTA 1 mM. 
___________________________________________________________________________________ 
 
 
 
Bacteria culture 
 
1. For most plasmids, inoculate 250 ml of LB with the appropriate antibiotic (see SOP 8.0) with: 
- a tip that has touched a colony on an Agar plate 
- a few ml of a mini-prep culture 
- a chunk of a glycerol stock taken with a yellow tip 
2. Incubate o/n at 37°C in a shaker. 
3. If required, take 1 ml of the culture to prepare a glycerol stock (put this one ml in an Eppendorf tube, 
centrifuge in an Eppendorf centrifuge at 4’000 rpm for 5 min, discard the supernatant and resuspend 
the pellet in 300-500 l of a sterile 10% glycerol solution; store at –70°C). 
 
Maxi prep 
 
1. Principle. 
The procedure employs a modified alkaline/SDS method to prepare the cleared lysate. After 
neutralization, the lysate is applied onto a JETstar column and the plasmid DNA is bound to the anion 
exchange resin. Washing the resin removes RNA and all other impurities. Afterwards, the purified 
plasmid is eluted from the column and finally concentrated by alcohol precipitation. 
The supplier says that the JETstar purified plasmid DNA is of a higher quality than 2 x CsCl purified 
plasmid DNA. 
The expected yield for a maxi column is between 300-500 g of DNA. 
 
2. Centrifuge the cultures in 250 ml bottles at 5’000 rpm for 5-10 min at 4°C using the GSA rotor in the 
Sorvall RC-5B centrifuge. Check that the rotor is clean before and after use. Clean if necessary and 
always remove any liquid present. 
3. Place the column on the “blue cow”. Add 30 ml of solution E4 in the column and let flow by gravity. 
4. Note: RNAse must be added to solution E1 prior to its first use. Just poor the lyophilized RNAse 
powder into bottle E1 and mix. Add the sticker indicating that the RNAse has been added, the date and 
your name. 
Discard the supernatant. Resuspend the pellet in 10 ml of solution E1. 
5. Add 10ml of solution E2 and mix gently. Incubate 5min at room temp on a rocker (Rocker lnotech; 
shake 9, timer 5, frequency 17). 
6. Add 10 ml of solution E3 and mix immediately by inverting the bottle 5 times. Transfer to a 50 ml blue 
Falcon tube (do not use yellow Falcon tube since they are more fragile and may break during the 
centrifugation). Centrifuge at 9’000 rpm for 10 min at 20°C using the SLA 600TC rotor in the Sorvall 
RC-5B centrifuge. 
7. Poor the supernatant on the column and let flow by gravity. Wash the resin with 60 ml of solution E5. 
8. Place the column on a 50 ml blue Falcon tube and secure the column on the tube with tape. Add 15 of 
solution E6 and let flow by gravity. 
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9. Add 10.5 of isopropanol. Mix and incubate on ice for at least 1 hour (alternatively, the tube can be 
stored o/n at –20°C). 
10. Centrifuge at 10’000 rpm for 30 min at 4°C using the SLA 600TC rotor in the Sorvall RC-5B 
centrifuge. Discard the supernatant being very careful not to loose the pellet that is not always firmly 
adherent (sometimes not at all). 
11. Add about 20 ml of 70% ethanol. Centrifuge at 10’000 rpm for 10 min at 4°C using the SLA 600TC 
rotor in the Sorvall RC-5B centrifuge. Discard the supernatant as above. Aspirate all the residual drops 
with a long white tip. 
12. Resuspend the pellet in 500 l of TE. 
13. Measure the concentration with the spectrophotometer using a 1/100 dilution in a quartz cuvette. One 
OD at 260 nm corresponds to 50 g/ml of DNA. The ratio between the OD at 260 nm and the OD at 
280 nm should be between 1.8 and 2.0. 
14. Write down the concentration of the maxi prep in the plasmid files as well as on the tube. 
 
___________________________________________________________________________________ 
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Day 1  
 
Put two coverslips per well in a 6 well plate and incubate 30 minutes with gelatine 0.1%. After this 
time remove the gelatine and put the cells over them. Make sure the coverslip is well attached to the 
surface of the well (push it down softly with a tip). 
 
Day 2 
 
1. Put 1 coverslip / well in a new 6 well plate and wash with 2 ml of PBS 1x 
2. Fix the cells to the coverslip surface by treating with PAF 2% (parafolmaldehide diluted in 
PBS) for 15 minutes 
3. Wash once with PBS 
4. In order to permeabilize the membranes, incubate the coverslips with triton 0.2% (diluted in 
PBS) for 10 minutes  
5. Wash once with PBS 
6. To block unspecific binding sites of the antibody incubate 15 minutes with DMEM + 10% 
FCS 
7. Dilute the antibody in DMEM + 10% FCS (see dilution in the datasheet of each antibody). Put 
a drop of 60 ul in a parafilm very well straightened over the bench and place the coverslip 
upside down over the drop (the cells have to be in contact with the antibody solution). 
Incubate 1 hour at room temperature in a humid environment. We usually use a polystyrene 
box with a wet absorbing paper stick inside and cover the coverslips with this box.  
8. Remove the excess of the antibody solution by touching an absorbing paper with the border of 
the coverslip and place it with the cells facing up in a new well. Wash with PBS 1x. 
 
Sometimes the antibody solution can be recycled, add 0.05% azide to avoid contamination and store it 
at 4°C 
 
9. Dilute the secondary antibody in DMEM + 10% FCS, according to experimental experience, 
usually it’s between 1/300-1/500 
 
If we use an antibody coupled to a fluorophore, from now on everything has to be done in low light 
conditions 
 
10. Proceed as in step 7  
11. Proceed as in step 8. Wash extensively, around 4 washes of 20 minutes each.  
12. Incubate the coverslips with Hoechst diluted in PBS 1x (1/1000) for 10 minutes  
13. Mounting of the slides: More than one coverslip per slide can be placed. Put 2 ul of per 
coverslip)Vectashield (mounting medium) and place the coverslip very carefully upside down 
(cells facing towards the vectashield) over it. 
14. Seal the coverslips with nail polishing. Store at 4°C and away from the light. 
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Apparatus 
Spectrophotometer Beckmann Life Science DU®530 
 
 
 
Materials and reagents 
 
Chemicals Source/Company Code/quantities 
   
Bovine serum albumin 
(BSA) 
Sigma A-7906 
Orthophosphoric acid Acros 201140010 
Coomassie blue Acros 191480250 
Ethanol Biosolve 20655 
Whatman paper Whatman 3030917 
Plastic microcuvettes 1.5ml Brand 7590.15 
NaOH Fluka 71690 
   
 
 
BSA standrard 
Concentration (mg/ml) l of stock (10 mg/ml) l of water 
   
0.0 0 1000 
0.5 50 950 
1.0 100 900 
1.5 150 850 
2 200 800 
   
 
Standards are kept at -20°C. Each person makes her/his own standards. 
 
 
 
Bradford reagent 
Reagents Quantity 
  
Orthophosphoric acid 400 ml 
Coomassie blue 0.4 g 
Ethanol 95% 200 ml 
Water Up to 4 l 
  
 
Important: Add the Coomassie Brilliant Blue powder only at the end, after preparing the 
whole solution!!!! 
Filter through WHATMAN 
 
 
 
Cuvettes:  
Disposable cuvettes 
1.5 semimicro 
Dimensions 12.5 x 12.5 x 45mm 
Brand cat : 7590.15 
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Measure of the concentration of proteins: 
 
 Standard (duplicate) Samples (duplicate) Blank 
 
NaOH 0.2N 200ul 200ul  
Lysate  3.3ul  
Standard 10ul   
Bradford’s reagent 1.8ml 1.8ml 1.8ml 
 
Bradford’ reagent has a dispenser ready with 1.8ml 
 
 Keep in dark before to measure min. 15 minutes (not necessary) 
 Standards and samples must be measured twice.  
 Read the absorption at 590-600nm: 
 Main menu fixed λ Blank    
 Make an average of standards 
 Read the samples 
 Put the paper, online, print 
 Make an average of your samples and the difference between of them should be less as 5% 
 Use the excel program to calculate yours concentrations 
 
 
 
 
 
Another way to measure the protein concentrations is as follow: 
Introduce the values into the spectrophotometer twice: 
 
Main menu  Protein assay bradford  enter  STD curve enter more enter create table enter 0 enter 0 
enter 0.5 enter 0.5 enter 1.0 enter 1.0 enter 1.5 enter 1.5 enter entry done.  
 
Zero with Bradford’s reagent  
Lecture of standards, when we have the curve:    entry done 
Dil 1.00 Changer and put factor 3.00 enter 
 
Read yours samples and you have directly the protein’s concentration then is the same thing as the possibility 
number one. 
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IMPORTANT NOTE 
The viral supernatants produced by these methods might, depending upon your retroviral insert, contain 
potentially hazardous recombinant virus. The user of these systems must exercise due caution in the production, 
use and storage of recombinant retroviral virions, especially those with amphotropic and polytropic host ranges. 
This consideration should be applied to all genes expressed as amphotropic and polytropic pseudotyped 
retroviral vectors. Appropriate guidelines should be followed in the use of these recombinant retrovirus 
production systems. 
The user is strongly advised NOT to create retroviruses capable of expressing known oncogenes in amphotropic 
or polytropic host range viruses. 
__________________________________________________________________________________________ 
 
According to the Swiss Legislation all the manipulations done using lentiviruses, must be performed in a 
P2 security Laboratory. 
For details and authorization for using the P2 Lab, contact Sylvain Lengacher at the Institute of Physiology (tel. 
021 692 55 46, email: Sylvain.Lengacher@unil.ch) 
__________________________________________________________________________________________ 
 
For some additional information concerning the Lentiviral Systems you can check the following websites. 
Garry Nolan’s Lab website at Stanford University: http://www.stanford.edu/group/nolan/ 
Didier Trono’s Lab website at Geneva University:  http://www.tronolab.com/ 
__________________________________________________________________________________________ 
 
Reagents. 
Hexadimethrine bromide (Polybrene), Fluka (Sigma Cat. N° 52495) 
Sucrose, Fluka (Sigma Cat. N° 84100) 
Paraformaldehyde 95 %, (Sigma Cat. N° 441244) 
Penicillin-Streptomycin Glutamine 100x solution, (GibcoBRL Cat N° 10378-016) 
0.45 µm filters, Millex-HN, 0.45um, 25mm, stérile, 50/PK (Milian Cat N° SLHN025NS) 
0.22 µm filters, Millex-GN, 0.22um, 25mm, stérile, 50/PK (Milian Cat N° SLGN025NS) 
Chloroquine (Sigma Cat. N°C6628). 
Laminin, mouse (1 mg) (BD Bioscience Cat. N° 354232) 
Poly-D-Lysine (20 mg) (BD Bioscience Cat. N° 354210) 
Biocidal ZF (1 l) (WAK Chemie Cat N° WAK-ZF-1) 
 
Solutions. 
 
1X Phosphate Buffered Saline (PBS) 
NaCl,  8 g 
KCl,  0.2 g 
Na2PO4,  1.44 g  
KH2PO4  0.24 g  
H2Odd  800ml  
Adjust pH to 7.4 with HCl. 
Adjust volume to 1 liter with additional distilled H2O. Sterilize by autoclaving. 
 
Tris-EDTA (TE) buffer. (10 mM Tris; 1 mM EDTA; pH 8.0)  
1 M Tris pH 8.0  1 ml   
0.5 M EDTA pH 8.0  0.2 ml   
H2Odd 98.8 ml   
Autoclave 
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Polybrene 5 mg/ml (10 ml). 
Dissolve 5 mg of Polybrene in 10 ml of PBS. Filter through a 0.22 µM filter, aliquot in eppendorf tubes (1 ml 
per tube) and store either at 4°C or at -20°C. 
 
Chloroquine 25 mM (50 ml). 
Dissolve 399.8 mg of Chloroquine in 50 ml of PBS. Filter through a 0.22 µM filter, aliquot in 15 ml falcon tubes 
(10 ml per tube) and store at -20°C. 
 
Sodium Acetate 3 M pH 5.2 (100 ml). 
To 24.6 gr of sodium acetate (Sigma Cat. N° S-2889), add 90 ml of nanopure water. Adjust the pH to 5.2 (with 
glacial acetic acid) and complete to 100 ml. 
 
Fixation Solution (2% Paraformaldehyde 3% Sucrose). 
a. Weigh 0.2 gr paraformaldehyde in a 15 ml tube. 
b. Add 6 ml PBS. 
c. Warm up to 60˚C and vortex. 
d. Add drops of 0.5 M NaOH, warm up to 60° C and vortex until it dissolves. 
e. Add 0.3 gr of Sucrose and make up the volume to 10 ml with PBS. 
f. Make sure the final solution is neutral. 
 
Procedure 
Note: for details on the transfection protocol, refer to SOP001 Transfection (calcium-phosphate). 
Day 0. 
1. Prepare five 10 cm gelatinized Petri dishes containing 2 - 2.5x106 HEK293T cells in 10 ml medium. 
Gelatinization of the dishes. 
Place between 2 to 5 ml of PBS/0.1% gelatin in the dish [See SOP001] (tilt the plate to cover the entire surface 
with the solution). Wait at least 10 min. Just before adding the cells to the plates, aspirate the PBS/0.1% gelatin 
(do not allow the plates to dry). 
Day 1. 
2. Prewarm all the solutions in a 37°C water bath (at least 20 min). In case the buffer is thawed, mix very well 
before using. 
3. Add 25 M chloroquine (10 µl of the 25 mM solution) to the cell culture medium (not necessary to change 
the medium). Place the plates back in the incubator for at least 10 min. 
The addition of chloroquine to the medium appears to increase retroviral titer by approximately two fold. This 
effect is presumably due to the lysosomal neutralizing activity of the chloroquine (3). It is extremely important 
that the length of chloroquine treatment does not exceed 12 hours. Longer periods of chloroquine treatment have 
a toxic effect on the cells causing a decrease in retroviral titers. 
4. In a 15 ml Falcon tube prepare the following master mix: 
 
 Volume or quantities 
H2O  
pCMV delta R8.91 
pMD.G 
Lentiviral vector (e.g. Prom.lti) 
encoding the gene of interest 
CaCl2 
2xHepes  
Variable 
37,5 µg 
12,5 µg 
50 µg 
 
250 μl 
2500 μl 
FINAL VOLUME 5 ml 
All the plasmid should be prepared using Qiagen or Genomed Maxiprep kits and ethanol precipitated. In case 
the yield of the plasmid is not very high it should be purified using the CsCl purification method. 
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 Ethanol Precipitation: 
a- Carefully calculate the volume of your DNA solution. 
b- Add 1/10 volume of 3 M Sodium Acetate pH 5.2, mix well. 
c- Add 2 volumes of cold absolute ethanol. 
d- Keep at -20° C for at least 1 hour. 
e- Centrifuge 10’ at maximum speed. 
f- Discard supernatant and wash pellet with ethanol 70 % three times. 
g- Air dry and resuspend in TE. 
h- Measure DNA concentration. 
5. Mix well, by passing 5 times the solution through a 5 ml pipette.  
6. Exactly 60 seconds after mixing the 2xHepes with the CaCl2-DNA mixture, add 1 ml precipitate per plate. 
7. Incubate for 6-8 hours in an incubator (37°C - 5% CO2). 
8. Remove medium, wash once with PBS and put fresh medium containing penicillin and streptomycin to 
avoid contamination (the DNA used for the transfection is generally not sterile!). 
9. 48 hours after the transfection, collect the supernatant of the plates in a 50 ml Falcon Tube. 
10. Centrifuge for 5’ at 1500 rpm (~400 g) at 4°C to pellet the detached cells (ALC PK 130 centrifuge, rotor N° 
T535). 
11. Filter the cleared virus-containing supernatant through a 0.45 µm filter, wrapping everything in a towel 
humidified with biocidal to avoid aerosols. 
12. Once the virus is filtered, aliquot in 15 ml falcon tubes. 
Note: The size of the aliquots may change according the use you will give to your virus.  
13. Keep the virus at -80°C. 
Freezing does not appear to cause more than a 2-fold drop in titer, as long as the cells do not undergo more 
than one freeze/thaw cycle. If the cells undergo more than one freeze/thaw cycle, there is a significant drop in 
retroviral titer. 
14. If the virus encodes for a protein that can be detected, calculate functional titer by immunocytochemistry 
(See SOP011 Immunocytochemistry), as detailed below [for siRNA encoding lentiviruses you may calculate 
your functional titer by monitoring by western blot the conditions that lead to the best decrease of the 
targeted proteins, (See SOP006.1 Western Blot)]. 
1. Laminin-Polylysin coating 
PolyLysine.  
Comes as 20 mg/vial. Add sterile H2O to the vial to a final volume of 1 ml to make a 1 mg/ml stock solution (in 
a 50 ml falcon tube). Make 1 ml (=1 mg) aliquots. Store at -20 C. 
Laminin. 
Comes as 1 mg/vial. Add sterile H2O to the vial to a final volume of 1 ml to make a 1 mg/ml stock solution. 
Make 100 µl (=100 µg) aliquots. Store at -70 C. 
Coating Coverslips. 
1. Thaw 1 tube of polylysine and laminin solution. 
2. Add laminin, poly-lysine to 25 ml of sterile H2O. 
3. Use 50 µl solution for each coverslips. Place at 37° C for 2 hrs. 
4. Rinse 3x with PBS, and use to plate cells. 
 
2. Plate the appropriate number of cells (according to your cells type) in six-well dishes, with two laminin-
coated coverslips in each well. 
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Cells 
Number per 
well (6 well-
plates) 
Medium Coating 
GAP 
+/+ 
and 
derived cell lines 
3-5
.
10
4
 DMEM; 10% NBCS 
Polylysin 
/Laminin  
HEK 293 and 
derived cell lines 
35
.
10
4
 DMEM; 10% NBCS 
Polylysin 
/Laminin  
β-Tc-Tet and 
derived cell lines 
10
5
 
DMEM (without L-Glu); 15% 
Horse Serum (Heat 
decomplemented); 2,5% FCS; 
2 mM L-Glu; 10 mM Hepes 
pH 8; 1 mM Na-Pyruvate 
Polylysin 
/Laminin  
3. Incubate cells at 37°C, for 12-18 hours.  
Important: infect cells when they are not more than 50% confluent. 
4. The following day, thaw the frozen virus at 37°C (shake often) and once nearly completely thawed, 
keep on ice. The virus should stay at 0°C all the time. 
5. Add various amounts of viruses according to the table below, add 2 μl of a 5 mg/ml polybrene stock 
solution and complete with fresh medium to 3 ml. 
Cell # 0 ml 0.25 ml 
0.5 ml 1 ml 2 ml 
6. Immediately thereafter, seal the plates with parafilm and centrifuge them 45' at 2’500 rpm (~800 g) 
(ALC PK 130 centrifuge, rotor N° T537). 
7. Incubate overnight in incubator (37°C - 5% CO2). 
8. Change medium after 24 hours. 
9. Remove medium 72 hs after infection and rinse once with 2 ml of PBS. 
10. Fix cells by adding 1 ml of PBS-2% paraformaldehyde-3% Sucrose, for 15 minutes. 
11. The following immunocytochemistry steps can be performed on the bench (See SOP011). 
12. Knowing the number of cells at the moment of infection and the smallest volume that leads to 
expression of the gene of interest in ~100% of the cells, you can estimate the number of infective 
particles per ml. 
__________________________________________________________________________________________ 
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Introduction. 
In molecular biology, reverse transcription polymerase chain reaction (RT-PCR) is a laboratory 
technique for amplifying a defined piece of a ribonucleic acid (RNA) molecule. The RNA strand is first 
reverse transcribed into its DNA complement or complementary DNA, followed by amplification of 
the resulting DNA using polymerase chain reaction. This can either be a 1 or 2 step process. 
Polymerase chain reaction itself is the process used to amplify specific parts of a DNA molecule, via 
the temperature-mediated enzyme DNA polymerase. 
Reverse transcription PCR is not to be confused with real-time polymerase chain reaction which is also 
marketed as RT-PCR. 
The present SOP only describes the reverse transcription part of the procedure. 
 
RNA isolation. 
 
 Day 0 
1. Add 500 μl of TRI reagent (for 105 to 3 x 107 cells) to the cells and scrape them. Incubate at 
room temperature for 5 minutes. 
2. Add 200 μl of Chloroform, vortex and incubate 5 minutes at room temperature. 
3. Spin 15 minutes at maximum speed (13’000 rpm in the Eppendorf centrifuge 5415R; 16’100 x 
g). 
4. Transfer the aqueous phase into a new tube, add 500 μl of isopropanol, mix by inverting the 
tube a few times and put at -20°C o/n. 
 
 Day 1 
1. Spin 20 minutes at high speed (13’000 rpm in the Eppendorf centrifuge 5415R; 16’100 x g). 
At this stage if you do not see the pellet, add 40 μl of NaCl 5 M, mix by inverting the tube a 
few times and spin down again 15 minutes. 
2. Aspirate the isopropanol. 
3. Wash with 800 μl of ethanol 70%. 
4. Place the tubes in the thermomixer (Eppendorf Thermomixer Comfort, it is located in the lab) 
at 60°C for 10 minutes without shaking to let them dry. 
5. Resuspend the pellet in 50 μl of high quality water. 
6. Quantitate the RNA using the Eppendorf Biophotometer located in the lab. Push button n°9 to 
select the program to quantitate RNA, take the quartz cuvette QS 1.000  (usually located next 
to the Biophotometer), fill the cuvette with 200 μl of TE pH 8.0 and add 2 μl of your RNA. 
Mix. Click on the button labelled “Dilution” and enter the dilution (2:200). Proceed with the 
quantitation. Do not forget to do first the blank by  filling the same cuvette with 200 μl of TE 
and subsequently clicking on the button labelled ‘Blank’. You will get 260 nm values. An 
A260 reading of 1.0 is equivalent to ~40 μg/ml single-stranded RNA. 
Note that measuring the 260 nm/280 nm absorbance ratio of your samples is not a very informative method to monitor 
the purity of your preparation (despite what is written in some protocols) (Glasel, 1995). Note also that this ratio is 
influenced by the pH and ionic strength of the solution. As pH increases, the A280 decreases while the A260 is 
unaffected. This results in an increasing A260/A280 ratio (Wilfinger et al., 1997). Because water often has an acidic 
pH, it can lower the A260/A280 ratio. It is recommended to use a buffered solution with a slightly alkaline pH, such 
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as TE (pH 8.0), as a diluent (and as a blank) to assure accurate and reproducible readings. An example of the variation 
in A260/A280 ratio at different pH values is shown below 
 
BLANK/DILUENT A260/A280 ratio 
 
DEPC-treated water (pH 5-6) 1.60 
Nuclease-free water (pH 6-7) 1.85 
TE (pH 8.0) 2.14 
 
7. To have a better idea of the quality of your RNA, run it on an agarose-formaldehyde gel as 
follows: 
a. Melt 0.5 g of agarose in 37 ml of H2O, cool down a little bit, add 5 ml of 10x MOPS 
buffer and 8.75 ml of formaldehyde 36.5 %. 
b. RNA loading: prepare a mix composed of a few micro litres of your RNA 
(corresponding more or less to 500 ng), one fifth of the final volume with 5X RNA 
denaturing buffer, and water (usually up to a final volume of 10 μl). 
c. Perform electrophoresis in 1x MOPS. 
d. If your RNA preparation is good, you should see 2 bands, the highest one 
corresponds to the 28S RNA, the lowest one to the 18S RNA. 
 
 
 
Reverse Transcription 
0.5-1.0 μg total RNA 
1.0 l of a 500 ng/ l oligo dT solution in water. 
The Olido dT primer is purchased from Microsynth; you have to sent an e-mail to the following address: 
administration@microsynth.ch asking for Random Hexamer D(N)6. Once you receive the tube (the quantity received is indicated 
on the datasheet), dissolve the oligo dT in water to get a concentration of 500 ng/ l. The oligo dT solution can be stored at -80 °C 
(alternatively, if you use them quite often, you can store some aliquots at -20 °C). For the delivery you can write in the e-mail 
your customer number, like that they automatically know your delivery address). 
Add water to 11 μl. 
3 minutes at 70°C and then keep on ice 
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Prepare the mix according to the table below. The buffer 5x, the DTT, the dNTPs, the RNAsin, and the 
reverse transcriptase come from the Superscript II Reverse Transcriptase Kit. 
Reagent μl 
    
dNTPs 10 mM each 5 
RNAsin 0.5 
Buffer 5x  5 
DTT 2 
Superscript reverse transcriptase 0.5 
H20 1 
    
Total 14 
 
Add the RNA to the mix and perform an incubation at 39ºC for 1 hour followed by 15 minutes at 70ºC. 
Your cDNA is now ready to be amplified by PCR. 
 
************************************** 
 
Materials and reagents Source/Company Code 
Agarose Eurogenetec EP-0010-10 
-mercaptoethanol  Sigma M6250 
Bromophenol blue Fluka 18030 
EDTA Fluka 03620 
Ethidium Bromide Acros 170960010 
Formamide (25 M) Fluka 47670 
Formaldehyde 36.5% (13.2 M) Fluka 47629 
Ficoll Pharmacia Biotech 17-0400-01 
Guanidinium Thiocyanate  AppliChem 593-84-0 
MOPS (morpholinopropanesulphonic acid) Sigma M3183 
N-Lauryl Sarcosil sodium  Sigma L9150 
NaOH Fluka 71690 
Phenol (water saturated) EUROBIO GEXPHE01-0U 
RNA sin Promega N211A 
SDS Sigma L4390 
Sodium Acetate  Sigma S288 
Sodium Citrate  Sigma C8532 
dATP Promega U120D 
dGTP Promega U121D 
dCTP Promega U122D 
dTTP Promega U123D 
Superscript II Reverse Transcriptase Kit ( Buffer 5x, DTT 
and Superscript reverse transcriptase) Invitrogen 18064-014 
 
TRI solution (1.7 M guanidinium thiocyanate, 0.1 M sodium citrate, 0.25% sarcosyl, 0.05 M -
mercaptoethanol, 0.1M sodium acetate) 
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Mix 10 ml guanidinium thiocyanate 4 M, 352 μl sodium citrate 0.75 M (pH 7), 528 μl sarcosyl 10% 
and 76 μl -mercaptoethanol 14.3 M for a total volume of 10.9 ml. 
Place 10 ml of this mixture in a new tube, add 1 ml 2 M sodium acetate pH 4 and 10 ml of water-
saturated phenol. This is the final TRI solution that is good for at least 2 month at 4°C. 
 
10x MOPS buffer (0.2 M MOPS, 50 mM sodium acetate and 5 mM EDTA) 
200 ml of  MOPS 1M 
25 ml of sodium acetate 2M pH 4 
5 ml of EDTA 1 M 
Up to 1 liter with water 
The buffer is adjusted to pH 7.0 with 1 M NaOH and sterilised by autoclaving. Keep at 4 º C protected 
from light. 
 
Ethidium bromide 1mg/ml solution. 
Ethidium bromide is prepared under the chemical hood (wear gloves, protection glasses and mask) by 
dissolving the appropriate amount of powder in water; the solution is then stored at 4 º C. After 
preparing the solution wrap the tube with aluminium paper because EtBr is sensitive to light. 
 
FESB solution (Ficoll 10%, EDTA 10 mM, SDS 0.5% and bromophenol blue 0.02%) x 10 ml 
5 ml of Ficoll 20%   
100 μl of EDTA 1 M 
250 μl  of SDS 20% 
2 mg of bromophenol blue. 
 
RNA denaturing buffer 5x (Formaldehyde 2.6 M, Formamide 12.5 M, 2% Ficoll, 2mM EDTA, 
0.1%SDS, 0.004% bromophenol blu , ethidium bromide 40 μg/ml, in MOPS 1x) 
For ~1 ml 
200 μl of formaldehyde 36.5 %. 
500 μl of formamide. 
100 μl of MOPS 10x buffer. 
40 μl of ethidium bromide 1 mg/ml 
200 μl of FESB solution. 
Store at -20 °C. 
 
Tris-EDTA (TE) buffer  (10 mM Tris; 1 mM EDTA; pH 8.0)  
1 M Tris pH 8.0  1 ml   
0.5 M EDTA pH 8.0  0.2 ml   
H2Odd 98.8 ml   
Autoclave 
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Introduction. 
In molecular biology Cell Fractioning is a laboratory technique used to break cells and separate their 
molecular and structural components. Cell Fractioning can be divided in two steps: Homogenization 
and Fractionation. The Homogenization phase, whose purpose is to break the cell, is obtained either by 
the osmotic alteration of the media where cells are broken open through the utilization of an hypotonic 
buffer or by mechanical disruption. The Fractionation phase relies on the utilization of centrifugations 
at different speeds and times to separate cellular components on the basis of their size. 
 
Cell Fractioning (Nuclei/Cytoplasm). 
 
Day 0 
Spread at least 2.10
6 
in a 10 cm plate. If you want to look at the localization of one or more exogenous 
protein transfect your cells according to either SOP 1.0 or SOP 3.0, depending on the cell type with 
which you are working. 
 
Day 1 
1. Wash your 10 cm plate with PBS. 
2. Add 400 μl of lysis buffer 0.5% Triton X-100. 
3. Scrape cells and incubate on ice for 20 minutes. 
4. Centrifugate at 13.000 rpm (16’100 x g) in the Eppendorf centrifuge 5415R located in the lab. 
5. Transfer the supernatant (membrane/cytoplasm fraction) into a new Eppendorf tube and keep 
the pellet. 
6. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
7. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Cytoplasmic fraction is ready to be loaded or 
alternatively you can store it at -20 °C. 
8. Rinse the pellet representing the nuclear/mithocondrial fraction with the lysis buffer once and 
resuspend in the lysis buffer containing 0.5% SDS. Shear the released genomic DNA by 
sonication. The sonicator (Heischer DmbH) is now located downstairs, in a room that is in 
front of Peter Clark’s group cell culture room. The settings you have to use are the followings: 
Cycle (representing the number of cycles per second): 0.8-0.9. 
Amplitude: 80% 
9. Once there you have to insert the metallic tip of the sonicator inside your Eppendorf tube and 
press the black button located on the top of the sonicator for 10 seconds. Two sonications are 
enough to completely break the DNA. After each sonication place the sample back on ice for a 
few seconds. Before processing the next sample, wash the metallic tip of the sonicator first 
with ethanol 70% and then with water. Dry the tip with a clean tissue. 
10. After sonication, centrifuge at 13.000 rpm  (16’100 x g) in the Eppendorf centrifuge 5415R 
and transfer the supernatant in a new Eppendorf. 
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11. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
12. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Nuclear fraction is ready to be loaded or alternatively 
you can store it at -20 °C. 
 
Cell Fractioning (Nuclei, Mitochondria, Cytoplasm and Membrane) 
Day 0 
Start from at least 10
.
10
6 
using 10 cm plates. If you want to look at the localization of one or more 
exogenous protein transfect your cells according to either SOP 1.0 or SOP 3.0, depending on the cell 
type with which you are working. 
 
Day 1 
1. Wash your 10 cm plate with PBS. 
2. Add 300 μl of hypotonic lysis buffer. 
3. Scrape cells and incubate on ice for 20 minutes. 
4. Centrifugate at 300 x g 5 minutes at 4 °C in the Eppendorf centrifuge 5415R to pellet nuclei. 
5. Transfer the supernatant in a new eppendorf and wash the pellet twice with the lysis buffer. 
For each wash add 250 μl of lysis buffer, centrifugate at 300 x g and discard the supernatant. 
6. Resuspend the pellet in 200 μl of lysis buffer + Triton X100 1%. 
7. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
8. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Nuclear fraction is ready to be loaded or alternatively 
you can store it at -20 °C. 
9. For the mitochondrial fraction start from point number 5. After transferring the supernatant in 
a new Eppendorf tube, centrifugate at 10’000 x g in the Eppendorf centrifuge 5415R located 
in the lab for 10 minutes at 4 °C to pellet mithocondria. 
10. Transfer the supernatant in a new Eppendorf tube and resuspend the pellet in 200 μl of lysis 
buffer + Triton X100 1%.  
11. Sonicate as described above. 
12. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
13. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Mitochondrial fraction is ready to be loaded or 
alternatively you can store it at -20 °C. 
14. Take the supernatant you transferred in a new Eppendorf tube (point number 10) and 
centirfugate at 100’000 x g 1.5 hours at 4 °C. For this centrifugation, you have to use the ultra-
centrifuge named Centrikon T-108 located in the P2 lab. The rotor, ‘Kontron 18425’, is 
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located in the fridge in front of Romano Regazzi’s lab. Tubes that suit the rotor are provided 
from Beckman and the maximum volume you can put in the tubes is 1 ml. After the 
centrifugation (as well as before using it) clean it with ethanol 70% and water. Do not forget 
to put the rotor back to its storage place. 
15. Transfer the supernatant in a new Eppendorf tube. 
16. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
17. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Cytoplasmic fraction is ready to be loaded or 
alternatively you can store it at -20 °C. 
18. Resuspend the pellet in 150 μl of lysis buffer + Triton X100 1%. 
19. Sonicate as described above. 
20. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
21. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Membrane fraction is ready to be loaded or alternatively 
you can store it at -20 °C. 
 
Materials and reagents Source/Company Code 
TRIS (Trizma base) Sigma T1503 
Triton X-100 Fluka 93426 
NaCl Acros 207790050 
Glycerol Fluka 49780 
MgCl2 MERCK TA 808932 
KCl Fluka 60130 
SDS (sodium dodecyl sulphate) Sigma L4390 
HEPES AppliChem A3724 
Centrifuge tubes 11 x 34 mm Beckman 343778 
 
 
Lysis buffer (0.5% Triton X-100, 500 mM Tris-HCl pH 7.5, 137 mM NaCl, 10% glycerol, 0.5% 
Triton X-100) 
For 10 ml 
5 ml of Tris-HCl pH 7.5 1M 
274 μl of NaCl 5M 
1 ml of glycerol 100% 
50 μl of Triton X-100 
Up to 10 ml with water 
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Hypotonic lysis buffer (10 mM Hepes pH 7.4, 10 mM MgCl2 , 42 mM KCl) 
For 10 ml 
200 μl of Hepes pH 7.4 500 mM 
100 μl of MgCl2 1 M 
420 μl of KCl 1 M 
Up to 10 ml with water 
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Materials and reagents 
 
Materials and reagents Source/Company Code 
Coplin Jar (Figure 1)    
Ethanol Merck K38929083 
Xilene   
Tris 1M pH7.6  Sigma 1297640 
BSA Sigma A7906 
Tween 20 Acros 233360010 
Citric acid Sigma C8532 
EDTA pH8 Fluka 03620 
Liquid blocker  Daido Sangyo Co. 22309 
Hoechst   
Vectashield Mounting medium Reactolab H-1000 
Incubation chamber 
Plastic flat box with 
wet tissue on the 
bottom   
Coverslips Menzel-Glaser 
Available in the 
DBCM stock 
 
 
 
 
 
 
 
Figure 1: Coplin Jar. In the laboratory, we have jars accommodating 8 and 12 slides. 
 
Buffers 
 
20X TBS (1M Tris base, 18% NaCl, pH 7.6) 
Weigh 122 g of Tris and 180 g NaCl dissolve in 800 ml of distilled water. Adjust the pH to 7.6 with 
HCl 37%. The volume of HCl to add is approximately 65 to 70 ml. Add water to 1000 ml. Store this 
solution at room temperature. Dilute 1:20 with distilled water before use and adjust pH if necessary. 
 
I) IHC with fluorescence 
 
Buffer 1: TBS 1x pH 7.6 
Dilute TBS 20X, 1:20 with distilled water 
Buffer 2: TBS 1x pH 7.6+ Tween 20 0.5% 
Dilute TBS 20X, 1:20 with distilled water and add 5 ml of Tween 100% (0.5%). 
Buffer 3: TBS 1x pH 7.6 + Tween 20 0.5% + BSA 0.2% 
Dilute TBS 20X, 1:20 with distilled water. Add 5 ml of Tween 100% and 2 g of BSA. 
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Experimental protocol 
 
Slide deparaffinization.  
 
Put the slides on a plate and incubate at 60°C until the paraffin is completely dissolved. Immediately 
after this (it has to be fast because the paraffin can solidify again), immerse the slides in the first 
incubation solution described below and then proceed with the subsequent washes. 
 
Incubate sections sequentially in: 
1°_ xylene 5’ 
2°_ xylene 3’ 
3°_ Ethanol 100% 3’ 
4°_ Ethanol 100% 2’ 
5°_ Ethanol 90%, 2’ 
6°_ Ethanol 75%, 2’ 
7°_ Ethanol 50%, 2’ 
8°_ Wash with water from the sink, distilled water is not necessary. 
 
These solvents are located in a hood besides the radio in Peter Clarkes’s lab. Turn on the aeration 
system (top left) of the hood before starting with deparaffinization. 
If you have problems of detachment there is an alternative deparaffinization protocol in the annexe. 
 
The slides are now ready for the IHC 
 
Antigen retrieval 
 
The antigen retrieval protocol should be assessed for each antibody. There are cases where no antigen 
retrieval is needed but this has to be tested for each particular antibody. In the attached table there is a 
list of already standardised antigen retrieval protocols. 
The following two protocols are the most common ones. 
 
Tris-EDTA Buffer (10 mM Tris Base, 1 mM EDTA, 0.01% Tween 20, pH 9) 
Tris-base  1.21 g 
EDTA 0.37 g 
Distilled H2O 1000 ml 
Adjust the pH to 9 and then add 0.1 ml of Tween 20. Mix well. 
Prepare 1000 ml and put it in a pressure casserole and heat until the second red line is seen on the 
pressure marker (approximately 10 minutes but it’s better to be there before in case there is liquid 
spilling out the casserole, in this case, remove the recipient from the heating plaque immediately). At 
this point wait 2 minutes and take the casserole out of the heating plaque. Release the pressure (by 
pushing down the pressure indicator) and place the casserole in the sink. Pour cold water on the cover 
without opening it. 
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Once the vapour is all out open the casserole and take the slides out. Wash immediately with tap water 
and begin with the immunohistochemistry staining. 
 
 
Sodium Citrate Buffer (10 mM Sodium citrate pH 6.0) 
Tri-Sodium citrate (dehydrate) 2.94 g 
Distilled H2O 1000 ml 
Adjust the pH to 6 with HCl and mix well.  
This buffer is commonly used and works perfectly well with most antibodies. It gives very nice intense 
staining with very low background. 
This buffer can be used either with the pressure casserole or in the microwaves. 
Usually I use it in the microwave. Put the slides into 1000 ml of buffer in a microwave-resistant 
recipient with a cover. Use the highest power setting until the liquid boils (takes about 7 to 8 minutes). 
Once the buffer is boiling, lower the power to the minimum and keep heating for 11 minutes.  
Once the procedure is finished, leave the slides to cool down in the same buffer for at least one hour 
with agitation. To shorten this period of time, ice can be placed into the recipient. For certain 
antibodies, there is no need to let the buffer get completely cold.  
Wash with tap water before starting the immuno-histochemistry procedure. 
 
 
Immunostaining 
 
Before starting, surround the samples about to be stained with liquid blocker to ensure a minimal 
area in which the incubations will be done. Air dry the liquid blocker for a few seconds (but do not 
dry out the sample!). The liquid blocker should be kept at 4°C.  
 
1. Incubate the slides in a Coplin jar with buffer 1 for 5 minutes on a shaker. Repeat this washing 
step with buffer 2. All the washing steps should be done on the shaker. 
2. Blocking of unspecific sites: add 100 l of blocking solution (buffer 3) onto the section and 
into the area delimited by the liquid blocker. Incubate the slides in a humid chamber for at 
least 30 minutes at room temperature. The humid chamber is a plastic box with a wet tissue 
inside; keep it close to maintain humidity. If desired 15% of serum of the species in which the 
secondary antibody was made, can be added to the blocking solution (for example, if the 
secondary antibody is a goat anti-mouse antibody, you have to choose goat serum). Adding 
serum is not essential but it can be important when doing a double or triple staining.  
3. Incubation with the first antibody: Add 100 l per slide of the primary antibody diluted in 
buffer 3 according to the datasheet of the given antibody. Incubate in a humid chamber for 1 
hour at room temperature. For some antibodies you can increase the signal by incubating the 
slides over night at 4°C. To avoid evaporation of the liquid you can cover the slide (with the 
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antibody solution) with parafilm (just put it over it without pressing). This will also ensure a 
homogeneous spreading of the liquid. 
4. Washings: wash the slides three times in buffer 2 for 5 minutes or two times for 10 minutes. 
5. Incubation with secondary antibody: put 100 l per slide of the secondary antibody diluted in 
buffer 3. Usually, the dilution is between 1/200 and 1/500 but this should be tested when new 
antibodies are employed. Incubate the slides in a humid and dark chamber for 1 hour at room 
temperature. Secondary antibodies are located on the first freezer you find when entering the 
lab, in the top right drawer.  
6. Wash the samples extensively in a dark or covered Coplin Jar. Perform at least 6 washes of 20 
minutes each, in buffer 2. An overnight washing at 4°C is recommended but not essential.  
7. Nucleus staining: Dilute the Hoechst dye (located in the first fridge you find when entering in 
the culture room) 1:1000 in buffer 2 and put 100ul per slide. Incubate in a humid and dark 
chamber for 10 minutes at room temperature (longer incubation time can result in a saturated 
staining) 
8. Mount the slides with Vectashield mounting medium. This is a special medium used to 
conserve the fluorescence for longer time. Anyway do not wait too much to observe the slides 
as the quality would not be as good as if you look at them within one week. The volume of 
Vectashield to be used should be between 5 µl, for small samples, to 20 µl, for big ones. Place 
a coverslip over it trying to avoid the formation of bubbles  
9. Surround the coverslip with nail polish in order to protect the samples from drying out. Keep 
the slides at 4°C in the dark. 
 
 
Annexe  
 
Alternative deparaffinization protocol 
 
Put the slides over a plate at 60°C until the paraffin is completely dissolved. Soon after this, immerse 
the slides on the first incubation solution described below. 
 
Incubate sections sequentially in: 
1°_    xylene 5’ 
2°_    xylene 3’ 
3°_    Ethanol 100% 3’ 
4°_ Ethanol 80%, 2’  
5°_ Put the slides over the plate at 60°C until they dry out completely 
6°_     Wash with water from the sink, distilled water is not necessary. 
 
 
Antigen retrieval protocol for some antibodies used in the laboratory 
 
Antibody Company Antigen retrieval protocol 
Survivin  Cell signalling (2808) Citrate buffer + microwave 
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Cytokeratin 5 (MK5) Covance (PRB-160P) Citrate buffer + microwave 
Cytokeratin 10 (MK10) Covance (PRB-159P) Citrate buffer + microwave 
Active caspase-3 Cell signalling (9664) Citrate buffer + microwave 
pAkt (Ser473) Cell signalling (9271) Tris-EDTA + pressure 
KI-67 Dako (M7249) Tris-EDTA + pressure 
Comments: 
There is an alternative staining method that uses the peroxidase enzyme to visualize the stained 
structures. 
This technique is useful if it is important to see the structure of the tissue you are working with. 
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Materials and reagents 
 
Materials and reagents Source/Company Code 
Falcon tubes 15 ml * Corning 430971 
Ethanol Merck K38929083 
PBS 1x CHUV 10003240 
Propidium iodide Sigma P-4170 
Trypsin-EDTA solution (1x) Sigma T3924 
Tri-sodium citrate (dehydrate) Sigma C-8532 
FCS (fetal calf serum or fetal bovine serum) GIBCO 10270106 
RNase A Boehringer Mannheim 85340025 
Scanning tubes  Beckman Coulter 2523749 
*any 15 ml tube can be employed. 
 
 
 
 
 
 
 
Figure 1: Propidium iodide structure and excitation and emission spectra. Excitation at 488 nm is done 
with the laser of the Cytometer Beckman Coulter Fc-500 located at the Department of Physiology (2
nd
 
floor). 
 
 
Solutions 
Citrate solution (0.038 M) [molecular mass 294.10 Da] 
 
Citrate stock solution 10 mM: dissolve 2.94 g of tri-sodium citrate (dehydrate) and dissolve it in 1000 
ml of water. Adjust pH to 7 with HCl. 
Citrate 0.038 M: add 380 l of citrate buffer 1 M in 9.62 ml of distilled water. 
 
Propidium iodide (PI)
1
 solution (1 mg/ml) [molecular mass 668.4 Da] 
 
                                                 
1
 Propidium iodide (or PI) is an intercalating agent and a fluorescent that can be used to stain DNA. When excited by 488 nm of 
laser light, it can be detected with 562-588 nm band pass filter. Flow cytometry is used to evaluate cell viability or DNA content 
in cell cycle analysis. It can be used to differentiate necrotic, apoptotic and normal cells. 
PI binds to DNA by intercalating between the bases with little or no sequence preference and with a stoichiometry of one dye per 
4–5 base pairs of DNA. PI also binds to RNA, necessitating treatment with nucleases to distinguish between RNA and DNA 
staining. Once the dye is bound to nucleic acids, its fluorescence is enhanced 20- to 30-fold, the fluorescence excitation 
maximum is shifted ~30–40 nm to the red and the fluorescence emission maximum is shifted ~15 nm to the blue. Although its 
molar absorptivity (extinction coefficient) is relatively low, PI exhibits a sufficiently large Stokes shift to allow simultaneous 
detection of nuclear DNA and fluorescein-labeled antibodies, provided the proper optical filters are used. PI is suitable for 
fluorescence microscopy, confocal laser scanning microscopy, flow cytometry, and fluorometry. 
PI is membrane impermeant and generally excluded from viable cells. PI is commonly used for identifying dead cells in a 
population and as a counterstain in multicolor fluorescent techniques. 
[From Wikipedia, the free encyclopedia]. 
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Dissolve 1 mg of PI in 1 ml of citrate buffer 0.038 M. 
Store at 4°C protected from light. 
Staining buffer 
Make a 3 M solution of PI by diluting 1 mg/ml (1.5 mM) stock solution 1/500 in staining buffer 
Tris pH 7.4 100 mM 
NaCl 150 mM 
CaCl2 1 mM 
MgCl2 0.5 mM 
NP-40 (Igepal) 0.1% 
RNase A 20 g/ml 
 
Recipe for 10 ml: 
Tris 1 M 1 ml 
NaCl 5M 300 l 
CaCl2 1M 10 l 
MgCl2 1M 5 l 
NP-40 10% 100 l 
RNase A 25 mg/ml 8 l    
PI 1 mg/ml 20 l 
 
Keep this solution at 4°C in the dark. Do not store it for a long time. If it is more than 1 month old, 
prepare a new one.  
Alternatively the buffer can be stored at 4°C for longer periods of time (4-5 months) without RNase 
and PI. Do not forget to add these last two before use!  
 
Experimental protocol 
 
The protocol described here is for solution containing ~500’000 cells/ml. 
 
1) Harvest the cells by trypsinization (for 3.5 cm dish):  
Put the medium of the cells in which they were cultivated into a tube, wash once with 2 ml of PBS and 
add this PBS washing volume to the collected medium, trypsinize by adding 100 l of trypsine and 
incubating for 1-2 minutes at 37°C. Then flush the cells with the medium and PBS that were previously 
collected. 
2) Washing: wash once or twice (if you have few cells wash only once) with cold PBS.  
The centrifugation during the washing steps should be 1’200 rpm for 5 minutes (276 g) (Centrifuge 
SIGMA 3-16PK, rotor 11180, adaptors for 15 ml tubes). 
 
Fixation 
Prepare a 15 ml tube with 3 ml of ice-cold ethanol 100%. 
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3) After the last washing step, discard the supernatant very carefully and resuspend the pellet in 
500 l cold PBS. Mix thoroughly by pippeting up and down. It is very important to obtain a single cell 
solution because clumps of cells can clog the tubing of the FACS apparatus. 
4) Add drop by drop the cells into the ethanol while thoroughly vortexing the tube. 
Incubate at -20°C for at least 15 minutes. The cells can be stored at this step at -20°C. 
 
Staining 
5) Pellet the cells by centrifugation at 1’200 rpm (276 g) (Centrifuge SIGMA 3-16PK, rotor 11180, 
adaptors for 15 ml tubes) for 5 minutes and wash once with PBS, 1% FCS (serum helps pelleting the 
cells by preventing their adhesion to the walls of the tubes). Centrifuge 5 minutes at 1’200 rpm (276 g) 
(Centrifuge SIGMA 3-16PK, rotor 11180, adaptors for 15 ml tubes). 
 6) Discard the supernatant very carefully and resuspend in 100 l of cold PBS. Add 1 ml of 
staining buffer to the cells. Mix thoroughly by pippeting up and down to ensure a single cell 
suspension. 
Transfer the cells in a scanning tube (protect from light) and incubate at room temperature for 15 
minutes. The cells are ready to be scanned. 
 
After staining, cells can be stored at 4°C in the dark for a maximum of 4 days.  
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Flow cytometer parameters  
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